

CITATION REPORT

List of articles citing

Nonalcoholic fatty liver disease

DOI: 10.1056/nejmra011775

New England Journal of Medicine, 2002, 346, 1221-31.

Source: <https://exaly.com/paper-pdf/34063313/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2295	Structure of the pentapeptide proctolin, a proposed neurotransmitter in insects. 1975 , 17, 1253-6		243
2294	The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease. 1998 , 22, 663		3
2293	ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. 2002 , 33, 2337-41		159
2292	Estrogen-receptor polymorphism and hormone-replacement therapy. <i>New England Journal of Medicine</i> , 2002 , 347, 762-3; author reply 762-3	59.2	0
2291	Development of Kaposi's sarcoma at the site of a biopsy. <i>New England Journal of Medicine</i> , 2002 , 347, 763-4; author reply 763-4	59.2	6
2290	Treatment of migraine. <i>New England Journal of Medicine</i> , 2002 , 347, 764-6; author reply 764-6	59.2	5
2289	Nonalcoholic fatty liver disease. <i>New England Journal of Medicine</i> , 2002 , 347, 768-9; author reply 768-9	59.2	27
2288	Mechanical extraction of a basilar-artery embolus with the use of flow reversal and a microbasket. <i>New England Journal of Medicine</i> , 2002 , 347, 769-70	59.2	31
2287	Schistosomiasis. <i>New England Journal of Medicine</i> , 2002 , 347, 766-8; author reply 766-8	59.2	13
2286	Hepatic steatosis, insulin resistance, and adipose tissue disorders. 2002 , 87, 3019-22		103
2285	ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. 2002 , 106, 1024-8		410
2284	Nonalcoholic steatohepatitis: what we know in the new millennium. 2002 , 97, 2714-2724		15
2283	Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. 2002 , 360, 1410-8		162
2282	Non-alcoholic Steatohepatitis. 2002 , 30, 62		1
2281	ACC/AHA/NHLBI clinical advisory on the use and safety of statins. 2002 , 40, 567-72		504
2280	Nonalcoholic steatohepatitis: what we know in the new millennium. 2002 , 97, 2714-24		136
2279	Treatment of nonalcoholic fatty liver disease. 2002 , 1, 12-19		62

2278	Therapeutic Options in Nonalcoholic Fatty Liver Disease. 2002 , 5, 425-436	10
2277	Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. 2002 , 17, 1098-105	199
2276	Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. 2002 , 60, 289-93	187
2275	Steatohepatitis in obese individuals. 2002 , 16, 733-47	53
2274	Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. 2002 , 36, 403-9	252
2273	Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. 2003 , 48, 2173-81	107
2272	Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. 2003 , 37, 909-16	519
2271	Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. 2003 , 37, 1202-19	1468
2270	CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. 2003 , 38, 428-35	114
2269	Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). 2003 , 38, 436-42	41
2268	Treatment of Nonalcoholic Fatty Liver Disease. 2003 , 6, 455-463	14
2267	Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. 2003 , 5, 18-25	67
2266	Impact of steatosis on perioperative outcome following hepatic resection. 2003 , 7, 1034-44	339
2265	Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. 2003 , 38, 1529-39	251
2264	Iron as a co-morbid factor in nonhemochromatotic liver disease. 2003 , 30, 137-44	80
2263	Hepatobiliary, renal and bone complications of intestinal failure. 2003 , 17, 907-29	66
2262	Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. 2003 , 18, 588-94	129
2261	Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. 2003 , 18, 386-92	62

2260	Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. 2003 , 18, 124-38	164
2259	Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. 2003 , 3, 27	20
2258	Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats. 2003 , 5, 234-43	56
2257	The liver and statin drug therapy: uncertain navigation in the sea of risk-benefit. 2003 , 12, 303-6	7
2256	Antiretroviral-associated liver injury. 2003 , 7, 475-99	41
2255	Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. 2003 , 98, 2348-2350	19
2254	Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. 2003 , 124, 1451-64	89
2253	Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. 2003 , 125, 437-43	803
2252	Metformin: new understandings, new uses. 2003 , 63, 1879-94	233
2251	Advances in the understanding and treatment of nonalcoholic fatty liver disease. 2003 , 63, 2379-94	43
2250	Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. 2003 , 35, 172-8	66
2249	Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. 2003 , 124, 248-50	144
2248	Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. 2003 , 114, 370-6	95
2247	Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. 2003 , 38, 1529-1539	92
2246	Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. 2003 , 38, 414-8	99
2245	A major health hazard: the metabolic syndrome. 2003 , 73, 2395-411	149
2244	Aldehyde dehydrogenase 2 and beta3-adrenergic receptor gene polymorphisms: their association with elevated liver enzymes and metabolic syndrome. 2003 , 52, 1096-101	14
2243	Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. 2003 , 39, 756-64	198

2242	Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. 2003 , 39, 978-83	269
2241	Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. 2003 , 143, 500-5	371
2240	Hepatic function and physiology in the newborn. 2003 , 8, 337-46	68
2239	Hyperlactataemia syndromes associated with HIV therapy. 2003 , 3, 329-37	99
2238	Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. 2003 , 100, 3065-70	140
2237	Current best treatment for non-alcoholic fatty liver disease. 2003 , 4, 611-23	23
2236	Community-based study of hepatitis C virus infection and type 2 diabetes: an association affected by age and hepatitis severity status. 2003 , 158, 1154-60	53
2235	Visceral fat and liver fat are independent predictors of metabolic risk factors in men. 2003 , 284, E1065-71	189
2234	Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. 2003 , 23, 688-94	63
2233	Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. 2003 , 98, 2348-50	32
2232	Nonalcoholic fatty liver disease (NAFLD)--two decades later: are we smarter about its natural history?. 2003 , 98, 1915-7	23
2231	Glitazones: good for glycemia. Good for the liver?. 2003 , 5, 43-4	1
2230	Targeted disruption of GPR7, the endogenous receptor for neuropeptides B and W, leads to metabolic defects and adult-onset obesity. 2003 , 100, 10540-5	100
2229	[NASH -- nonalcoholic steatohepatitis]. 2003 , 41, 77-90	0
2228	Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. 2003 , 96, 699-709	41
2227	Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. 2003 , 88, 5674-9	44
2226	Stearoyl-CoA desaturase-1 and the metabolic syndrome. 2003 , 3, 271-80	75
2225	Hepatobiliary pathology. 2003 , 19, 185-93	3

2224	Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease?. 2003 , 37, 399-402	37
2223	Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. 2003 , 36, 266-8	28
2222	Obesity. 2003 , 38, 238-241	
2221	Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. 2003 , 37, 177-82	43
2220	Announcements. 2003 , 38, 241	
2219	Concurrent exercise prevents high-fat-diet-induced macrovesicular hepatic steatosis. 2003 , 94, 2127-34	135
2218	CE Test: Nonalcoholic Fatty Liver Disease. 2003 , 26, 154-155	0
2217	Nonalcoholic Fatty liver disease. 2003 , 26, 150-4; quiz 154-5	9
2216	Current World Literature. 2003 , 6, 599-606	
2215	Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. 2003 , 285, E906-16	309
2214	A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. 2003 , 36, 723-9	33
2213	Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. 2003 , 2, 183-185	2
2212	Healthy ranges for alanine aminotransferase levels. 2003 , 138, 156-7; author reply 156-7	3
2211	Amelioration of microvascular angina with arginine supplementation. 2003 , 138, 160	4
2210	Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. 2004 , 3, 108-112	45
2209	N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?. 2004 , 44, 289-99	162
2208	Fatty liver: How frequent is it and why?. 2004 , 3, 63-65	58
2207	The Relationship of Overweight and Obesity to High Mortality Rates from Liver Cirrhosis in Mexico. 2004 , 3, 66-71	5

2206	. 2004,	7
2205	[Alcoholic hepatitis: bad prognosis due to concomitant bacterial infections]. 2004, 37, 199-203	2
2204	Another animal model for nonalcoholic steatohepatitis: how close to the human condition?. 2004, 79, 350-1	9
2203	Nonalcoholic steatohepatitis. 2004, 24, 3-20	338
2202	Estrogen regulation of growth hormone action. 2004, 25, 693-721	354
2201	Randomized Trial Evaluating a Predominately Fetal Growth-Based Strategy to Guide Management of Gestational Diabetes in Caucasian Women: Response to Kitzmiller. 2004, 27, 2091-2092	
2200	In vivo MRS measurement of liver lipid levels in mice. 2004, 45, 1364-71	33
2199	Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. 2004, 27, 2498-500	150
2198	Improper insulin compliance may lead to hepatomegaly and elevated hepatic enzymes in type 1 diabetic patients: response to Yu and Howard. 2004, 27, 2094-5	2
2197	Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: Response to Holt, Citrome and Volevka, Isaac and Isaac, and Boehm et al.. 2004, 27, 2089-2090	9
2196	Randomized trial evaluating a predominately fetal growth-based strategy to guide management of gestational diabetes in caucasian women: response to Schaefer-Graf et al. 2004, 27, 2090-1; author reply 2091-2	1
2195	Hypoadiponectinemia is closely associated with nonalcoholic hepatic steatosis in obese subjects. 2004, 27, 2085-6	27
2194	Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. 2004, 27, 2088-9; author reply 2089-90	27
2193	Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group III: worldwide comorbidities of obesity. 2004, 110, e476-83	125
2192	The human insulin analog aspart can induce insulin allergy. 2004, 27, 2084-5	22
2191	Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. 2004, 27, 2088; author reply 2089-90	21
2190	Peripheral arterial disease in people with diabetes: response to consensus statement. 2004, 27, 2095; author reply 2095	11
2189	p53 involvement in the pathogenesis of fatty liver disease. 2004, 279, 20571-5	87

2188	A standardized triglyceride and carbohydrate challenge: response to Mohanlal and Holman. 2004 , 27, 2092-3; author reply 2093	18
2187	Cytochrome P450 and liver diseases. 2004 , 5, 273-82	141
2186	Poor correlation of pulse-wave velocity and intima-media thickness in diabetic subjects. 2004 , 27, 2084	25
2185	Circulating soluble CD14 monocyte receptor is associated with increased alanine aminotransferase. 2004 , 50, 1456-8	9
2184	Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. 2004 , 27, 2669-75	38
2183	Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. 2004 , 27, 2086-7; author reply 2089-90	4
2182	Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: response to Nesto. 2004 , 27, 2096; author reply 2096	11
2181	A Standardized Triglyceride and Carbohydrate Challenge: Response to Thanopoulou, Karamanos, and Roussi. 2004 , 27, 2093-2093	
2180	Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: a consensus statement from the American Heart Association and American Diabetes Association: Response to Elasy and Griffin. 2004 , 27, 2096-2096	4
2179	Peripheral Arterial Disease in People With Diabetes: Response to Hoyt. 2004 , 27, 2095-2095	1
2178	Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. 2004 , 27, 2087-8; author reply 2089-90	14
2177	Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. 2004 , 27, 2166-71	108
2176	Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. 2004 , 45, 941-7	103
2175	Role of simvastatin as an immunomodulator in type 2 diabetes: response to Lopes-Virella et al. 2004 , 27, 2093-4	
2174	Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. 2004 , 287, G1035-43	212
2173	Nonalcoholic fatty liver disease: is all the fat bad?. 2004 , 34, 187-91	27
2172	Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?. 2004 , 19, 368-74	103
2171	High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population. 2004 , 19, 289-95	16

2170	Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. 2004 , 19, 799-804	63
2169	Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. 2004 , 19, 694-8	145
2168	Hepatic steatosis in obese patients: clinical aspects and prognostic significance. 2004 , 5, 27-42	224
2167	Obesity in children and young people: a crisis in public health. 2004 , 5 Suppl 1, 4-104	2497
2166	Metformin in the treatment of patients with non-alcoholic steatohepatitis. 2004 , 19, 537-44	283
2165	Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. 2004 , 20, 23-8	253
2164	Review article: the evolving role of liver biopsy. 2004 , 20, 249-59	81
2163	A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. 2004 , 20, 623-8	134
2162	Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. 2004 , 61, 700-3	93
2161	Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. 2004 , 61, 711-5	22
2160	Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. 2004 , 24, 471-6	37
2159	Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. 2004 , 28, 167-72	77
2158	Central obesity and elevated liver enzymes. 2004 , 62, 394-9	18
2157	Fatty acid synthase blockade protects steatotic livers from warm ischemia reperfusion injury and transplantation. 2004 , 4, 1440-7	44
2156	Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. 2004 , 135, 48-58	259
2155	[Obesity and alcoholic and viral chronic liver disease]. 2004 , 28, 268-71	1
2154	[Hepatocellular carcinoma without cirrhosis in a patient with nonalcoholic steatohepatitis]. 2004 , 28, 497-9	19
2153	Is there value in liver function test and creatine phosphokinase monitoring with statin use?. 2004 , 94, 30F-34F	45

2152	Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. 2004 , 37, 1499-507	182
2151	Results of laparoscopic gastric bypass in patients with cirrhosis. 2004 , 14, 47-53	118
2150	Clinical characteristics and prevalence of GB virus C, SEN virus, and HFE gene mutation in Japanese patients with nonalcoholic steatohepatitis. 2004 , 39, 654-60	25
2149	Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. 2004 , 39, 1215-8	88
2148	Non-alcoholic fatty liver disease: an emerging pathological spectrum. 2004 , 444, 3-12	81
2147	Nicht alkoholische Fettleberkrankheit (NAFLK). 2004 , 152, 864-869	
2146	The keratin cytoskeleton in liver diseases. 2004 , 204, 367-76	98
2145	Adiponectin, hepatocellular dysfunction and insulin sensitivity. 2004 , 60, 256-63	83
2144	Valproate therapy and nonalcoholic fatty liver disease. 2004 , 55, 729-32	70
2143	Clinical impact of antibody formation to botulinum toxin A in children. 2004 , 55, 732-5	54
2142	Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. 2004 , 39, 770-8	549
2141	Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. 2004 , 39, 608-16	119
2140	Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. 2004 , 39, 909-14	175
2139	Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. 2004 , 39, 1277-85	97
2138	Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. 2004 , 40, 46-54	805
2137	Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. 2004 , 40, 185-94	619
2136	Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. 2004 , 40, 386-93	157
2135	Diverse regulation of NF-kappaB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver. 2004 , 40, 376-85	76

2134	Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. 2004 , 40, 1387-95	2757
2133	Obesity and diabetes as a risk factor for hepatocellular carcinoma. 2004 , 10, S69-73	162
2132	Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. 2004 , 10, 599-606	21
2131	Obesity in potential living donors: success with simplicity. 2004 , 10, 726-7	2
2130	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. 2004 , 18, 1089-104	58
2129	High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. 2004 , 39, 864-9	84
2128	Coenzyme Q10 and Adverse Effects of Statins. 2004 , 14, 17-28	2
2127	Stress- (and diet-) related regulation of hepatic nuclear receptors and its relevance for ABC-transporter functions. 2004 , 36, 391-406	3
2126	Screening for colorectal cancer in Europe. 2004 , 39, 805-6	2
2125	Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. 2004 , 36, 398-405	38
2124	[Insulin resistance. A cause or consequence of liver disease?]. 2004 , 27, 552-7	1
2123	Acquired and inherited lipodystrophies. <i>New England Journal of Medicine</i> , 2004 , 350, 1220-34	59.2 670
2122	Alteraciones hepáticas y diabetes mellitus. 2004 , 51, 449-451	
2121	Lipid metabolism in hepatic steatosis. 2004 , 8, 639-71, xi	88
2120	Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. 2004 , 126, 586-97	368
2119	Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. 2004 , 1, 98-105	362
2118	Is obesity a risk factor in acute pancreatitis? A meta-analysis. 2004 , 4, 42-8	93
2117	Animal models of nonalcoholic fatty liver disease and steatohepatitis. 2004 , 8, 559-74, ix	55

2116	Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. 2004 , 279, 32345-53	937
2115	Nonalcoholic fatty liver disease: a review of current understanding and future impact. 2004 , 2, 1048-58	294
2114	Hepatitis C and steatosis. 2004 , 8, 881-92, ix	12
2113	Non-alcoholic steatohepatitis: review of a growing medical problem. 2004 , 15, 10-21	75
2112	GDF-3 is an adipogenic cytokine under high fat dietary condition. 2004 , 321, 1024-31	32
2111	NASH: are genes blowing the hits?. 2004 , 40, 853-6	11
2110	A novel aminosterol reverses diabetes and fatty liver disease in obese mice. 2004 , 41, 391-8	31
2109	Silent non-alcoholic fatty liver disease-a clinical-histological study. 2004 , 41, 751-7	129
2108	Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. 2004 , 41, 926-34	170
2107	Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. 2004 , 41, 943-9	150
2106	Radiological evidence of nonalcoholic fatty liver disease in familial combined hyperlipidemia. 2004 , 116, 847-9	20
2105	Long term prognosis of fatty liver: risk of chronic liver disease and death. 2004 , 53, 750-5	353
2104	Insulin sensitivity and hepatic steatosis in obese subjects with normal glucose tolerance. 2004 , 14, 200-4	19
2103	Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. 2004 , 14, 215-24	32
2102	Liver abnormalities in celiac disease. 2004 , 2, 107-12	69
2101	Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. 2004 , 174, 193-6	148
2100	Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. 2004 , 40, 147-54	94
2099	Esteatohepatitis no alcool?lica. 2004 , 9, 459-465	

2098 El h?gado en las enfermedades sist?micas. **2004**, 9, 561-568

2097 Mice heterozygous for Atp10c, a putative amphipath, represent a novel model of obesity and type 2 diabetes. **2004**, 134, 799-805 62

2096 Leptin and the control of metabolism: role for stearyl-CoA desaturase-1 (SCD-1). **2004**, 134, 2455S-2463S 117

2095 Bibliography. Current world literature. Neuroscience. **2004**, 10, 162-72

2094 The first donor death after living-related liver transplantation in Japan. **2004**, 77, 634 121

2093 Dengue shock syndrome in a renal transplant recipient. **2004**, 77, 634-5 25

2092 Bibliography. Current world literature. Liver. **2004**, 20, 288-98

2091 Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. **2004**, 18, 1089-1104 3

2090 The wide spectrum of steatohepatitis: a report of four cases and a review of the literature. **2004**, 16, 1043-50 13

2089 Case-control study of diabetes mellitus in HIV-infected patients. **2004**, 37, 1464-9 22

2088 The epidemiology of fatty liver. **2004**, 16, 1087-93 94

2087 HEPATITIS C AND STEATOSIS: DOES FAT MATTER?. **2004**, 5, 30-31

2086 Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. **2004**, 16, 593-8 52

2085 Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. **2004**, 106, 261-8 366

2084 Management of NASH: Current and Future Perspectives on Treatment. 194-207 1

2083 Specific Disorders Associated With NAFLD. 249-262 1

2082 The Epidemiology and Risk Factors of NASH. 23-37 10

2081 Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. **2004**, 287, G264-73 141

2080 Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. **2004,**

2079 Intermediate filament protein inclusions. **2004, 78, 205-28**

12

2078 The use of very-low-calorie diets (VLCDs) and meal replacements for weight control. **2005, 379-411**

2077 The metabolic syndrome in children and adolescents. **2005, 10, 41-7**

15

2076 Nonalcoholic fatty liver disease in the pediatric population: a review. **2005, 17, 636-41**

91

2075 Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. **2005, 39, 540-3**

347

2074 Type 2 diabetes mellitus complicated with smoldering myeloma and non-alcoholic steatohepatitis. **2005, 44, 838-42**

2

2073 Liver fat content measured by magnetic resonance spectroscopy at 3.0 tesla independently correlates with plasminogen activator inhibitor-1 and body mass index in type 2 diabetic subjects. **2005, 206, 23-30**

24

2072 Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. **2005, 33, 122-7**

46

2071 The role of leptin in progression of non-alcoholic fatty liver disease. **2005, 33, 151-4**

65

2070 CYP17 polymorphism and tamoxifen-induced hepatic steatosis. **2005, 33, 178-80**

10

2069 Liver steatosis classification using high-frequency ultrasound. **2005, 31, 599-605**

20

2068 Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters. **2005, 15, 228-37**

39

2067 Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. **2005, 15, 497-501**

90

2066 Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. **2005, 25, 779-86**

143

2065 Microarray technology in the study of obesity and non-alcoholic fatty liver disease. **2005, 25, 1091-6**

11

2064 Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled Type 2 diabetic patients. **2005, 22, 1146-50**

18

2063 Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. **2005, 22, 1354-8**

134

2062	Diabetic fatty liver. 2005 , 22 Suppl 1, 14-8	15
2061	Hepatitis C virus infection in renal transplant patients: a comparative study with immunocompetent patients. 2005 , 19, 763-8	8
2060	Stearoyl-CoA desaturase as a new drug target for obesity treatment. 2005 , 6, 169-74	144
2059	Histological progression of non-alcoholic fatty liver disease in Chinese patients. 2005 , 21, 407-13	69
2058	A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. 2005 , 21, 871-9	185
2057	Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. 2005 , 22 Suppl 2, 24-7	75
2056	Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. 2005 , 35, 369-74	86
2055	Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. 2005 , 13, 1180-6	139
2054	Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. 2005 , 37, 1072-81	412
2053	Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. 2005 , 29, 140S-145S	115
2052	Hypomagnesemia, insulin resistance, and non-alcoholic steatohepatitis in obese subjects. 2005 , 36, 362-6	27
2051	Chronological development of elevated aminotransferases in a nonalcoholic population. 2005 , 41, 64-71	149
2050	p18(INK4c) expression in hepatocellular carcinoma. 2005 , 41, 405; author reply 406	1
2049	Measurement of hepatic venous pressure gradient in patients with active variceal bleeding. 2005 , 41, 406-7; author reply 407	
2048	Reduced plasma adiponectin in NASH: central obesity as an underestimated causative risk factor. 2005 , 41, 401; author reply 401-2	7
2047	A challenge on the use of the words embryonic and perinatal in the context of biliary atresia. 2005 , 41, 403-4; author reply 404-5	12
2046	Preprocedure coagulation tests are unnecessary before abdominal paracentesis in emergency departments. 2005 , 41, 402-3	11
2045	Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. 2005 , 41, 372-9	274

2044	Reply:. 2005 , 41, 401-402	4
2043	Reply:. 2005 , 41, 407-407	
2042	Reply:. 2005 , 41, 406-406	
2041	Reply:. 2005 , 41, 404-405	
2040	Persistence of antibody after hepatitis B vaccine and the question of boosters. 2005 , 41, 940; author reply 941	
2039	Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. 2005 , 41, 939; author reply 939-40	5
2038	More on the need for boosters 15 years after neonatal vaccination. 2005 , 41, 940-1; author reply 941	
2037	Percutaneous ablation for hepatocellular carcinoma. 2005 , 41, 942; author reply 942-3	
2036	Reply:. 2005 , 41, 941-941	
2035	Reply:. 2005 , 41, 939-940	3
2034	Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. 2005 , 41, 753-60	188
2033	Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis. 2005 , 41, 943	10
2032	Reply. 2005 , 41, 942-943	0
2031	Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. 2005 , 42, 44-52	944
2030	Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. 2005 , 42, 473-80	469
2029	Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors. 2005 , 42, 959-961	8
2028	Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice. 2005 , 11, 298-308	76
2027	[Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis]. 2005 , 46, 1324-30	3

2026	Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. 2005 , 48, 2282-91	162
2025	Elevated urine neopterin levels in nonalcoholic steatohepatitis. 2005 , 38, 187-90	13
2024	Glycated hemoglobin and liver disease in diabetes mellitus. 2005 , 155, 411-5	10
2023	Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. 2005 , 447, 996-9	43
2022	Nonalcoholic fatty liver disease: a clinical review. 2005 , 50, 171-80	200
2021	Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. 2005 , 5, 35	40
2020	Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. 2005 ,	1
2019	Mecanismos de hepatotoxicidade. 2005 , 85, 25	11
2018	Apoptosis in alcoholic and nonalcoholic steatohepatitis. 2005 , 10, 3093-9	155
2017	Effect of Chitin-Chitosan Treatment on Fatty Liver in Rats with a High Fat Diet. 2005 , 37, 87-94	2
2016	Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. 2005 ,	
2015	. 2005 ,	9
2014	25.2 Spezielle Differenzialdiagnose des Ikterus. 2005 ,	
2013	CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients. 2005 , 13, 485	1
2012	Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. 2005 , 289, G592-8	47
2011	Hepatic triglyceride contents are genetically determined in mice: results of a strain survey. 2005 , 288, G1179-89	43
2010	Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. 2005 , 289, E829-38	89
2009	Reduced intestinal fat absorptive capacity but enhanced susceptibility to diet-induced fatty liver in mice heterozygous for ApoB38.9 truncation. 2005 , 289, G146-52	10

2008	PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. 2005 , 288, E1195-205	286
2007	Steatohepatitis develops rapidly in transgenic mice overexpressing Abcb11 and fed a methionine-choline-deficient diet. 2005 , 288, G1321-7	17
2006	Evidence of hepatic glucagon resistance associated with hepatic steatosis: reversal effect of training. 2005 , 26, 432-41	30
2005	Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. 2005 , 54, 237-41	501
2004	Mutations in anionic trypsinogen gene are not associated with tropical calcific pancreatitis. 2005 , 54, 728-9	21
2003	Elevated plasma protein C levels correlate with the presence of fatty liver (NASH and NAFLD). 2005 , 54, 729	9
2002	Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. 2005 , 57, 445-52	167
2001	Nonalcoholic fatty liver disease and atherosclerosis. 2005 , 25, e117; author reply e117-8	2
2000	Plasma adiponectin is decreased in nonalcoholic fatty liver disease. 2005 , 152, 113-8	200
1999	Moderate caloric restriction, but not physiological hyperleptinemia per se, enhances mitochondrial oxidative capacity in rat liver and skeletal muscle—tissue-specific impact on tissue triglyceride content and AKT activation. 2005 , 146, 2098-106	34
1998	Treatment strategies in nonalcoholic fatty liver disease. 2005 , 2, 148-55	48
1997	Therapeutic potential of curcumin in non-alcoholic steatohepatitis. 2005 , 18, 212-21	22
1996	Nonalcoholic Fatty Liver (NAFL): Overview. 2005 , 1-43	
1995	Should nonalcoholic fatty liver disease be treated differently in elderly patients?. 2005 , 2, 208-9	2
1994	The relationship between apoptosis and non-alcoholic fatty liver disease: an evolutionary cornerstone turned pathogenic. 2005 , 43, 211-7	19
1993	Recent advances in the treatment of non-alcoholic fatty liver disease. 2005 , 14, 29-35	4
1992	Imaging features of perivascular fatty infiltration of the liver: initial observations. 2005 , 237, 159-69	79
1991	Histological characteristics and prognosis in patients with fatty liver. 2005 , 40, 460-7	31

1990	Nonalcoholic fatty liver disease. 2005 , 172, 899-905	364
1989	Hepatitis C virus-induced hepatocellular steatosis. 2005 , 100, 711-5	63
1988	Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. 2005 , 288, E228-35	182
1987	3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. 2005 , 19, 1552-4	112
1986	Coexistent chronic idiopathic intestinal pseudo obstruction and inflammatory bowel disease. 2005 , 54, 729-30	10
1985	CORRECTION. 2005 , 54, 734-734	78
1984	The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. 2005 , 143, 722-8	739
1983	Inflammatory bowel disease stimulates formation of carcinogenic N-nitroso compounds. 2005 , 54, 731	30
1982	Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. 2005 , 28, 2211-6	54
1981	Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. 2005 , 90, 1578-82	214
1980	Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. 2005 , 45, 1012-8	170
1979	Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. 2005 , 54, 732	14
1978	Genotypes 677TT and 677CT+1298AC of methylenetetrahydrofolate reductase are associated with the severity of ulcerative colitis in central China. 2005 , 54, 733-4	14
1977	New imaging techniques of fat, muscle and liver within the context of determining insulin sensitivity. 2005 , 64 Suppl 3, 38-44	14
1976	Associations between liver histology and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. 2005 , 25, 2687-8	25
1975	Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. 2005 , 288, E462-8	1132
1974	Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. 2005 , 28, 1518-23	35
1973	Treatment of hepatitis C virus in HIV patients: a review. 2005 , 19 Suppl 3, S166-73	8

1972	Should nonalcoholic fatty liver disease be renamed?. 2005 , 23, 72-82	54
1971	Clinical syndromes of alcoholic liver disease. 2005 , 23, 255-63	80
1970	Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. 2005 , 25, 1979-84	95
1969	Liver fat and insulin resistance are independently associated with the -514C>T polymorphism of the hepatic lipase gene. 2005 , 90, 4238-43	30
1968	The Use of Protein Tyrosine Phosphatase 1B and Insulin Receptor Immunostains to Differentiate Nonalcoholic From Alcoholic Steatohepatitis in Liver Biopsy Specimens. 2005 , 123, 503-509	31
1967	Evaluaci3n macrosc3pica y microsc3pica del efecto de la atorvastatina sobre la progresi3n-regresi3n de la esteatosis hep3tica en un modelo aviar. 2005 , 17, 270-276	
1966	Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. 2005 , 25, 193-7	179
1965	Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. 2005 , 25, 1045-50	285
1964	[Iron overload and insulin resistance]. 2005 , 34, 1391-8	1
1963	Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBL. 2005 , 178, 107-13	19
1962	Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease. 2005 , 25, 946-53	68
1961	Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. 2005 , 22, 330-8	77
1960	Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. 2005 , 96, 1042-52	270
1959	La st3tohepatite non alcoolique. 2005 , 66, 71-80	3
1958	Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. 2005 , 3, 1260-8	179
1957	Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. 2005 , 3, 384-9	46
1956	Non-alcoholic Fatty liver disease and malignancy as complications of insulin resistance. 2005 , 3, 316-27	2
1955	Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques--initial experience. 2005 , 237, 507-11	145

1954	Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. 2005 , 40, 1469-77	63
1953	Invasive and non-invasive investigations for non-alcoholic steatohepatitis: the benefit of histology. 2005 , 40, 1260	5
1952	Is liver disease a threat to patients with metabolic disorders?. 2005 , 37, 333-46	22
1951	Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. 2005 , 100, 2218-24	53
1950	Euonymus alatus prevents the hyperglycemia and hyperlipidemia induced by high-fat diet in ICR mice. 2005 , 102, 326-35	69
1949	The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. 2005 , 42, 132-8	680
1948	Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. 2005 , 43, 1060-6	234
1947	Nrf1 gene expression in the liver: a single gene linking oxidative stress to NAFLD, NASH and hepatic tumours. 2005 , 43, 1096-7	15
1946	Hepatic adaptations to sucrose and fructose. 2005 , 54, 1189-201	120
1945	Swelling of hepatocytes injured by oxidative stress suggests pathological changes related to macromolecular crowding. 2005 , 64, 818-25	40
1944	Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH). 2005 , 65, 377-9	13
1943	Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. 2005 , 336, 215-22	288
1942	Gastrointestinal complications of diabetes mellitus. 2005 , 51, 620-63	17
1941	The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. 2005 , 166, 1655-69	200
1940	[Pathogenesis of primary nonalcoholic fatty liver disease]. 2005 , 124, 668-77	5
1939	[Medical management of primary nonalcoholic fatty liver disease]. 2005 , 125, 108-16	0
1938	[Nonalcoholic steatohepatitis associated with ovarian stromal hyperplasia]. 2005 , 28, 375-7	2
1937	Morphology of alcoholic liver disease. 2005 , 9, 37-53	147

1936	The natural history of nonalcoholic fatty liver disease: a population-based cohort study. 2005 , 129, 113-21	2108
1935	The metabolic consequences of childhood obesity. 2005 , 19, 405-19	171
1934	Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice. 2005 , 54, 1490-8	18
1933	Steatosis and chronic hepatitis C virus infection: mechanisms and significance. 2005 , 9, 399-410, vi	22
1932	Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. 2005 , 54, 3458-65	405
1931	A review of the metabolic effects of sibutramine. 2005 , 21, 457-68	85
1930	Nonalcoholic Fatty Liver Disease: A new entry in the Metabolic Syndrome?. 2005 , 383-392	
1929	Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. 2005 , 54, 3541-6	449
1928	The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. 2006 , 101, 1824-33	137
1927	A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. 2006 , 4, 639-44	235
1926	The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. 2006 , 55, 1604-9	93
1925	Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. 2006 , 91, 4287-94	293
1924	Drug-related hepatotoxicity. <i>New England Journal of Medicine</i> , 2006 , 354, 731-9	59.2 736
1923	Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. 2006 , 169, 2042-53	131
1922	Síndrome metabólico: ¿cómo diagnosticarlo y cómo tratarlo?. 2006 , 18, 49-55	
1921	The evolving role of leptin and adiponectin in chronic liver diseases. 2006 , 101, 2629-40	145
1920	Is hyperuricemia another facet of the metabolic syndrome?. 2006 , 69, 104-9	21
1919	Incidence of statin hepatotoxicity in patients with hepatitis C. 2006 , 4, 902-7; quiz 806	90

1918	Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. 2006 , 130, S78-90	246
1917	Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. 2006 , 130, 1564-72	223
1916	Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. 2006 , 130, 2023-30	193
1915	Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. 2006 , 131, 934-45	274
1914	[Epidemiology and natural history of primary nonalcoholic fatty liver disease]. 2006 , 29, 244-54	6
1913	Mechanisms underlying nonalcoholic steatohepatitis. 2006 , 3, 479-488	8
1912	Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. 2006 , 29, 55-60	74
1911	Challenges of laparoscopic colectomy in the obese patient: a review. 2006 , 192, 357-65	60
1910	Epidemiologic research and the action plan for liver disease research. 2006 , 16, 861-5	2
1909	Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. 2006 , 4, 185-98	468
1908	Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. 2006 , 4, 199-210	418
1907	Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. 2006 , 340, 1111-8	130
1906	Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. 2006 , 342, 1152-9	99
1905	Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. 2006 , 33, 252-7	62
1904	Psammomys obesus (sand rat), a new animal model of non-alcoholic fatty liver disease. 2006 , 72, 1-5	17
1903	Organ systems dependent on nitric oxide and the potential for nitric oxide-targeted therapies in related diseases. 2006 , 8, 63-73	6
1902	The importance of early physical trauma in the development of autism. 2006 , 66, 441-2	2
1901	Rosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: new treatment for global dangers. 2006 , 66, 440-1	5

1900	Hepatic steatosis and insulin resistance: does etiology make a difference?. 2006 , 44, 190-6	116
1899	Adult onset type II citrullinemia as a cause of non-alcoholic steatohepatitis. 2006 , 44, 236-9	31
1898	Mice heterozygous for the Mdr2 gene demonstrate decreased PEMT activity and diminished steatohepatitis on the MCD diet. 2006 , 44, 586-92	16
1897	Non-alcoholic steatohepatitis: from cell biology to clinical practice. 2006 , 44, 197-208	152
1896	Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. 2006 , 44, 679-85	39
1895	Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. 2006 , 44, 1167-74	407
1894	'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. 2006 , 44, 1196-207	97
1893	Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. 2006 , 6, 1-28	496
1892	Low adherence of a clinically healthy Italian population to nutritional recommendations for primary prevention of chronic diseases. 2006 , 16, 436-44	19
1891	[Insulin resistance/hyperinsulinemia associated diseases not included in the metabolic syndrome]. 2006 , 50, 360-7	16
1890	Alcoholic and nonalcoholic fatty liver disease. 2006 , 547-564	1
1889	Tratamento multidisciplinar reduz o tecido adiposo visceral, leptina, grelina e a prevalência de esteatose hepática não alcoólica (NAFLD) em adolescentes obesos. 2006 , 12, 263-267	20
1888	[Non-alcoholic liver disease (NASH)]. 2006 , 95, 1267-9	
1887	Liver Biopsy Histopathology. 2006 , 205-234	
1886	Non-alcoholic Steatohepatitis. 2006 , 279-303	5
1885	n-3 fatty acids and the metabolic syndrome. 2006 , 83, 1499S-1504S	211
1884	Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys. 2006 , 47, 542-50	27
1883	Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis. 2006 , 5, 25-29	7

1882	Future directions in reducing hepatic lipotoxicity. 2006 , 1, 331-341	3
1881	Chapter 13 Hepatic CCAAT/enhancer binding protein [C/EBP] engineer of diabetes, obesity, and inflammatory disease processes. 2006 , 5, 255-319	
1880	Alanine amino transferase concentrations are linked to folate intakes and methylenetetrahydrofolate reductase polymorphism in obese adolescent girls. 2006 , 43, 234-9	16
1879	Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease?. 2006 , 40, 444-8	17
1878	Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: two cases. 2006 , 18, 101-5	10
1877	The Natural History of Nonalcoholic Fatty Liver Disease: A Population Based Cohort Study. 2006 , 2006, 432-434	
1876	Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. 2006 , 18, 233-7	124
1875	Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. 2006 , 40, 551-4	24
1874	Fatty liver and transaminase changes with adjuvant tamoxifen therapy. 2006 , 17, 709-13	29
1873	Anesthesia for adolescent bariatric surgery. 2006 , 44, 17-31	34
1872	Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. 2006 , 20, 387-95	78
1871	Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy. 2006 , 18, 1241-5	74
1870	Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. 2006 , 30, 37-43	73
1869	The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. 2006 , 6, 33	1135
1868	Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease. 2006 , 6, 34	199
1867	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. 2006 , 6, 6	304
1866	Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. 2006 , 210, 469-77	52
1865	Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. 2006 , 21, 138-43	283

1864	Mitochondrial glutathione: hepatocellular survival-death switch. 2006 , 21 Suppl 3, S3-6	91
1863	PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. 2008 , 23, 102-9	75
1862	Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. 2006 , 23, 403-9	125
1861	Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. 2006 , 26, 856-63	198
1860	Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. 2006 , 26, 864-71	67
1859	Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. 2006 , 26, 1000-5	29
1858	Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats. 2006 , 41, 79-84	110
1857	Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. 2006 , 64, 337-41	67
1856	Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. 2006 , 64, 679-83	141
1855	Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. 2006 , 65, 40-4	87
1854	Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. 2006 , 23, 1143-51	318
1853	Combined effects of high-fat diet and ethanol induce oxidative stress in rat liver. 2006 , 40, 185-91	50
1852	Exacerbation of dietary steatohepatitis and fibrosis in obese, diabetic KK-A(y) mice. 2006 , 36, 217-28	41
1851	Recent findings concerning thiazolidinediones in the treatment of diabetes. 2006 , 15, 243-50	71
1850	Change in liver size and fat content after treatment with Optifast very low calorie diet. 2006 , 16, 697-701	162
1849	Hepatic outcomes after jejunoileal bypass: is there a publication bias?. 2006 , 16, 1171-8	20
1848	Nonalcoholic fatty liver disease of obesity. 2006 , 16, 1412-9	9
1847	Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. 2006 , 16, 1584-93	45

1846	Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis. 2006 , 51, 1725-9	8
1845	Leptin in the field of hepatic fibrosis: a pivotal or an incidental player?. 2006 , 51, 1685-96	19
1844	Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. 2006 , 63, 1393-409	109
1843	Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. 2006 , 49, 945-52	205
1842	Signalling mechanisms linking hepatic glucose and lipid metabolism. 2006 , 49, 1732-41	82
1841	Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in <i>Psammomys obesus</i> : impact of dietary n-3 fatty acids. 2006 , 49, 1937-45	39
1840	Should all diabetic patients receive statins?. 2006 , 8, 13-8	3
1839	Development of type 2 diabetes in children and adolescents. 2006 , 6, 182-7	16
1838	<i>Acanthopanax senticosus</i> reverses fatty liver disease and hyperglycemia in ob/ob mice. 2006 , 29, 768-76	37
1837	Effects of insulin treatment on intracellular lipid metabolism in liver of diabetic rats. 2006 , 26, 284-7	1
1836	Transcriptional networks in a rat model for nonalcoholic fatty liver disease: a microarray analysis. 2006 , 81, 202-10	13
1835	Pathophysiology, diagnosis, and management of dyslipidemia. 2006 , 31, 445-86	17
1834	Nonalcoholic steatohepatitis and the cardiometabolic syndrome. 2006 , 1, 36-40	18
1833	Stearoyl-CoA desaturase: a new therapeutic target of liver steatosis. 2006 , 67, 643-650	17
1832	Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. 2006 , 22, 437-43	239
1831	Nonalcoholic fatty liver disease: from steatosis to cirrhosis. 2006 , 43, S99-S112	1802
1830	Reversal of hepatic fibrosis -- fact or fantasy?. 2006 , 43, S82-8	308
1829	JNK1 but not JNK2 promotes the development of steatohepatitis in mice. 2006 , 43, 163-72	306

1828	Noninvasive measures of liver fibrosis. 2006 , 43, S113-20	257
1827	In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. 2006 , 44, 27-33	545
1826	NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. 2006 , 44, 458-65	273
1825	Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. 2006 , 44, 983-91	122
1824	Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. 2006 , 44, 874-80	241
1823	Global challenges in liver disease. 2006 , 44, 521-6	587
1822	Nonalcoholic fatty liver disease and liver transplantation. 2006 , 12, 523-34	108
1821	Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. 2006 , 44, 245-8	11
1820	Serum gamma-glutamyl transpeptidase is a determinant of insulin resistance independently of adiposity in Pima Indian children. 2006 , 91, 1419-22	49
1819	Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. 2006 , 291, E282-90	124
1818	Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. 2006 , 290, G1339-46	133
1817	Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. 2006 , 291, G1011-9	25
1816	Hepatic Fibrosis and Cirrhosis. 2006 , 87-109	7
1815	Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson disease: hepatic manifestation in Wilson disease as a consequence of augmented oxidative stress. 2006 , 60, 472-7	58
1814	Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. 2006 , 291, E275-81	528
1813	A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation. 2006 , 290, G1170-6	13
1812	Identification of a novel single-stranded DNA fragment associated with human hepatitis. 2006 , 193, 1089-97	11
1811	Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. 2006 , 155, 735-43	75

1810	Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. 2006 , 55, 2159-70	322
1809	Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. 2006 , 29, 1325-30	312
1808	Fatty liver: imaging patterns and pitfalls. 2006 , 26, 1637-53	274
1807	Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. 2006 , 147, 943-51	409
1806	Demographic and clinicopathological characteristics of nonalcoholic fatty liver disease in the East-Southeastern Anatolia regions in Turkey. 2006 , 15, 62-8	8
1805	The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemlar). 2006 , 103, c100-5	2
1804	Invasive and non-invasive investigations for non-alcoholic steatohepatitis (NASH): the need for biochemical markers. 2006 , 41, 372	4
1803	Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. 2006 , 101, 2247-53	155
1802	Treatment of non-alcoholic fatty liver disease. 2006 , 82, 315-22	184
1801	Review: Non-alcoholic fatty liver disease in childhood. 2006 , 6, 264-268	1
1800	Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. 2006 , 91, 1081-6	152
1799	Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk. 2007 , 27, 4-7	52
1798	Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. 2007 , 48, 2334-43	142
1797	Pathology of nonalcoholic fatty liver disease. 2007 , 128, 837-47	229
1796	Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. 2007 , 282, 21327-36	51
1795	Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. 2007 , 30, 2119-21	395
1794	FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. 2007 , 56, 2501-10	100
1793	Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. 2007 , 102, 1912-9	56

1792	Non-alcoholic fatty liver disease in the metabolic syndrome. 2007 , 13, 2193-8	41
1791	Adipose tissue distribution in relation to insulin resistance in type 2 diabetes mellitus. 2007 , 293, E435-42	49
1790	Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. 2007 , 166, 196-203	121
1789	Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. 2007 , 30, 1075-80	73
1788	Incidence rates and causes of cirrhosis in a Norwegian population. 2007 , 42, 1501-8	21
1787	PPARs, Obesity, and Inflammation. 2007 , 2007, 95974	170
1786	Nonalcoholic fatty liver disease and diabetes mellitus. 2007 , 32, 59-69	16
1785	Reduced inflammatory response and increased microcirculatory disturbances during hepatic ischemia-reperfusion injury in steatotic livers of ob/ob mice. 2007 , 292, G1385-95	51
1784	Abdominal obesity and fatty liver. 2007 , 29, 77-87	123
1783	Non-Alcoholic Fatty Liver Disease in Children. 2007 , 3, 141-144	
1782	Steatohepatitis in HIV-infected subjects: pathogenesis, clinical impact and implications in clinical management. 2007 , 5, 490-8	18
1781	HGF ameliorates a high-fat diet-induced fatty liver. 2007 , 293, G204-10	19
1780	Searching for genetic factors of fatty liver in SMXA-5 mice by quantitative trait loci analysis under a high-fat diet. 2007 , 48, 2039-46	17
1779	Insulin protects liver cells from saturated fatty acid-induced apoptosis via inhibition of c-Jun NH2 terminal kinase activity. 2007 , 148, 3338-45	33
1778	Current concepts in the evaluation of patients for liver transplantation. 2007 , 1, 307-20	1
1777	Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. 2007 , 20, 351	48
1776	Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease. 2007 , 44, 446-52	64
1775	Liver diseases in the elderly: an update. 2007 , 25, 138-43	41

1774	Crosstalk between high-molecular-weight adiponectin and T-cadherin during liver fibrosis development in rats. 2007 , 20, 725		1
1773	Pioglitazone in nonalcoholic steatohepatitis. <i>New England Journal of Medicine</i> , 2007 , 356, 1067; author reply 1068-9	59.2	18
1772	Interobserver and intraobserver variability in the sonographic assessment of fatty liver. 2007 , 189, W320-3		278
1771	Lipid metabolism in the liver. 2007 , 45, 35-41		84
1770	Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). 2007 , 56, 1330-1		177
1769	Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. 2007 , 47, 1028-34		24
1768	Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. 2007 , 56, 443-4		35
1767	Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. 2007 , 30, 2940-4		189
1766	Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state. 2007 , 30, 3093-8		104
1765	Obstructive sleep apnoea, glucose tolerance and liver steatosis in obese women. 2007 , 35, 458-66		10
1764	Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. 2007 , 4, 285-96		91
1763	Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. 2007 , 127, 954-60		136
1762	Prevalence and risk factors of fatty liver disease in the Shuiguohu district of Wuhan city, central China. 2007 , 83, 192-5		24
1761	Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. 2007 , 243, 422-30		54
1760	Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo. 2007 , 21, 53-60		54
1759	Pravastatin-Induced Hepatotoxicity in a Patient With Fatty Liver Disease: A Case Presentation With Literature Review. 2007 , 20, 192-197		1
1758	Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. 2007 , 194, 539-50		117
1757	Relationships between estimates of adiposity, insulin resistance, and nonalcoholic fatty liver disease in a large group of nondiabetic Korean adults. 2007 , 30, 2113-8		49

1756	Nonalcoholic fatty liver disease: from pathogenesis to patient care. 2007 , 3, 458-69	69
1755	Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. 2007 , 32, 453-68	159
1754	Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. 2007 , 105, 151-6	14
1753	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. 2007 , CD005166	50
1752	Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. 2007 , CD005160	21
1751	Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. 2007 , 245, 44-50	111
1750	Steatosis as a risk factor in liver surgery. 2007 , 245, 20-30	214
1749	Association between nonalcoholic fatty liver disease and coronary artery disease. 2007 , 18, 433-6	76
1748	High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. 2007 , 19, 281-7	42
1747	Early stage of biliary atresia is associated with significant changes in 8-hydroxydeoxyguanosine and mitochondrial copy number. 2007 , 45, 329-34	32
1746	Ultrasound diagnosis of fatty liver in patients with chronic liver disease: a retrospective observational study. 2007 , 41, 624-9	41
1745	Liver enzymes and histology in obese patients with obstructive sleep apnea. 2007 , 41, 918-21	71
1744	Incidence of Statin Hepatotoxicity in Patients With Hepatitis C. 2007 , 2007, 446-448	
1743	Hepatic structural alteration in adult programmed offspring (severe maternal protein restriction) is aggravated by post-weaning high-fat diet. 2007 , 98, 1159-69	40
1742	Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. 2007 , 17, 517-24	294
1741	Nonalcoholic fatty liver disease. 2007 , 17, 863-9	229
1740	Positive effects of cryopreserved adult or fetal liver cell transplants on hypercholesterolemia and hepatic antioxidant defenses in cholesterol-fed rabbits. 2007 , 55, 72-9	1
1739	Cytokines and chronic liver disease. 2007 , 18, 143-57	27

1738	NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. 2007 , 46, 304-13	38
1737	NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. 2007 , 46, 700-7	86
1736	Identification of a gene-pathway associated with non-alcoholic steatohepatitis. 2007 , 46, 708-18	44
1735	Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. 2007 , 47, 135-41	211
1734	Pioglitazone: the beginning of a new era for NASH?. 2007 , 47, 160-2	13
1733	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. 2007 , 47, 412-7	159
1732	Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. 2007 , 47, 711-7	391
1731	Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. 2007 , 581, 5664-70	130
1730	The safety of statins in clinical practice. 2007 , 370, 1781-90	593
1729	Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. 2007 , 37, 579-95	14
1728	Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis. 2007 , 37, 1034-43	45
1727	Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. 2007 , 30, 1212-8	709
1726	Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. 2007 , CD005165	56
1725	Non-alcoholic fatty liver disease. 2007 , 42, 1023-30	39
1724	Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. 2007 , 53, 686-92	164
1723	Nonalcoholic fatty liver disease as a complication of insulin resistance. 2007 , 91, 1125-49, ix	117
1722	Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. 2007 , 102, 409-11	12
1721	Nonalcoholic Fatty liver disease and obesity. 2007 , 22, 1-10	51

1720	Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. 2007 , CD004996	36
1719	Steatosi epatica non alcolica: un aspetto emergente della sindrome metabolica. 2007 , 8, 136-143	
1718	Ultrasonographic evaluation of liver volume and the metabolic syndrome in obese women. 2007 , 30, 104-10	12
1717	Metabolic conditions of fatty liver in non-diabetic obese women. 2007 , 30, 672-6	1
1716	[Liver steatosis and in-out of phase MR imaging: theory and clinical applications at 3T]. 2007 , 88, 1845-53	7
1715	Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. 2007 , 5, 1221-8	387
1714	Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. 2007 , 5, 496-501	126
1713	Obesity management. 2007 , 36, 191-210, viii	9
1712	Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. 2007 , 56, 470-5	63
1711	Lack of association of CPT1A polymorphisms or haplotypes on hepatic lipid content or insulin resistance in Japanese individuals with type 2 diabetes mellitus. 2007 , 56, 656-61	17
1710	Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study. 2007 , 56, 792-8	52
1709	Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 2007 , 149, 114-25	26
1708	The effect of citrus flavonoids on the redox state of alimentary-induced fatty liver in rats. 2007 , 21, 274-81	13
1707	Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. 2007 , 30, 734-43	321
1706	Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. 2007 , 132, 282-93	197
1705	Insulin resistance: cause or consequence of nonalcoholic steatohepatitis?. 2007 , 132, 444-6	25
1704	The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. 2007 , 132, 1434-46	115
1703	Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. 2007 , 132, 1947-54	127

1702	The epidemiology of obesity. 2007 , 132, 2087-102	1101
1701	Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. 2007 , 132, 2191-207	242
1700	Bariatric surgery: a review of procedures and outcomes. 2007 , 132, 2253-71	310
1699	Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. 2007 , 5, 388-93	60
1698	Metabolic Outcomes of Bariatric Surgery. 2007 , 388-393	
1697	N. 2007 , 138	
1696	Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. 2007 , 13, 837-44	150
1695	Serum gamma-glutamyltransferase, alanine aminotransferase, and aspartate aminotransferase activity in Iranian healthy blood donor men. 2007 , 13, 889-94	18
1694	Endoscopic and ultrasonographic evaluation before and after Roux-en-Y gastric bypass for morbid obesity. 2007 , 44, 8-13	18
1693	[Non-alcoholic steatohepatitis induced by fast weight loss during the use of intragastric balloon--a case report]. 2007 , 51, 631-4	5
1692	The multifaceted associations of hepatobiliary disease and diabetes. 2007 , 13, 300-12	31
1691	Non Alcoholic Fatty Liver Disease- Is It Always Benign?. 2007 , 25, 144-152	1
1690	Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity. 2007 , 6, 255-261	12
1689	Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse. 2007 , 13, 5635-41	33
1688	CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. 2007 , 45, 1108-17	124
1687	Omega-3 fatty acids and liver disease. 2007 , 45, 841-5	55
1686	Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. 2007 , 45, 1366-74	728
1685	Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. 2007 , 46, 582-9	341

1684	Bioinformatics as tool to identify gene/protein-pathways associated with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. 2007 , 46, 1306; author reply 1306-7	2
1683	Liver disease in adolescents: A cohort study of high-risk individuals. 2007 , 46, 1750-8	32
1682	The liver in celiac disease. 2007 , 46, 1650-8	141
1681	Reply:. 2007 , 46, 1306-1307	
1680	Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. 2008 , 47, 51-8	157
1679	Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. 2008 , 47, 668-76	97
1678	Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. 2008 , 47, 484-92	71
1677	Measurement of liver fat content using selective saturation at 3.0 T. 2007 , 25, 743-8	25
1676	Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units. 2007 , 7, 41	30
1675	Obelix and the trouble of fatty liver disease in childhood. 2007 , 24, 292-294	1
1674	Non-alcoholic fatty liver disease: what is it, when does it occur, and why does it matter?. 2007 , 24, 310-316	0
1673	Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. 2007 , 15, 24-31	93
1672	Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. 2007 , 22, 846-51	36
1671	Essential pathogenic and metabolic differences in steatosis induced by choline or methionine-choline deficient diets in a rat model. 2007 , 22, 1526-33	80
1670	Lifestyle advice in non-alcoholic fatty liver disease. 2007 , 22, 604-5	
1669	What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?. 2007 , 22, 794-800	196
1668	Role of adipocytokines in hepatic fibrogenesis. 2007 , 22 Suppl 1, S87-92	58
1667	Adipose tissue and liver lipid metabolism in obese children: role of the body mass index and the presence of acanthosis nigricans. 2007 , 24, 1192-8	8

1666	Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. 2007 , 22, 778-87	227
1665	How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. 2007 , 22, 788-93	274
1664	Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. 2007 , 14, 714-20	7
1663	Population drinking and liver cirrhosis mortality: is there a link in eastern Europe?. 2007 , 102, 1212-23	34
1662	Review article: Non-alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery. 2007 , 26 Suppl 2, 195-201	82
1661	Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue. 2007 , 31, S15-21	29
1660	Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. 2007 , 27, 220-6	14
1659	The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. 2007 , 27, 708-15	130
1658	Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. 2007 , 27, 764-71	41
1657	Liver: an alarm for the heart?. 2007 , 27, 891-4	64
1656	Prediction of coronary atherosclerotic disease with liver transaminase level. 2007 , 27, 895-900	34
1655	Clinicopathological improvement of non-alcoholic steatohepatitis associated with weight loss during a 14-year follow-up period. 2007 , 27, 1422-7	1
1654	Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. 2007 , 28, 398-403	20
1653	Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis. 2007 , 7, 31	10
1652	Regenerative capacity differs between micro- and macrovesicular hepatic steatosis. 2007 , 59, 205-13	15
1651	Hepatitis C and steatosis. 2007 , 38, 621-7	42
1650	Monitoring liver safety in drug development: the GSK experience. 2007 , 49, 90-100	18
1649	Nonalcoholic fatty liver disease in overweight children and adolescents. 2007 , 96, 1209-13	51

1648	Suppressive effects of germinated buckwheat on development of fatty liver in mice fed with high-fat diet. 2007 , 14, 563-7	23
1647	Dietary habits and nutrient intake in non-alcoholic steatohepatitis. 2007 , 23, 46-52	185
1646	[Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis]. 2007 , 48, 154-63	6
1645	Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men. 2007 , 50, 1024-32	36
1644	Adiposity, inflammation and hyperglycaemia in rural and urban Indian men: Coronary Risk of Insulin Sensitivity in Indian Subjects (CRISIS) Study. 2008 , 51, 39-46	39
1643	The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. 2007 , 52, 2368-74	83
1642	Association among C-reactive protein, Fatty liver disease, and cardiovascular risk. 2007 , 52, 2375-9	25
1641	Hepatic glycogenesis: an underrecognized source of abnormal liver function tests?. 2007 , 52, 936-8	20
1640	Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). 2007 , 52, 2512-9	61
1639	The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. 2007 , 52, 2387-95	84
1638	Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. 2007 , 52, 3455-64	62
1637	Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. 2007 , 42, 375-81	68
1636	High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. 2007 , 42, 573-82	193
1635	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. 2007 , 7, 175-80	46
1634	Nonalcoholic fatty liver disease and cardiovascular disease risk. 2007 , 7, 181-7	28
1633	Pioglitazone and nonalcoholic steatohepatitis. 2007 , 7, 221-2	
1632	Non-alcoholic fatty liver disease and childhood obesity. 2007 , 74, 401-7	31
1631	Comment, en Afrique, gfer les comorbiditš en hpatologie?. 2007 , 1, 63-70	

1630	Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. 2007 , 17, 45-56	44
1629	Effect of high fat diet on the volume of liver and quantitative feature of Kupffer cells in the female rat: a stereological and ultrastructural study. 2007 , 17, 1381-8	31
1628	Metabolic and nutritional status changes after 10% weight loss in severely obese patients treated with laparoscopic surgery vs integrated medical treatment. 2007 , 17, 1592-8	31
1627	Klinische Bedeutung Sinn und Unsinn der Leberbiopsie bei NAFLD. 2007 , 3, 192-201	
1626	Fettleber und Lipidstoffwechsel. 2007 , 3, 184-191	
1625	Modified jejunoileal bypass surgery with biliary diversion for morbid obesity and changes in liver histology during follow-up. 2007 , 11, 1033-8	9
1624	Effect of body mass index on Argatroban therapy during percutaneous coronary intervention. 2008 , 25, 273-9	11
1623	Methionine deficiency and hepatic injury in a dietary steatohepatitis model. 2008 , 53, 767-76	49
1622	Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. 2008 , 53, 1352-7	46
1621	Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. 2008 , 53, 1358-63	36
1620	Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. 2008 , 53, 3218-24	55
1619	Low hepatic stearyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. 2008 , 51, 648-56	78
1618	Impact of obesity, hepatic steatosis, and insulin resistance on hepatitis C treatment outcomes. 2008 , 7, 127-133	1
1617	Correlations of laparoscopy with histology and laboratory studies on liver diseases in bariatric patients. 2008 , 18, 204-11	4
1616	Pentoxifylline: not just for alcoholic hepatitis anymore?. 2008 , 2, 137-9	
1615	Metformin treatment of rats with diet-induced overweight and hypertriglyceridemia decreases plasma triglyceride concentrations, while decreasing triglyceride and increasing ketone body output by the isolated perfused liver. 2008 , 45, 143-5	13
1614	Nonalcoholic fatty liver disease in Japanese patients with severe obesity who received laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) in comparison to non-Japanese patients. 2008 , 43, 86-92	18
1613	Liver diseases and metabolic syndrome. 2008 , 43, 509-18	128

1612	Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. 2008 , 43, 720-8	59
1611	Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). 2008 , 8, 27	53
1610	Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study. 2008 , 8, 44	14
1609	Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). 2008 , 8, 53	60
1608	Liver surgery in the presence of cirrhosis or steatosis: Is morbidity increased?. 2008 , 2, 8	13
1607	Redox mechanisms in hepatic chronic wound healing and fibrogenesis. 2008 , 1, 5	267
1606	Quantitative ATP synthesis in human liver measured by localized 31P spectroscopy using the magnetization transfer experiment. 2008 , 21, 437-43	54
1605	Stearoyl-CoA desaturase: A novel control point of lipid metabolism and insulin sensitivity. 2008 , 110, 93-100	20
1604	High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. 2008 , 47, 677-85	131
1603	The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. 2008 , 47, 1495-503	192
1602	A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. 2008 , 47, 1916-23	115
1601	Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain?. 2008 , 47, 1431-3	52
1600	Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. 2008 , 47, 1924-35	144
1599	Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. 2008 , 48, 109-18	43
1598	Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. 2008 , 48, 442-8	292
1597	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. 2008 , 48, 792-8	481
1596	Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. 2008 , 48, 1477-86	135
1595	Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. 2008 , 48, 1791-8	221

1594	Using controlled clinical trials to learn more about acute drug-induced liver injury. 2008 , 48, 1680-9	84
1593	Pathology of fatty liver: differential diagnosis of non-alcoholic fatty liver disease. 2008 , 14, 586-597	3
1592	Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. 2008 , 29, 698-706	219
1591	ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. 2008 , 16, 770-6	76
1590	Liver steatosis in obese prepubertal children: a possible role of insulin resistance. 2008 , 16, 677-83	37
1589	Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. 2008 , 16, 1355-62	150
1588	Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. 2008 , 32, 381-7	126
1587	Using dynamic gene module map analysis to identify targets that modulate free fatty acid induced cytotoxicity. 2008 , 24, 29-37	9
1586	Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. 2008 , 9, 108-12	136
1585	Macaca radiata (bonnet monkey): a spontaneous model of nonalcoholic fatty liver disease. 2008 , 28, 856-64	10
1584	Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. 2008 , 28, 1026-33	156
1583	Independent and opposite associations of trunk fat and leg fat with liver enzyme levels. 2008 , 28, 1381-8	19
1582	Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet. 2008 , 23, e465-70	50
1581	Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease. 2008 , 23, e457-64	22
1580	Cholesterol and sphingolipids in alcohol-induced liver injury. 2008 , 23 Suppl 1, S9-15	25
1579	Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. 2008 , 23, 1082-8	76
1578	Undiagnosed cirrhosis occurs frequently in the elderly and requires periodic follow ups and medical treatments. 2008 , 8, 198-203	14
1577	Associates of change in liver fat content in the morbidly obese after laparoscopic gastric banding surgery. 2008 , 10, 661-7	30

1576	Relationship between gamma-glutamyltransferase and metabolic syndrome in a Korean population. 2008 , 25, 469-75	22
1575	Relationship between soluble CD40 ligand and gamma-glutamyltransferase concentrations in non-drinking, young Type 1 diabetic individuals. 2008 , 25, 1283-8	1
1574	Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. 2008 , 28, 200-8	93
1573	Systematic review: The evidence base for long-term management of coeliac disease. 2008 , 28, 1042-66	137
1572	Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. 2008 , 584, 118-24	120
1571	Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. 2008 , 588, 316-24	29
1570	The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. 2008 , 8, 667-72	165
1569	Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. 2008 , 115, 141-50	212
1568	Metabolic effects of thyroid hormone derivatives. 2008 , 18, 239-53	181
1567	Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus. 2008 , 57, 1445-51	49
1566	The role of adipokines in liver fibrosis. 2008 , 15, 91-101	90
1565	[Non-alcoholic hepatic steatosis. An update]. 2008 , 40, 419-24	1
1564	Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver disease. 2008 , 68, 323-34	39
1563	Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. 2008 , 134, 85-94	155
1562	Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. 2008 , 134, 424-31	378
1561	Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. 2008 , 134, 1369-75	403
1560	Obesity-induced lymphocyte hyperresponsiveness to chemokines: a new mechanism of Fatty liver inflammation in obese mice. 2008 , 134, 1459-69	63
1559	Comorbilidades del exceso ponderal en el adolescente. 2008 , 55, 41-59	0

1558	Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. 2008 , 40, 132-9	59
1557	A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. 2008 , 40, 200-5	169
1556	Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. 2008 , 40, 194-9	209
1555	Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). 2008 , 40, 371-8	287
1554	The Metabolic Syndrome. 2008 ,	7
1553	Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. 2008 , 103, 1036-42	147
1552	Nonalcoholic fatty liver disease in children. 2008 , 27, 667-76	54
1551	Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. 2008 , 5, 95-106	133
1550	Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. 2008 , 118, 2555-62	245
1549	Handbook of Obesity. 2008 ,	6
1548	The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. 2008 , 82, 983-90	71
1547	[Managing comorbidities in hepatology: toward a more holistic medicine]. 2008 , 37, 1274-80	
1546	Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. 2008 , 29, 58-66	129
1545	Mitochondrial involvement in non-alcoholic steatohepatitis. 2008 , 29, 22-35	78
1544	In vivo confocal laser laparoscopy allows real time subsurface microscopy in animal models of liver disease. 2008 , 48, 91-7	27
1543	Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). 2008 , 48, 471-8	107
1542	Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. 2008 , 48, 628-37	116
1541	Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. 2008 , 49, 123-33	81

1540	Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. 2008 , 49, 417-28	77
1539	Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. 2008 , 49, 600-7	315
1538	Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. 2008 , 14, 72-81	324
1537	Carotid artery intima-media thickness in nonalcoholic fatty liver disease. 2008 , 121, 72-8	164
1536	Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis. 2008 , 18, 545-52	14
1535	Insulin resistance, inflammation, and non-alcoholic fatty liver disease. 2008 , 19, 371-9	334
1534	Alleviative effects of s-allyl cysteine and s-ethyl cysteine on MCD diet-induced hepatotoxicity in mice. 2008 , 46, 3401-6	12
1533	A preliminary investigation of the association between haptoglobin polymorphism, serum ferritin concentration and fatty liver disease. 2008 , 398, 34-8	12
1532	Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. 2008 , 79, 185-90	52
1531	Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD (nonalcoholic fatty liver disease) in obese Korean children. 2008 , 81, 321-6	38
1530	Nonalcoholic Fatty Liver Disease: Pathogenesis, Identification, Progression, and Management. 2008 , 65, 376-384	33
1529	Obesity and nonalcoholic fatty liver disease. 2007 , 65, S57-63	90
1528	Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. 2008 , 57, 1583-91	77
1527	[Basic mechanisms of hepatocellular injury. Role of inflammatory lipid mediators]. 2008 , 31, 682-92	1
1526	Enfermedades hepáticas de origen metabólico. 2008 , 10, 651-659	
1525	Current studies on therapeutic approaches for ischemia/reperfusion injury in steatotic livers. 2008 , 38, 851-9	13
1524	Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. 2008 , 38, 1122-9	186
1523	Gene expression profiling of non-alcoholic steatohepatitis using gene set enrichment analysis. 2008 , 38, 1204-12	22

1522	Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. 2008 , 34, 634-7	95
1521	How to measure hepatic insulin resistance?. 2008 , 34, 664-73	34
1520	Non-invasive diagnosis of steatosis and fibrosis. 2008 , 34, 674-9	50
1519	Disease progression in a patient with nonalcoholic steatohepatitis. 2008 , 107, 816-21	6
1518	Fibrosis and cirrhosis reversibility: clinical features and implications. 2008 , 12, 901-13, x	55
1517	Nonalcoholic fatty liver disease in children: a single center experience. 2008 , 6, 799-802	37
1516	Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. 2008 , 6, 1249-54	124
1515	Metabolic syndrome and cardiovascular disease in the elderly: the Progetto Veneto Anziani (Pro.V.A.) study. 2008 , 20, 47-52	13
1514	Obesity and T2DM in youth. 2008 , 33, 59-72	4
1513	Nonalcoholic fatty liver disease and carotid atherosclerosis in children. 2008 , 63, 423-7	136
1512	Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. 2008 , 103, 1372-9	422
1511	Nonalcoholic steatohepatitis and the metabolic syndrome. 2008 , 6, 1-7	32
1510	Psoriatic arthritis, methotrexate and the liver--are rheumatologists putting their patients at risk?. 2008 , 47, 939-41	12
1509	Statins and sepsis. 2008 , 100, 288-98	58
1508	Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk?. 2008 , 8, 301-7	9
1507	TGFbeta1, TNFalpha, and insulin signaling crosstalk in regulation of the rat cholesterol 7alpha-hydroxylase gene expression. 2008 , 49, 1981-9	22
1506	Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. 2008 , 49, 2513-23	36
1505	SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. 2008 ,	42

1504	Disorders of Energy Balance. 2008 , 788-838	2
1503	Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. 2008 , 31, 165-9	156
1502	Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. 2008 , 57, 655-63	62
1501	Metabolic complications of childhood obesity: identifying and mitigating the risk. 2008 , 31 Suppl 2, S310-6	123
1500	Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. 2008 , 57, 649-54	135
1499	Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice. 2008 , 295, E331-8	55
1498	Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors. 2008 , 295, E692-7	15
1497	A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. 2008 , 294, E969-77	130
1496	Models for non-alcoholic fatty liver disease: a link with vascular risk. 2008 , 14, 378-84	8
1495	Inflammation is associated with liver function markers, independent of other metabolic risk factors in overweight women. 2008 , 8, 73-76	2
1494	Causes and metabolic consequences of Fatty liver. 2008 , 29, 939-60	394
1493	Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. 2008 , 103, 4-13	137
1492	Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. 2008 , 47, 250-7	165
1491	Nuclear factor-kappaB inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy. 2008 , 57, 570-2	17
1490	Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. 2008 , 28, 386-95	205
1489	Inhibition of ADRP prevents diet-induced insulin resistance. 2008 , 295, G621-8	87
1488	Multiple hepatic adenomas associated with liver steatosis at CT and MRI: a case-control study. 2008 , 191, 1430-5	24
1487	Nonalcoholic fatty liver disease: from clinical recognition to treatment. 2008 , 2, 59-79	10

1486	Plasma fetuin-A levels and the risk of type 2 diabetes. 2008 , 57, 2762-7	277
1485	Serum liver enzyme activities in healthy Miniature Schnauzers with and without hypertriglyceridemia. 2008 , 232, 63-7	23
1484	Management of Obesity and Childhood Obstructive Sleep Apnea: The Dangerous Combination. 2008 , 4, 338-343	1
1483	Metabolic Syndrome Is Associated with Greater Histologic Severity, Higher Carbohydrate, and Lower Fat Diet in Patients with NAFLD. 2008 , 2008, 485-486	
1482	Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. 2008 , 47, 68-75	60
1481	Is adipose tissue lipolysis always an adaptive response to starvation?: implications for non-alcoholic fatty liver disease. 2008 , 114, 543-5	26
1480	Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis. 2008 ,	7
1479	Differential response of vascular hepatocyte growth factor concentration and lipid accumulation between telmisartan and losartan in ApoE-deficient mice. 2008 , 1, 657-61	6
1478	Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. 2008 , 16, 71-5	39
1477	Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. 2008 , 20, 1205-13	18
1476	Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis. 2008 , 4, 100-108	1
1475	Nutrition and metabolism: non-alcoholic fatty liver disease - pathogenesis, cardiovascular risk and therapy. 2008 , 19, 92-4	6
1474	The role of increased gastrointestinal alcohol production in patients with the metabolic syndrome: Implications for the pathogenesis of non-alcoholic fatty liver disease. 2008 , 13, 48-56	1
1473	Declining frequency of liver enzyme abnormalities with statins: experience from general practice in Jerusalem. 2008 , 20, 1002-5	2
1472	Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury. 2008 , 138, 323-31	122
1471	Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease. 2008 , 11, 620-5	14
1470	Association of raised liver transaminases with physical inactivity, increased waist-hip ratio, and other metabolic morbidities in severely obese children. 2008 , 47, 172-8	15
1469	MRI in identifying hepatic steatosis in obese children and relation to ultrasonography and metabolic findings. 2008 , 47, 493-9	29

1468	Fatty liver and HDL-cholesterol: just a matter of quantity?. 2008 , 3, 225-227	
1467	Metabolic complications of obesity in childhood and adolescence: more than just diabetes. 2008 , 15, 21-9	111
1466	Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes. 2008 , 20, 399-403	17
1465	Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. 2008 , 19, 295-300	183
1464	. 2008 ,	2
1463	Effects of Alpha-lipoic Acid on SREBP-1c Expression in HepG2 Cells. 2008 , 23, 27	1
1462	Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. 2008 , 4, 575-96	177
1461	[Hepatoprotective effect of diheptanoin and tritreptanoin chronic consumption against steatosis in rats]. 2008 , 52, 1145-55	5
1460	Histological Changes on Liver Glycogen Storage in Mice (Mus musculus) Caused by Unbalanced Diets. 2008 , 1, 69-75	2
1459	Non-alcoholic fatty liver disease in the Philippines: comparable with other nations?. 2008 , 14, 913-7	17
1458	Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. 2008 , 14, 2888-93	57
1457	Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. 2008 , 14, 6395-400	151
1456	Soft drink consumption linked with fatty liver in the absence of traditional risk factors. 2008 , 22, 811-6	219
1455	The Enteric Flora in Intestinal Failure. 167-184	2
1454	Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. 2008 , 109, 137-48	135
1453	Leptin in nonalcoholic fatty liver disease. 2008 , 7, 249-254	34
1452	Liver biochemistry abnormalities in a quaternary care lipid clinic database. 2008 , 7, 63-66	3
1451	. 2008 ,	7

1450	Long-term feeding of a synthetic diet rich in disaccharides induces hepatic fibrosis in nonalcoholic fatty liver disease in Zucker rats. 2009 , 25,	1
1449	Molecular Basis of Liver Disease. 2009 , 395-419	
1448	Fatty Liver Disease. 2009 , 1087-1114	7
1447	Use of Obesity Biomarkers in Cardiovascular Epidemiology. 2009 , 26, 247-263	20
1446	Corneal arcus and cardiovascular risk factors in middle-aged subjects in Taiwan. 2009 , 338, 268-72	5
1445	[Model of experimental nonalcoholic steatohepatitis from use of methionine and choline deficient diet]. 2009 , 46, 69-74	6
1444	Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). 2009 , 8, S4-S8	199
1443	Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms. 2009 , 1, 72-8	102
1442	Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). 2009 , 8, 89-94	33
1441	Surgical morbidity in severely obese liver transplant recipients - A single Canadian Centre Experience. 2009 , 8, 38-40	39
1440	Metabolic syndrome and non-alcoholic fatty liver disease. 2009 , 8, S18-S24	108
1439	Nonalcoholic fatty liver disease and its association with cardiovascular disease. 2009 , 8, S40-S43	48
1438	Adipokines in a group of mexican patients with nonalcoholic steatohepatitis. 2009 , 8, 123-128	16
1437	NASH and cryptogenic cirrhosis: A histological analysis. 2009 , 8, 346-352	90
1436	Alcohol-related and hepatocellular cancer deaths by country of birth in England and Wales: analysis of mortality and census data. 2009 , 31, 250-7	16
1435	Salt-inducible kinase regulates hepatic lipogenesis by controlling SREBP-1c phosphorylation. 2009 , 284, 10446-52	43
1434	Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. 2009 , 58, 2616-23	261
1433	The correlation between sonographic diagnosis and laparoscopic observations on fatty liver. 2009 , 19, 163-9	2

1432	The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. 2009 , 104, 64-9	58
1431	Antilipogenic and hypolipidemic effects of ethanol extracts from two variants of <i>Artemisia princeps</i> Pampanini in obese diabetic mice. 2009 , 12, 1238-44	14
1430	Chronic liver disease among Alaska-Native people, 2003-2004. 2009 , 104, 363-70	25
1429	Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. 2009 , 47, 1055-62	35
1428	Triglycerides and alanine aminotransferase as screening markers for suspected fatty liver disease in obese children and adolescents. 2009 , 71, 83-8	6
1427	Risk factors for non-alcoholic fatty liver disease in obese children. 2009 , 72, 63-4	4
1426	Childhood NAFLD: a ticking time-bomb?. 2009 , 58, 1442	17
1425	The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. 2009 , 2, 157-63	107
1424	Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis. 2009 , 234, 10-6	29
1423	Obesity, hepatic metabolism and disease. 2009 , 63, 163-72; discussion 172-6, 259-68	8
1422	Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. 2009 , 94, 4103-6	75
1421	Role of ectopic fat in the pathogenesis of insulin resistance. 2009 , 4, 457-464	4
1420	Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics. 2009 , 64, 483-93	26
1419	Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population. 2009 , 3, 94-101	
1418	Insulin-like growth factor and epidermal growth factor treatment: new approaches to protecting steatotic livers against ischemia-reperfusion injury. 2009 , 150, 3153-61	24
1417	Acute liver failure in a metropolitan area in Germany: a retrospective study (2002 - 2008). 2009 , 47, 807-13	52
1416	Computer-assisted ultrasound analysis of liver echogenicity in obese and normal-weight children. 2009 , 192, W201-5	20
1415	MR spectroscopy of the liver: principles and clinical applications. 2009 , 29, 1653-64	77

1414	Gender-specific prevalences of fatty liver in obese children and adolescents: roles of body fat distribution, sex steroids, and insulin resistance. 2009 , 94, 3872-81	93
1413	Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. 2009 , 150, 4502-11	127
1412	Reduced insulin-mediated inhibition of VLDL secretion upon pharmacological activation of the liver X receptor in mice. 2009 , 50, 1374-83	21
1411	Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. 2009 , 9, 299-314	209
1410	Effects of exercise training on hepatic microsomal triglyceride transfer protein content in rats. 2009 , 41, 287-93	19
1409	Science to practice: can MR elastography be used to detect early steatohepatitis in fatty liver disease?. 2009 , 253, 1-3	26
1408	Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. 2009 , 2009, 831670	87
1407	Impact of cholesterol metabolism and the LXRAalpha-SREBP-1c pathway on nonalcoholic fatty liver disease. 2009 , 23, 603-8	52
1406	PPAR and liver injury in HIV-infected patients. 2009 , 2009, 906167	12
1405	Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. 2009 , 297, E1179-86	125
1404	Metabolic consequences of sleep-disordered breathing. 2009 , 50, 289-306	69
1403	Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. 2009 , 44, 6-14	48
1402	Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. 2009 , 58, 1419-25	53
1401	Nonviral Hepatitis. 2009 , 22, 388-404	5
1400	Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. 2009 , 250, 95-102	148
1399	Probiotic yogurt in the elderly with intestinal bacterial overgrowth: endotoxaemia and innate immune functions. 2009 , 101, 961-6	60
1398	High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. 2009 , 58, 1281-8	192
1397	Mcl-1 degradation during hepatocyte lipoapoptosis. 2009 , 284, 30039-48	34

1396	Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging. 2009 , 250, 130-6	100
1395	Association of elevated serum alanine aminotransferase with metabolic factors in obese children: sex-related analysis. 2009 , 58, 368-72	51
1394	Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice. 2009 , 58, 901-8	12
1393	Induction of non-alcoholic fatty liver disease and insulin resistance by feeding a high-fat diet in rats: does coenzyme Q monomethyl ether have a modulatory effect?. 2009 , 25, 1157-68	38
1392	Outcome after liver transplantation for NASH cirrhosis. 2009 , 9, 782-93	157
1391	High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. 2009 , 40, 571-5	50
1390	Curcumin ameliorates rabbits's steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. 2009 , 47, 924-31	58
1389	[Diagnosis and management of non alcoholic fatty liver disease]. 2009 , 33, 413-24	3
1388	[Non-alcoholic fatty liver disease: overview of the natural history]. 2009 , 33, 398-404	3
1387	[Noninvasive tools for the diagnosis of steatosis and fibrosis in patients with NAFLD]. 2009 , 33, 405-12	2
1386	Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best?. 2009 , 33, 110-5	62
1385	Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. 2009 , 49, 80-6	325
1384	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. 2009 , 49, 306-17	406
1383	VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. 2009 , 49, 989-97	186
1382	Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. 2009 , 49, 851-9	399
1381	Burning hepatic fat: therapeutic potential for liver-specific thymomimetics in the treatment of nonalcoholic fatty liver disease. 2009 , 49, 348-51	20
1380	Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. 2009 , 49, 1636-44	42
1379	Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link?. 2009 , 49, 1896-903	121

1378	Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. 2009 , 50, 56-67	156
1377	Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. 2009 , 50, 434-42	111
1376	Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. 2009 , 50, 1072-8	476
1375	Abnormal hepatic energy homeostasis in type 2 diabetes. 2009 , 50, 1079-86	137
1374	Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. 2009 , 50, 1113-20	139
1373	The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. 2009 , 115, 3189-95	62
1372	Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. 2009 , 115, 5651-61	304
1371	The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. 2009 , 25, 150-5	31
1370	Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content. 2009 , 30, 444-8	59
1369	Subnormothermic machine perfusion protects steatotic livers against preservation injury: a potential for donor pool increase?. 2009 , 15, 20-9	90
1368	Development of an in vitro cell culture model of hepatic steatosis using hepatocyte-derived reporter cells. 2009 , 102, 1466-74	35
1367	Nonalcoholic fatty liver disease during valproate therapy. 2009 , 168, 1391-4	18
1366	Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. 2009 , 16, 137-44	107
1365	Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. 2009 , 44, 608-14	31
1364	Nonalcoholic fatty liver is a risk factor for postprandial hyperglycemia, but not for impaired fasting glucose. 2009 , 44, 757-64	11
1363	Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. 2009 , 44, 1064-70	36
1362	The intertwined correlations among non-alcoholic fatty liver disease, atherosclerosis, and metabolic syndrome. 2009 , 44, 1162-4	5
1361	MRI findings in nonalcoholic steatohepatitis: correlation with histopathology and clinical staging. 2009 , 27, 976-87	17

1360	Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status. 2009 , 20, 1985-96	19
1359	Pathogenesis and clinical significance of liver injury in celiac disease. 2009 , 36, 62-70	48
1358	Diabetes und Fettleber. 2009 , 5, 653-665	0
1357	Elevated concentrations of liver enzymes and ferritin identify a new phenotype of insulin resistance: effect of weight loss after gastric banding. 2009 , 19, 80-6	15
1356	The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory. 2009 , 19, 1678-84	26
1355	Nonalcoholic fatty liver disease in children living in the obeseogenic society. 2009 , 5, 245-54	23
1354	Molecular mechanisms involved in NAFLD progression. 2009 , 87, 679-95	207
1353	Genetic factors for resistance to diet-induced obesity and associated metabolic traits on mouse chromosome 17. 2009 , 20, 71-82	33
1352	Modern strategies to identify new molecular targets for the treatment of liver diseases: The promising role of Proteomics and Redox Proteomics investigations. 2009 , 3, 242-62	9
1351	Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. 2009 , 9, 16	31
1350	Visceral obesity and the risk of Barrett's esophagus in Japanese patients with non-alcoholic fatty liver disease. 2009 , 9, 56	36
1349	Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. 2009 , 17, 370-4	14
1348	Liver NF-kappaB and AP-1 DNA binding in obese patients. 2009 , 17, 973-9	74
1347	Association of monocyte chemoattractant protein-1 with adipocyte number, insulin resistance and liver function markers. 2009 , 38, 418-24	12
1346	AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. 2009 , 196, 81-98	334
1345	Polymorphism of human leptin receptor gene is associated with type 2 diabetic patients complicated with non-alcoholic fatty liver disease in China. 2009 , 24, 228-32	30
1344	Marked elevation of serum mitochondrion-derived markers in mild models of non-alcoholic steatohepatitis in rats. 2009 , 24, 270-7	7
1343	Hyperadiponectinemia in alcoholic liver disease: friend or foe?. 2009 , 24, 507-8	2

1342	Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. 2009 , 24, 1284-8	136
1341	Open-labeled pilot study of cysteine-rich whey protein isolate supplementation for nonalcoholic steatohepatitis patients. 2009 , 24, 1045-50	36
1340	Elevated fasting plasma C-peptide occurs in non-diabetic individuals with fatty liver, irrespective of insulin resistance. 2009 , 26, 847-54	6
1339	Nonalcoholic fatty liver disease: quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy. 2009 , 10, 315-20	34
1338	Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance. 2009 , 1, 278-87	78
1337	Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. 2009 , 29, 113-9	353
1336	Association between combinations of glutathione-S-transferase M1, T1 and P1 genotypes and non-alcoholic fatty liver disease. 2009 , 29, 164-8	21
1335	Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. 2009 , 29, 525-9	36
1334	Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. 2009 , 29, 1078-85	58
1333	Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. 2009 , 29, 1431-8	102
1332	Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. 2010 , 30, 850-9	65
1331	Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. 2009 , 20, 765-70	47
1330	Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods. 2009 , 19, 2033-40	80
1329	UCP1 -3826 AG+GG genotypes, adiponectin, and leptin/adiponectin ratio in severe obesity. 2009 , 32, 525-9	22
1328	Advanced MRI methods for assessment of chronic liver disease. 2009 , 193, 14-27	144
1327	Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. 2009 , 23, 1946-57	448
1326	Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. 2009 , 84, 84-91	132
1325	Oxidative stress and thyroid hormones in patients with liver diseases. 2009 , 20, 703-8	47

1324	Ornithine carbamyltransferase is a sensitive marker for alcohol-induced liver injury. 2009 , 401, 100-4	17
1323	Paraoxonase: a multifaceted biomolecule. 2009 , 410, 1-12	97
1322	Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. 2009 , 1792, 1080-6	157
1321	Suppression of hepatic fat accumulation by highly purified eicosapentaenoic acid prevents the progression of d-galactosamine-induced hepatitis in mice fed with a high-fat/high-sucrose diet. 2009 , 1791, 281-8	11
1320	[Utility of Fibroscan in the evaluation of liver fibrosis]. 2009 , 32, 415-23	6
1319	Hepatic lipid metabolism and non-alcoholic fatty liver disease. 2009 , 19, 291-302	213
1318	Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. 2009 , 50, 797-804	101
1317	Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. 2009 , 50, 789-96	239
1316	Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. 2009 , 51, 371-9	393
1315	Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. 2009 , 51, 380-8	220
1314	Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. 2009 , 51, 931-8	37
1313	MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. 2009 , 41, 289-97	75
1312	Liver HCV-antigens and steatosis in chronic hepatitis C: role of different genotypes. 2009 , 41, 659-64	
1311	Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. 2009 , 41, 749-52	37
1310	Serum adipokine profile in Indian men with nonalcoholic steatohepatitis: Serum adiponectin is paradoxically decreased in lean vs. obese patients. 2009 , 3, 198-203	1
1309	The big burden of obesity. 2009 , 70, 752-7	20
1308	Abdominal adiposity and liver fat content 3 and 12 months after gastric banding surgery. 2009 , 58, 753-8	31
1307	Higher liver fat content among Japanese in Japan compared with non-Hispanic whites in the United States. 2009 , 58, 1200-7	50

1306	Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. 2009 , 154, 194-201	33
1305	New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). 2009 , 41, 265-78	95
1304	Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. 2009 , 44, 471-7	142
1303	High- or low-carbohydrate diets: which is better for weight loss, insulin resistance, and fatty livers?. 2009 , 136, 1490-2	23
1302	Genetics of common obesity and nonalcoholic fatty liver disease. 2009 , 136, 1492-5	16
1301	Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. 2009 , 137, 865-72	469
1300	c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. 2009 , 137, 1467-1477.e5	141
1299	Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. 2009 , 32, 787-800	35
1298	Adherence to the Mediterranean diet moderates the association of aminotransferases with the prevalence of the metabolic syndrome; the ATTICA study. 2009 , 6, 30	29
1297	Encyclopedia of Molecular Mechanisms of Disease. 2009 , 665-665	
1296	Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. 2009 , 30, 1-50	282
1295	Insulin Resistance. 2009 ,	
1294	Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. 2009 , 94, 3842-8	141
1293	Liver Transplantation. 2009 ,	1
1292	Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. 2009 , 3, 445-51	257
1291	Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. 2009 , 7, 800-6	52
1290	Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. 2009 , 44, 853-60	224
1289	The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. 2009 , 58, 1538-44	452

1288	Quantitative assessment of hepatic fat of intact liver tissues with coherent anti-stokes Raman scattering microscopy. 2009 , 81, 1496-504	45
1287	Histopathological and ultrastructural studies on the effects of electromagnetic fields on the liver of preincubated white Leghorn chicken embryo. 2009 , 28, 391-413	15
1286	Postgraduate Courses. 2009 , 44, 1-41	2
1285	The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. 2009 , 203, 581-6	92
1284	Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. 2009 , 204, 521-5	103
1283	Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. 2009 , 50, 140-9	60
1282	Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. 2009 , 116, 403-13	29
1281	Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. 2009 , 174, 1329-37	48
1280	Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. 2009 , 10, 278-86	125
1279	Prevalence of metabolic syndrome and its associations with other metabolic disorders and cardiovascular changes in health examination population in Beijing. 2009 , 24, 227-30	7
1278	Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearyl-CoA desaturase. 2009 , 284, 5637-44	287
1277	Assessment of hepatic steatosis and hepatic tissue blood flow by xenon computed tomography in nonalcoholic steatohepatitis. 2009 , 39, 31-9	15
1276	Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. 2009 , 39, 366-73	109
1275	Influence of inducible nitric oxide synthase polymorphisms in Japanese patients with non-alcoholic fatty liver disease. 2009 , 39, 963-71	22
1274	Apoptosis and cytokines in non-alcoholic steatohepatitis. 2009 , 13, 565-80	95
1273	Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed. 2009 , 38, 549-63	18
1272	Evaluation of the asymptomatic athlete with hepatic and urinalysis abnormalities. 2009 , 8, 77-84	3
1271	Methods for assessing intrahepatic fat content and steatosis. 2009 , 12, 474-81	33

1270	Children's toxicology from bench to bed--Liver Injury (2): Mechanism of antioxidant therapy for nonalcoholic fatty liver disease. 2009 , 34 Suppl 2, SP223-8	3
1269	Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. 2009 , 337, 98-102	53
1268	Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. 2009 , 15, 4387-91	40
1267	Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. 2009 , 53, 201-12	61
1266	Flaxseed oil prevents trans-10, cis-12-conjugated linoleic acid-induced insulin resistance in mice. 2009 , 101, 701-8	36
1265	Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults. 2009 , 48, 597-603	25
1264	Metabolic disturbances in non-alcoholic fatty liver disease. 2009 , 116, 539-64	192
1263	Children's toxicology from bench to bed--Liver Injury (3): Oxidative stress and anti-oxidant systems in liver of patients with Wilson disease. 2009 , 34 Suppl 2, SP229-36	15
1262	Nonalcoholic fatty liver disease in children. 2009 , 6, 83-91	3
1261	Influence of lifestyle measures on hypertriglyceridaemia. 2009 , 10, 344-55	6
1260	Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. 2010 , 22, 192-8	20
1259	Role of adipocytokines in hepatic fibrosis. 2010 , 16, 1929-40	24
1258	The importance of fatty liver disease in clinical practice. 2010 , 69, 518-27	13
1257	Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors. 2010 , 53, 278; author reply 278-81	4
1256	Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. 2010 , 298, G746-54	40
1255	Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. 2010 , 21, 247-52	62
1254	The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. 2010 , 20, 1-8	67
1253	Hemostatic alterations in fatty liver disease. 2010 , 21, 325-7	8

1252	Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation. 2010 , 13, 391-6	24
1251	Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. 2010 , 22, 18-23	89
1250	Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. 2010 , 22, 474-80	26
1249	The role of nutritional profile in the orexigenic neuropeptide secretion in nonalcoholic fatty liver disease obese adolescents. 2010 , 22, 557-63	17
1248	Treatment with omega-3 fatty acids but not exendin-4 improves hepatic steatosis. 2010 , 22, 1245-52	9
1247	Reply to "Nonalcoholic Fatty Liver Disease Among HIV-Infected Persons" 2010 , 53, 278-281	1
1246	HIV infection: an independent risk factor of peripheral arterial disease. 2010 , 53, 276-8	19
1245	Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 2010 , 44, e87-95	35
1244	Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. 2010 , 22, 24-32	135
1243	Diagnostic performance and accuracy of 3-D spoiled gradient-dual-echo MRI with water- and fat-signal separation in liver-fat quantification: comparison to liver biopsy. 2010 , 45, 465-70	31
1242	Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. 2010 , 28, 1699-707	84
1241	Alleviation of hepatic oxidative stress by Chinese herbal medicine Yin-Chen-Hao-Tang in obese mice with steatosis. 2010 , 25, 837-44	30
1240	Liver fat change in obese children after a 1-year nutrition-behavior intervention. 2010 , 51, 331-5	33
1239	Challenges of abdominal organ transplant in obesity. 2010 , 103, 532-40	22
1238	Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. 2010 ,	4
1237	Mammalian target of the rapamycin pathway is involved in non-alcoholic fatty liver disease. 2010 , 3, 909-15	18
1236	Trafficking and partitioning of fatty acids: the transition from fasted to fed state. 2010 , 5, 131-144	15
1235	Differentiation between true focal liver lesions and pseudolesions in patients with fatty liver: evaluation of helical CT criteria. 2010 , 20, 1726-37	11

1234	Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". 2010 , 105, 613-20	148
1233	Safety of liver resections in obese and overweight patients. 2010 , 34, 2960-8	54
1232	Steatosis hepatis. 2010 , 158, 1070-1076	1
1231	Continuous positive airway pressure improves sleep apnea associated fatty liver. 2010 , 188, 301-7	45
1230	Metabolic predictors for early identification of fatty liver using doppler and B-mode ultrasonography in overweight and obese adolescents. 2010 , 169, 1345-52	5
1229	Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome?. 2010 , 47, 5-14	66
1228	Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. 2010 , 45, 426-34	29
1227	The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity. 2010 , 45, 646-55	36
1226	Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet. 2010 , 45, 1247-54	29
1225	Nonalcoholic fatty liver disease in India - a lot done, yet more required!. 2010 , 29, 217-25	69
1224	Qushi Huayu Decoction (?????) inhibits protein and gene expression of cathepsin B in HepG2 cells induced by free fatty acids. 2010 , 16, 518-24	7
1223	Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. 2010 , 20, 1400-7	15
1222	A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. 2010 , 20, 685-91	42
1221	Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. 2010 , 55, 808-14	61
1220	The effects of a fat- and sugar-enriched diet and chronic stress on nonalcoholic fatty liver disease in male Wistar rats. 2010 , 55, 2227-36	27
1219	The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. 2010 , 55, 2644-50	85
1218	Nonalcoholic fatty liver disease: a review and update. 2010 , 55, 560-78	245
1217	Serum aminotransferase changes with significant weight loss: sex and age effects. 2010 , 59, 177-85	4

1216	The role of proliferator-activated receptor gamma coactivator-1alpha in the fatty-acid-dependent transcriptional control of interleukin-10 in hepatic cells of rodents. 2010 , 59, 215-23	16
1215	Obesity and diabetic hyperglycemia were associated with serum alanine aminotransferase activity in patients with hepatitis B infection. 2010 , 59, 486-91	16
1214	The possible role of liver steatosis in defining metabolic syndrome in prepubertal children. 2010 , 59, 671-6	25
1213	Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. 2010 , 59, 1092-105	78
1212	Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. 2010 , 59, 1327-30	82
1211	Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase. 2010 , 92, 54-61	18
1210	Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. 2010 , 245, 326-34	136
1209	Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. 2010 , 60, 87-92	13
1208	Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. 2010 , 184, 376-87	65
1207	Multinodular fatty sparing. 2010 , 34, 651-2	
1206	Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. 2010 , 210, 515-26	30
1205	Higher levels of alanine aminotransferase within the reference range predict unhealthy metabolic phenotypes of obesity in normoglycemic first-degree relatives of patients with type 2 diabetes mellitus. 2010 , 12, 301-8	7
1204	Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. 2010 , 51, 445-53	260
1203	Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. 2010 , 51, 121-9	823
1202	5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. 2010 , 51, 817-27	70
1201	The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. 2010 , 51, 1972-8	853
1200	The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. 2010 , 52, 894-903	333
1199	A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. 2010 , 52, 1281-90	160

1198	A protective role for CD154 in hepatic steatosis in mice. 2010 , 52, 1968-79	23
1197	Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. 2010 , 26, 187-92	24
1196	The Role of Biobanks for the Understanding of GeneEnvironment Interactions. 2010 , 51-62	
1195	Exercise training increases hepatic endoplasmic reticulum (er) stress protein expression in MTP-inhibited high-fat fed rats. 2010 , 28, 202-10	21
1194	Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. 2010 , 97, 1331-9	185
1193	Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection (Br J Surg 2010; 97: 1331-1339). 2010 , 97, 1339	2
1192	Noninvasive quantification of hepatic steatosis in rats using 3.0 T 1H-magnetic resonance spectroscopy. 2010 , 32, 148-54	24
1191	Improved rat steatotic and nonsteatotic liver preservation by the addition of epidermal growth factor and insulin-like growth factor-I to University of Wisconsin solution. 2010 , 16, 1098-111	18
1190	Dietary β -carotene and α -tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. 2010 , 21, 1200-6	56
1189	Nonalcoholic fatty liver disease. 2010 , 24, 695-708	140
1188	Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. 2010 , 11, 172	110
1187	Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. 2010 , 30, 365-75	33
1186	Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury. 2011 , 50, 213-21	45
1185	Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. 2010 , 64, 968-83	32
1184	Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. 2010 , 31, 396-406	64
1183	Increased soluble leptin receptor levels in morbidly obese patients with insulin resistance and nonalcoholic fatty liver disease. 2010 , 18, 2268-73	24
1182	Berry meals and risk factors associated with metabolic syndrome. 2010 , 64, 614-21	39
1181	Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. 2010 , 34, 190-4	141

1180	Obesity, overweight and liver disease in the Midspan prospective cohort studies. 2010 , 34, 1051-9	19
1179	Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. 2010 , 34, 899-907	49
1178	Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. 2010 , 34, 1255-64	84
1177	Reversibility of fibrosis, inflammation, and endoplasmic reticulum stress in the liver of rats fed a methionine-choline-deficient diet. 2010 , 90, 245-56	40
1176	Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. 2010 , 25, 156-63	116
1175	Serum ornithine carbamyltransferase reflects hepatic damage in diabetic obese mice. 2010 , 25, 413-9	0
1174	Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis. 2010 , 25, 613-8	24
1173	Electron microscopic findings in non-alcoholic fatty liver disease: is there a difference between hepatosteatosis and steatohepatitis?. 2010 , 25, 619-26	24
1172	A fresh look at NASH pathogenesis. Part 1: the metabolic movers. 2010 , 25, 672-90	132
1171	Nonalcoholic fatty liver disease in asymptomatic obese women. 2010 , 9, 144-149	8
1170	[Patomechanisms of hepatic steatosis]. 2010 , 151, 323-9	0
1169	Soft drinks consumption and nonalcoholic fatty liver disease. 2010 , 16, 2579-88	125
1168	Resolution of adipose tissue inflammation. 2010 , 10, 832-56	46
1167	Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery. 2010 , 47, 170-3	18
1166	[Nonalcoholic fatty liver disease]. 2010 , 56, 6-14	7
1165	The Liver. 2010 , 635-644	1
1164	Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review. 2010 , 3, 43-51	9
1163	Clinical characteristics associated with hepatic steatosis on ultrasonography in patients with elevated alanine aminotransferase. 2010 , 128, 342-7	7

1162	Cytoprotective and suicidal signaling in oxidative stress. 2010 , 43,	8
1161	Depressive Conditions in Relation to Asthma Severity and Control. 2010 , 69, 265	3
1160	The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis. 2010 , 47, 86-92	9
1159	Roles of liver innate immune cells in nonalcoholic fatty liver disease. 2010 , 16, 4652-60	67
1158	The role of cytokines in non-alcoholic fatty liver disease. 2010 , 28, 179-85	173
1157	Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice. 2010 , 391, 1441-9	19
1156	Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. 2010 , 171, 1195-202	67
1155	Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. 2010 , 26, 477-81	23
1154	A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. 2010 , 51, 500-13	54
1153	Palmitate protects hepatocytes from oxidative stress and triacylglyceride accumulation by stimulation of nitric oxide synthesis in the presence of high glucose and insulin concentration. 2010 , 44, 1425-34	3
1152	Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity. 2010 , 30, 1043-50	45
1151	Grape seed extract to improve liver function in patients with nonalcoholic fatty liver change. 2010 , 16, 194-7	22
1150	Persistent organic pollutant exposure leads to insulin resistance syndrome. 2010 , 118, 465-71	282
1149	Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression. 2010 , 31, 1367-75	18
1148	Herbal Medicine and Nonalcoholic Fatty Liver Disease. 2010 , 16, 15-21	2
1147	Paediatric non-alcoholic fatty liver disease. 2010 , 59, 561-4	14
1146	Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. 2010 , 67, 665-70	52
1145	Elevated liver enzymes in metabolic syndrome are associated with coronary stenosis in a Tunisian population. 2010 , 8, 249-54	3

1144	Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. 2010 , 285, 18528-36	159
1143	A novel non-alcoholic steatohepatitis animal model featured with insulin resistance, hepatic inflammation and fibrosis. 2010 , 45, 1360-71	10
1142	Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. 2010 , 105, 2389-95	75
1141	Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. 2010 , 61, 792-802	94
1140	Caso clínico-radiológico: Esteatosis hepática y sus manifestaciones en los distintos métodos de imágenes. 2010 , 21, 857-860	
1139	Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. 2010 , 285, 33652-61	273
1138	5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. 2010 , 184, 3978-87	111
1137	Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. 2010 , 38, 2293-301	142
1136	Hepatitis C and hepatic steatosis. 2010 , 103, 293-303	11
1135	Association of non-alcoholic fatty liver disease with diabetic microvascular and macrovascular complications in South Indian diabetic subjects. 2010 , 30, 208	9
1134	Extracellular signal-regulated kinases 1/2 suppression aggravates transforming growth factor-beta1 hepatotoxicity: a potential mechanism for liver injury in methionine-choline deficient-diet-fed mice. 2010 , 235, 1347-55	8
1133	Associations of metabolic parameters and ethanol consumption with messenger RNA expression of clock genes in healthy men. 2010 , 27, 194-203	25
1132	Effect of bezafibrate on hepatic oxidative stress: comparison between conventional experimental doses and clinically-relevant doses in mice. 2010 , 15, 123-30	10
1131	Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 2010 , 51, 3046-54	194
1130	Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. 2010 , 299, G1068-77	106
1129	Inflammatory mediators of hepatic steatosis. 2010 , 2010, 837419	70
1128	Environmental and genetic determinants of fatty liver in humans. 2010 , 28, 169-78	29
1127	Leptin: the prototypic adipocytokine and its role in NAFLD. 2010 , 16, 1902-12	46

1126	Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. 2010 , 256, 159-68	227
1125	Novel insights into the pathophysiology of nonalcoholic fatty liver disease. 2010 , 30, 391-401	88
1124	Nonalcoholic steatohepatitis: risk factors and diagnosis. 2010 , 4, 623-35	38
1123	Carotid intima-media thickness and liver histology in hemodialysis patients with nonalcoholic fatty liver disease. 2010 , 19, e132-e137	1
1122	Radiation Sensitivity and Tumor Susceptibility in ATM Phospho-Mutant ATF2 Mice. 2010 , 1, 316-330	15
1121	Investigating mildly abnormal serum aminotransferase values. 2010 , 341, c4039	18
1120	Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. 2010 , 340, c912	136
1119	Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. 2010 , 340, c1240	252
1118	Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. 2010 , 16, 1913-20	100
1117	Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. 2010 , 256, 640-7	283
1116	Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. 2010 , 95, 3332-41	45
1115	Insulin resistance in nonalcoholic fatty liver disease. 2010 , 16, 1941-51	238
1114	Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. 2010 , 194, 623-8	148
1113	Sequential changes of serum aminotransferase levels in severely obese patients after losing weight through enrollment in a behavioral weight loss program. 2010 , 122, 206-12	3
1112	Presence of coronary plaques in patients with nonalcoholic fatty liver disease. 2010 , 254, 393-400	145
1111	Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease. 2010 , 8, 1062-9	16
1110	[Hepatic lesions induced by systemic chemotherapy for digestive cancer]. 2010 , 30, 421-5	4
1109	Epidemiology of non-alcoholic fatty liver disease. 2010 , 28, 155-61	635

1108	Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age. 2010 , 70, 554-60		8
1107	Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. 2010 , 42, 503-8		493
1106	Insulin resistance, adipose depots and gut: interactions and pathological implications. 2010 , 42, 310-9		20
1105	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. 2010 , 42, 272-82		159
1104	C-reactive protein mediates the association of liver fat and carotid intima-media thickness in healthy men and men with the metabolic syndrome and/or uncomplicated type 2 diabetes. 2010 , 4, 160-164		
1103	Serum cholinesterase activity in the diagnosis of nonalcoholic fatty liver disease in type 2 diabetic patients. 2010 , 17, 29-32		4
1102	Repetitive orogastric gavage affects the phenotype of diet-induced obese mice. 2010 , 100, 387-93		25
1101	Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. <i>New England Journal of Medicine</i> , 2010 , 363, 1341-50	59.2	1353
1100	Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. 2010 , 2, 65		22
1099	Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. 2010 , 25, 212-20		100
1098	Serum resistin levels in nonalcoholic fatty liver disease and their relationship to severity of liver disease. 2010 , 15, 53-56		6
1097	Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. 2010 , 52, 903-12		47
1096	Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice. 2010 , 52, 913-20		225
1095	Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. 2010 , 52, 586-93		177
1094	Impaired liver regeneration of steatotic rats after portal vein ligation: a particular emphasis on (99m)Tc-DISIDA scintigraphy and adiponectin signaling. 2010 , 52, 540-9		8
1093	Near-infrared confocal imaging during mini-laparoscopy: a novel rigid endomicroscope with increased imaging plane depth. 2010 , 53, 84-90		55
1092	Pro-coagulant imbalance in patients with chronic liver disease. 2010 , 53, 586-7		8
1091	A position statement on NAFLD/NASH based on the EASL 2009 special conference. 2010 , 53, 372-84		726

1090	Non-alcoholic fatty liver disease, alcohol intake and psoriasis. 2010 , 53, 587	5
1089	Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens. 2010 , 64, 275-81	23
1088	Abnormal aortic elasticity in patients with liver steatosis. 2010 , 87, 44-50	5
1087	Normal range of alanine aminotransferase concentration is associated with carotid atherosclerosis. 2010 , 88, 111-6	10
1086	Fish oil-based emulsion for the treatment of parenteral nutrition associated liver disease in an adult patient. 2010 , 5, e243-e246	16
1085	Hepatic unsaturated fatty acids in patients with non-alcoholic fatty liver disease assessed by 3.0T MR spectroscopy. 2010 , 75, e102-7	23
1084	Fatty liver and lipotoxicity. 2010 , 1801, 299-310	200
1083	Tumor necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. 2010 , 391, 1731-6	43
1082	Maternal obesity programmes offspring development of non-alcoholic fatty pancreas disease. 2010 , 394, 24-8	45
1081	Chromium attenuates high-fat diet-induced nonalcoholic fatty liver disease in KK/HIJ mice. 2010 , 397, 459-64	24
1080	Cissus quadrangularis stem alleviates insulin resistance, oxidative injury and fatty liver disease in rats fed high fat plus fructose diet. 2010 , 48, 2021-9	77
1079	Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. 2010 , 93, 1220-6	33
1078	The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. 2010 , 411, 1735-40	29
1077	Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease. 2010 , 49, 407-19	35
1076	Enfermedad del hígado graso no alcohólico y riesgo cardiovascular. 2010 , 22, 259-271	
1075	Role of angiotensin II in liver fibrosis-induced portal hypertension and therapeutic implications. 2010 , 40, 95-104	17
1074	Proton magnetic resonance spectroscopy and ultrasound for hepatic fat quantification. 2010 , 40, 399-406	23
1073	Chymase inhibitor prevents the nonalcoholic steatohepatitis in hamsters fed a methionine- and choline-deficient diet. 2010 , 40, 514-23	24

1072	Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. 2010 , 40, 693-700	27
1071	Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. 2010 , 40, 566-73	100
1070	Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography-The Ludwigshafen Risk and Cardiovascular Health Study. 2010 , 208, 564-71	38
1069	Preclinical manifestations of organ damage associated with the metabolic syndrome and its factors in outpatient children. 2010 , 213, 611-5	16
1068	Lipid-induced insulin resistance: unravelling the mechanism. 2010 , 375, 2267-77	784
1067	A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. 2010 , 177, 153-65	33
1066	Targeting orphan nuclear receptor SHP in the treatment of metabolic diseases. 2010 , 14, 453-66	19
1065	Advances in the treatment of nonalcoholic fatty liver disease. 2010 , 1, 101-15	11
1064	Tumor necrosis factor alpha and its soluble receptors in obese children with NAFLD. 2010 , 55, 74-9	11
1063	Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. 2010 , 9, 78	35
1062	NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. 2010 , 9, 29	53
1061	Dietary saponins of sea cucumber alleviate orotic acid-induced fatty liver in rats via PPARalpha and SREBP-1c signaling. 2010 , 9, 25	61
1060	Redox control of liver function in health and disease. 2010 , 12, 1295-331	132
1059	Review: Polymeric Scaffold Materials for Two-Dimensional and Three-Dimensional in Vitro Culture of Hepatocytes. 2010 , 1-32	11
1058	The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis. 2011 , 43, 487-94	18
1057	Insulin resistance is independently associated with liver aminotransferases in diabetic patients without ultrasound signs of nonalcoholic fatty liver disease. 2011 , 9, 111-7	15
1056	Overweight and hypertriglyceridemia are risk factors for liver cirrhosis in middle-aged Swedish men. 2011 , 46, 738-44	10
1055	Thermal and refining processes, not fermentation, tend to reduce lipotropic capacity of plant-based foods. 2011 , 2, 483-504	6

1054	Isolation and anti-fatty liver activity of a novel cerebroside from the sea cucumber <i>Acaudina molpadioides</i> . 2011 , 75, 1466-71	41
1053	A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. 2011 , 9, 150-5	71
1052	A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. 2011 , 10, 2797-806	54
1051	Comment diagnostiquer de façon non invasive la fibrose au cours de la stéatopathie métabolique?. 2011 , 5, 60-65	
1050	Hepatic fat-content assessment using magnetic resonance-based methods. 2011 , 3, 193-206	3
1049	Chronic liver disease in the Hispanic population of the United States. 2011 , 9, 834-41; quiz e109-10	67
1048	Nonalcoholic fatty liver disease: pharmacologic and surgical options. 2011 , 40, 541-59	4
1047	Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. 2011 , 9, 700-704.e1	78
1046	Advances in pediatric nonalcoholic fatty liver disease. 2011 , 58, 1375-92, x	39
1045	Fatty liver and its clinical management in obese adolescents. 2011 , 58, 32-37	
1044	Nuclear receptors as new perspective for the management of liver diseases. 2011 , 140, 1120-1125.e1-12	80
1043	Do patients with nonalcoholic fatty liver disease die from their heart?. 2011 , 35, 163-5	4
1042	Omega-3 fatty acids reduce hepatic steatosis and consequently attenuate ischemia-reperfusion injury following partial hepatectomy in rats. 2011 , 43, 984-90	37
1041	Association of nonalcoholic fatty liver disease with metabolic syndrome in Indian population. 2011 , 5, 76-80	1
1040	[Fatty liver and its clinical management in obese adolescents]. 2011 , 58, 32-7	1
1039	Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet. 2012 , 5, 37-40	5
1038	Inflammation in nonalcoholic steatohepatitis. 2011 , 5, 189-200	60
1037	Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. 2011 , 5, 201-12	159

1036	Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed. 2011 , 58, 1241-55, xi	32
1035	Non-alcoholic fatty liver disease. 2011 , 48, 97-113	216
1034	Effect of Rice Bran and Soybean Fermented by <i>Bacillus</i> spp. on Lipid Profiles of Liver, Serum, and Feces in Rats Fed High Fat Diet. 2011 , 54,	5
1033	Diabetes mellitus, fasting glucose, and risk of cause-specific death. <i>New England Journal of Medicine</i> , 2011 , 364, 829-841	59.2 1730
1032	Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan. 2011 , 4, 341	2
1031	Diffuse parenchymal liver disease. 2011 , 104-119	
1030	Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. 2011 , 9, 428-33; quiz e50	292
1029	Endocrine diseases and the liver. 2011 , 15, 55-67	32
1028	A comprehensive untargeted metabolomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations. 2011 , 10, 4825-34	93
1027	Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. 2011 , 141, 1249-53	852
1026	Hipertrigliceridemia, esteatosis hepática y riesgo cardiovascular. 2011 , 23, 72-77	1
1025	Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. 2011 , 12, 80-5	51
1024	Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. 2011 , 412, 143-7	26
1023	Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome?. 2011 , 412, 587-92	20
1022	The role of oxidative stress in non-alcoholic steatohepatitis. 2011 , 412, 1297-305	233
1021	Small nucleolar RNAs U32a, U33, and U35a are critical mediators of metabolic stress. 2011 , 14, 33-44	156
1020	The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: intra- and interobserver variability and comparison with magnetic resonance spectroscopy. 2011 , 66, 434-9	24
1019	Fade-out sign on hepatic tissue harmonic compound sonography: a value as a new sign in the diagnosis of fatty liver. 2011 , 80, e258-62	3

1018	Phosphatidylcholine protects against steatosis in mice but not non-alcoholic steatohepatitis. 2011 , 1811, 1177-85	42
1017	Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease. 2011 , 409, 651-6	16
1016	Regular exercise prevents high-sucrose diet-induced fatty liver via improvement of hepatic lipid metabolism. 2011 , 413, 330-5	20
1015	Overexpression of 11 β hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. 2012 , 32, 392-9	34
1014	Death receptor 5 signaling promotes hepatocyte lipoapoptosis. 2011 , 286, 39336-48	93
1013	Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. 2011 , 11, 762-8	85
1012	Comparing morphometric, biochemical, and visual measurements of macrovesicular steatosis of liver. 2011 , 42, 356-60	25
1011	Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. 2011 , 54, 142-52	72
1010	Oleuropein attenuates hepatic steatosis induced by high-fat diet in mice. 2011 , 54, 984-93	81
1009	An apoptosis panel for nonalcoholic steatohepatitis diagnosis. 2011 , 54, 1224-9	137
1008	Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. 2011 , 55, 435-44	72
1007	Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. 2011 , 55, 666-672	264
1006	Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. 2011 , 55, 906-12	115
1005	Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. 2011 , 55, 920-32	205
1004	La st��tohepatite non alcoolique. Influence de la nutrition, de la physiopathologie au traitement. 2011 , 25, 153-163	
1003	Relationship between alcohol consumption and clinical manifestation of patients with fatty liver: a single-center study. 2011 , 10, 276-9	9
1002	Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. 2011 , 301, G825-34	275
1001	Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis. 2011 , 2, 483-9	8

1000	Histopathological characteristics of non-alcoholic fatty liver disease in children: Comparison with adult cases. 2011 , 41, 1066-74	22
999	Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis patients with dyslipidemia. 2011 , 41, 1025-6	
998	Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. 2011 , 15, 437-45	47
997	Ayurvedic formulation of Liv-Pro-08 reduces nonalcoholic fatty liver disease in rats fed with high-fat diet. 2011 , 4, 236-41	11
996	Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. 2011 , 21, 1714-20	35
995	Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia. 2011 , 216, 97-102	14
994	Diagnostic Accuracy of Serological Markers in Viral Hepatitis and Non Alcoholic Fatty Liver Disease. A Comparative Study in Tertiary Care Hospital of Western Nepal. 2011 , 1, 60-63	1
993	Hepatic Steatosis and Diabetes Mellitus: Risk Factors, Pathophysiology and with its Clinical Implications: A Hospital Based Case Control Study in Western Region of Nepal. 2011 , 1, 51-56	1
992	Hepatic steatosis in type 1 diabetes. 2011 , 8, 454-67	71
991	Características Estereológicas del Hígado de Rata (<i>Rattus norvergicus</i>) sometidas a Menopausia Inducida por Ovariectomía. 2011 , 29, 1470-1478	1
990	Liver MR imaging at 3T: challenges and opportunities. 67-81	
989	Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis. 2011 , 48, 179-85	
988	Is there any progress in the treatment of non-alcoholic fatty liver disease?. 2011 , 2, 1-5	11
987	Hepatic and biochemical repercussions of a polyunsaturated fat-rich hypercaloric and hyperlipidic diet in Wistar rats. 2011 , 48, 153-8	2
986	The relationship between normal serum uric acid and nonalcoholic fatty liver disease. 2011 , 26, 386-91	46
985	Prevalence of non-alcoholic fatty liver disease and its relation to hypo adiponectinaemia in the middle-aged and elderly Chinese population. 2011 , 7, 665-72	14
984	JAK-STAT signaling in hepatic fibrosis. 2011 , 16, 2794-811	44
983	Serum ferritin levels are associated with metabolic syndrome in postmenopausal women but not in premenopausal women. 2011 , 18, 1120-4	21

982	Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR- α 2011 , 9, 162-6	9
981	Prophylactic analgesia before percutaneous liver biopsy: a clinical comparative study. 2011 , 23, 782-6	7
980	Quantification of liver fat in the presence of iron and iodine: an ex-vivo dual-energy CT study. 2011 , 46, 351-8	81
979	Toward a biochemical diagnosis of NASH: insights from pathophysiology for distinguishing simple steatosis from steatohepatitis. 2011 , 18, 725-32	14
978	Celecoxib attenuates liver steatosis and inflammation in non-alcoholic steatohepatitis induced by high-fat diet in rats. 2011 , 4, 811-6	20
977	Complications des obésités. 2011 , 8, 1-12	1
976	Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. 2011 , 120, 239-50	98
975	Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. 2011 , 121, 179-89	47
974	Coffee Consumption is Associated with a Lower Incidence of Fatty Liver in Middle-aged Men. 2011 , 57, 406-413	5
973	Elevated peripheral blood monocyte fraction in nonalcoholic fatty liver disease. 2011 , 223, 227-33	11
972	Serum dehydroepiandrosterone sulphate levels in patients with non-alcoholic fatty liver disease. 2011 , 50, 1657-61	12
971	Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis. 2011 , 115, 270-3	7
970	Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. 2011 , 17, 3377-89	187
969	The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. 2011 , 50, 1081-7	47
968	Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease. 2011 , 2, 1077-1081	65
967	Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH). 2011 , 16, 76-8	94
966	Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress. 2011 , 26, 30-46	100
965	Insulin Resistance in Childhood and Adolescence. 2011 , 294-309	1

964	Modulation of liver fibrosis by adipokines. 2011 , 29, 371-6	26
963	Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease. 2011 , 342, 383-7	15
962	Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1) H-magnetic resonance spectroscopy in a rat model. 2011 , 26, 356-63	40
961	Hepatic steatosis and hepatitis C: Still unhappy bedfellows?. 2011 , 26 Suppl 1, 96-101	34
960	Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. 2011 , 26, 517-22	32
959	Plasma reactive carbonyl species levels and risk of non-alcoholic fatty liver disease. 2011 , 26, 1010-5	20
958	Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. 2011 , 26, 1411-6	16
957	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. 2011 , 34, 1202-16	94
956	The changing face of hepatitis in boys with haemophilia associated with increased prevalence of obesity. 2011 , 17, 689-94	16
955	Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease. 2011 , 31, 348-53	43
954	Recurrence of non-viral liver disease after orthotopic liver transplantation. 2011 , 31, 291-302	20
953	Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. 2011 , 31, 700-6	109
952	Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction. 2011 , 31, 1315-24	35
951	Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice. 2011 , 278, 3119-29	32
950	Predictors of ectopic fat accumulation in liver and pancreas in obese men and women. 2011 , 19, 1747-54	79
949	Downregulation of hepatic glucose-6-phosphatase in patients with hepatic steatosis. 2011 , 19, 2322-6	6
948	A case-control study on nutritional risk factors in non-alcoholic fatty liver disease in Indian population. 2011 , 65, 533-7	29
947	Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. 2011 , 35, 270-8	32

946	Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease. 2011 , 35, 1233-40	27
945	Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. 2011 , 12, 10-6	61
944	Plasma metabolomic profile in nonalcoholic fatty liver disease. 2011 , 60, 404-13	318
943	Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. 2011 , 60, 735-9	108
942	Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. 2011 , 60, 860-6	64
941	Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. 2011 , 60, 1278-84	57
940	Plasma adiponectin--an independent indicator of liver fat accumulation. 2011 , 60, 1515-20	15
939	Nutrient intake in Italian obese patients: relationships with insulin resistance and markers of non-alcoholic fatty liver disease. 2011 , 27, 672-6	23
938	Lipotropic capacity of raw plant-based foods: A new index that reflects their lipotrope density profile. 2011 , 24, 895-915	10
937	Elevated systemic monocyte chemoattractant protein-1 in hepatic steatosis without significant hepatic inflammation. 2011 , 91, 780-3	25
936	Methylenetetrahydrofolate reductase 677 C->T polymorphism: a link between birth weight and insulin resistance in obese adolescents. 2011 , 6, e312-7	18
935	The negative impact of fatty liver on maximum standard uptake value of liver on FDG PET. 2011 , 35, 437-41	30
934	A novel agonist of PPAR- δ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance. 2011 , 659, 244-51	25
933	Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis. 2011 , 63, 569-74	42
932	Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. 2011 , 42, 337-53	29
931	Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. 2011 , 42, 690-7	16
930	Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. 2011 , 1807, 664-78	101
929	Nonalcoholic Fatty Liver Disease. 2011 , 804-810.e2	

928	The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. 2011 , 21, 87-97	338
927	Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. 2011 , 7, 456-65	227
926	Correlation analysis between gene expression profile of rat liver tissues and high-fat emulsion-induced nonalcoholic fatty liver. 2011 , 56, 2299-308	26
925	Fatty liver is associated with recurrent bacterial infections independent of metabolic syndrome. 2011 , 56, 3328-34	26
924	Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. 2011 , 56, 3439-49	69
923	Cryptogenic chronic hepatitis and its changing guise in adults. 2011 , 56, 3421-38	36
922	Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. 2011 , 38, 1145-50	47
921	Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. 2011 , 46, 101-7	143
920	Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. 2011 , 46, 1300-6	77
919	Obesity, metabolic syndrome, and insulin dynamics in children after craniopharyngioma surgery. 2011 , 170, 763-9	22
918	Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese. 2011 , 30, 777-87	61
917	[Nonalcoholic steatohepatitis. Predictor and consequence of diabetes]. 2011 , 52, 389-94	
916	Dissociation between fatty liver and insulin resistance: the role of adipose triacylglycerol lipase. 2011 , 54, 7-9	16
915	Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. 2011 , 54, 641-7	49
914	Rückbildung einer Steatosis hepatis mit Hepatomegalie durch Ausdauertraining. 2011 , 41, 28-31	
913	Differential effect of gender on hepatic fat. 2011 , 41, 1146-53	6
912	Combination of conjugated linoleic acid with fish oil prevents age-associated bone marrow adiposity in C57Bl/6J mice. 2011 , 22, 459-69	34
911	La patologia epatica cronica nell'anziano. 2011 , 7, 106-112	

910	Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. 2011 , 40, 332-43	53
909	Non-viral causes of hepatocellular carcinoma. 2011 , 42, 191-4	8
908	Peroxisome proliferators-activated receptor α Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. 2010 , 5, 575-80	21
907	Role of lipid droplet proteins in liver steatosis. 2011 , 67, 629-36	71
906	Acoustic radiation force impulse elastography of the liver: can fat deposition in the liver affect the measurement of liver stiffness?. 2011 , 29, 639-43	24
905	NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. 2011 , 21, 310-5	26
904	Characterization of the insulin sensitivity of ghrelin receptor KO mice using glycemic clamps. 2011 , 11, 1	31
903	Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes. 2011 , 10, 120	141
902	Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. 2011 , 10, 23	54
901	Integration of genome-wide computation DRE search, AhR ChIP-chip and gene expression analyses of TCDD-elicited responses in the mouse liver. 2011 , 12, 365	83
900	Increased production of sonic hedgehog by ballooned hepatocytes. 2011 , 224, 401-10	113
899	Differential expression of intermediate filaments in the process of developing hepatic steatosis. 2011 , 11, 2777-89	21
898	Hypolipidaemic and hypoglycaemic effects of total flavonoids from seed residues of Hippophae rhamnoides L. in mice fed a high-fat diet. 2011 , 91, 1446-51	38
897	Hepatic steatosis assessment with CT or MRI in patients with colorectal liver metastases after neoadjuvant chemotherapy. 2011 , 104, 10-6	10
896	Long-TE 1H MRS suggests that liver fat is more saturated than subcutaneous and visceral fat. 2011 , 24, 238-45	60
895	Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis. 2011 , 54, 122-32	170
894	Lack of de novo phosphatidylinositol synthesis leads to endoplasmic reticulum stress and hepatic steatosis in cdIPT-deficient zebrafish. 2011 , 54, 452-62	59
893	Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. 2011 , 54, 145-52	164

892	The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. 2011 , 54, 1208-16	323
891	Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. 2011 , 54, 1398-409	78
890	Use of three-dimensional spheroids of hepatocyte-derived reporter cells to study the effects of intracellular fat accumulation and subsequent cytokine exposure. 2011 , 108, 1171-80	26
889	Safety of hepatic resection in overweight and obese patients with cirrhosis. 2011 , 98, 1147-54	45
888	Fibrosis in alcoholic and nonalcoholic steatohepatitis. 2011 , 25, 231-44	50
887	Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease. 2011 , 46, 2003-10	52
886	Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. 2011 , 22, 393-400	122
885	Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. 2011 , 22, 699-711	138
884	Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. 2011 , 300, G1094-104	41
883	Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules. 2011 , 9, 61-9	3
882	Measurement of ER stress response and inflammation in the mouse model of nonalcoholic fatty liver disease. 2011 , 489, 329-48	21
881	Activin A in nonalcoholic fatty liver disease. 2011 , 85, 323-42	8
880	Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. 2011 , 32, 876-81	44
879	ASH and NASH. 2011 , 29, 202-10	59
878	Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET/CT. 2011 , 196, 176-80	35
877	Carotid intima-media thickness and liver histology in hemodialysis patients with nonalcoholic Fatty liver disease. 2011 , 20, 149-56	9
876	Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men. 2011 , 43, 48-54	34
875	Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. 2011 , 60, 1394-402	259

- 874 Increased liver fat content and unfavorable glucose profiles in subjects without diabetes. **2011**, 13, 149-55 19
- 873 Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men. **2011**, 9, 305-11 19
- 872 Genetic determinants of hepatic steatosis in man. **2011**, 52, 593-617 90
- 871 Nonalcoholic fatty liver and steatohepatitis in obese children. **2011**, 1, 73-80
- 870 Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. **2011**, 52, 318-29 162
- 869 The metabolically benign and malignant fatty liver. **2011**, 60, 2011-7 139
- 868 Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis. **2011**, 34 Suppl 2, S367-70 29
- 867 Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. **2011**, 26, 565-76 78
- 866 Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. **2011**, 259, 749-56 320
- 865 Iron overload in nonalcoholic steatohepatitis. **2011**, 55, 105-32 33
- 864 Metabolic syndrome in childhood from impaired carbohydrate metabolism to nonalcoholic fatty liver disease. **2011**, 30, 295-303 27
- 863 Quantification of liver fat in mice: comparing dual-echo Dixon imaging, chemical shift imaging, and ¹H-MR spectroscopy. **2011**, 52, 1847-55 23
- 862 Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. **2011**, 5, 223-31 42
- 861 A selective estrogen receptor β agonist ameliorates hepatic steatosis in the male aromatase knockout mouse. **2011**, 210, 323-34 47
- 860 Insulin sensitizers in the treatment of non-alcoholic fatty liver disease: a systematic review. **2011**, 15, 1-110 49
- 859 Fibrogenesis in nonalcoholic steatohepatitis. **2011**, 5, 179-87 25
- 858 Teucrium polium reversed the MCD diet-induced liver injury in rats. **2011**, 30, 1303-12 6
- 857 Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. **2011**, 31, 1927-32 115

856	Low concentrations of serum n-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease patients with liver injury. 2011 , 49, 159-62	10
855	Serum gamma-glutamyl transferase within its normal concentration range is related to the presence of impaired fasting glucose and diabetes among Japanese community-dwelling persons. 2011 , 36, 64-73	9
854	(99m)Tc sulfur colloid and (99m)Tc mebrofenin hepatobiliary functional liver imaging in normal and diabetic rats. 2011 , 20, 129-32	4
853	Diagnosis and management of chronic liver disease in older people. 2011 , 21, 1-15	7
852	Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. 2011 , 108, 5748-52	119
851	Combined effects of coffee consumption and serum γ -glutamyltransferase on serum C-reactive protein in middle-aged and elderly Japanese men and women. 2011 , 49, 1661-7	13
850	Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. 2011 , 49, 13-32	16
849	Nonalcoholic Fatty Liver Disease. 2011 , 435-440	1
848	Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. 2012 , 5, 729-33	97
847	Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients. 2011 , 29, 117-8	6
846	Assessment of liver steatosis and fibrosis in rats using integrated coherent anti-Stokes Raman scattering and multiphoton imaging technique. 2011 , 16, 116024	45
845	Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. 2011 , 52, 190-7	38
844	Recent advances in imaging hepatic fibrosis and steatosis. 2011 , 5, 91-104	15
843	Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. 2011 , 39, 2395-402	99
842	Ablation of PI3K p110 β prevents high-fat diet-induced liver steatosis. 2011 , 60, 1483-92	37
841	L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin. 2011 , 286, 34800-8	54
840	Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes. 2011 , 34, 448-53	144
839	Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. 2011 , 34, 1139-44	254

838	Monitoring nutrition therapy in the critically ill patient with obesity. 2011 , 35, 44S-51S	18
837	Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. 2011 , 9, 321-8	33
836	Epidemiological survey of prevalence of fatty liver disease and its risk factors among the university staffs in Changchun city. 2011 ,	
835	Obesidad y sus complicaciones. 2011 , 22, 20-26	0
834	Serum alanine aminotransferase and its association with metabolic syndrome in children: the bogalusa heart study. 2011 , 9, 211-6	19
833	The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study. 2011 , 14, 677-80	37
832	Relationships between hepatic stearyl-CoA desaturase-1 activity and mRNA expression with liver fat content in humans. 2011 , 300, E321-6	26
831	Comparison of portal vein doppler indices and hepatic vein doppler waveform in patients with nonalcoholic fatty liver disease with healthy control. 2011 , 11, 740-4	11
830	Pharmacological activation of peroxisome proliferator-activated receptor α improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice. 2011 , 43, 631-5	20
829	Obesity and air pollution: global risk factors for pediatric non-alcoholic fatty liver disease. 2011 , 11, 794-802	27
828	High incidence of fatty liver and insulin resistance in long-term adult survivors of childhood SCT. 2011 , 46, 416-25	19
827	Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. 2011 , 141, 1062-9	117
826	Non-alcoholic fatty liver disease is not related to the incidence of diabetic nephropathy in Type 2 Diabetes. 2012 , 13, 14698-706	16
825	Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. 2012 , 167, 67-74	85
824	Lipids promote survival, proliferation, and maintenance of differentiation of rat liver sinusoidal endothelial cells in vitro. 2012 , 302, G375-88	23
823	Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. 2012 , 47, 108-15	39
822	Pentoxifylline attenuates methionine- and choline-deficient-diet-induced steatohepatitis by suppressing TNF- α expression and endoplasmic reticulum stress. 2012 , 2012, 762565	16
821	Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. 2012 , 13, 579-95	35

820	Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. 2012 , 123, 459-71	48
819	Liver Patt1 deficiency protects male mice from age-associated but not high-fat diet-induced hepatic steatosis. 2012 , 53, 358-367	17
818	A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. 2012 , 47, 836-41	22
817	Genetically modified mouse models for the study of nonalcoholic fatty liver disease. 2012 , 18, 1141-53	53
816	Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr ^{-/-} mice. 2012 , 142, 1495-503	35
815	MRI steatosis grading: development and initial validation of a color mapping system. 2012 , 198, 582-8	37
814	Detection of hepatic steatosis on contrast-enhanced CT images: diagnostic accuracy of identification of areas of presumed focal fatty sparing. 2012 , 199, 44-7	48
813	The impact of bariatric surgery on nonalcoholic steatohepatitis. 2012 , 32, 80-91	53
812	The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. 2012 , 7, 471-481	15
811	Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. 2012 , 113, 1-6	62
810	Alcoholic and Nonalcoholic Steatohepatitis. 2012 , 996-999	1
809	Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. 2012 , 92, 713-23	114
808	Docosahexaenoic acid prevents trans-10, cis-12-conjugated linoleic acid-induced nonalcoholic fatty liver disease in mice by altering expression of hepatic genes regulating fatty acid synthesis and oxidation. 2012 , 10, 175-80	15
807	Effect of moderate weight loss on hepatic, pancreatic and visceral lipids in obese subjects. 2012 , 2, e32	22
806	What should we recommend to our patients with NAFLD regarding alcohol use?. 2012 , 107, 976-8	52
805	Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. 2012 , 36, 774-82	28
804	Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. 2012 , 107, 253-61	173
803	Early maternal undernutrition programs increased feed intake, altered glucose metabolism and insulin secretion, and liver function in aged female offspring. 2012 , 302, R795-804	68

802	Hepatic left lobe volume is a sensitive index of metabolic improvement in obese women after gastric banding. 2012 , 36, 336-41	13
801	Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. 2012 , 287, 10277-10288	45
800	Group IVA phospholipase A2 participates in the progression of hepatic fibrosis. 2012 , 26, 4111-21	28
799	A simple Indian diabetes risk score could help identify nondiabetic individuals at high risk of non-alcoholic fatty liver disease (CURES-117). 2012 , 6, 1429-35	5
798	Pediatric Metabolic Syndrome. 2012 ,	5
797	The role of metformin in the management of NAFLD. 2012 , 2012, 716404	126
796	Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. 2012 , 2012, 925807	38
795	Utility of quantitative ultrasound in community screening for hepatic steatosis. 2021 , 111, 106329	1
794	Recent Epidemiology of Nonalcoholic Fatty Liver Disease. 2021 , 15, 206-216	9
793	Discovery through Machine Learning and Preclinical Validation of Novel Anti-Diabetic Peptides. 2021 , 9,	5
792	Abnormal fucosylation of alpha-fetoprotein in patients with nonalcoholic steatohepatitis. 2021 , 51, 548-553	1
791	Effects of lacto-ovo-vegetarian diet standard-weight-loss diet on obese and overweight adults with non-alcoholic fatty liver disease: a randomised clinical trial. 2021 , 1-9	0
790	Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes. 2021 , 1	3
789	Use of a convolutional neural network and quantitative ultrasound for diagnosis of fatty liver. 2021 , 47, 556-568	2
788	S-adenosylmethionine upregulates the angiotensin receptor-binding protein ATRAP via the methylation of HuR in NAFLD. 2021 , 12, 306	4
787	Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity. 2021 , 21, 122	7
786	Noninvasive assessment of liver fibrosis by dual-layer spectral detector CT. 2021 , 136, 109575	1
785	Branched-chain amino acids and l-carnitine attenuate lipotoxic hepatocellular damage in rat cirrhotic liver. 2021 , 135, 111181	5

784	Functional Foods for the Management of Non-Alcoholic Fatty Liver Disease.	0
783	Early initiation of insulin attenuates histological and functional changes in the liver of streptozotocin-induced diabetic rats using Tc-sulfur colloid functional imaging. 2021 , 1-7	
782	Effect of bariatric surgery on fatty liver disease in obese patients: A prospective one year follow-up study. 2021 ,	0
781	On the Relationship Between Non-alcoholic Fatty Liver Disease with Body Composition and Bone Mineral Density in Overweight/Obese Adolescents. 2021 , 21,	1
780	Higher plain water intake is related to lower newly diagnosed nonalcoholic fatty liver disease risk: a population-based study. 2021 , 75, 1801-1808	
779	Mechanism of Huo-Xue-Qu-Yu Formula in Treating Nonalcoholic Hepatic Steatosis by Regulating Lipid Metabolism and Oxidative Stress in Rats. 2021 , 2021, 6026319	0
778	Perinatal exposure to di-(2-ethylhexyl) phthalate induces hepatic lipid accumulation mediated by diacylglycerol acyltransferase 1. 2021 , 40, 1698-1709	3
777	Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. 2021 , 142, 110180	16
776	Echinacoside improves diabetic liver injury by regulating the AMPK/SIRT1 signaling pathway in db/db mice. 2021 , 271, 119237	4
775	Who should return for an oral glucose tolerance test? A proposed clinical pathway based on retrospective analysis of 332 children. 2021 , 34, 877-884	1
774	Effect of on the Liver Protection of Non-Alcoholic Fatty Liver Disease Based on In Vitro and In Vivo Models. 2021 , 43,	5
773	2D Gadolinium Oxide Nanoplates as T Magnetic Resonance Imaging Contrast Agents. 2021 , 10, e2001780	7
772	Metabolic Complementation between Glucose and Amino Acid Drives Hepatic De Novo Lipogenesis and Steatosis.	0
771	Graves Disease.	
770	Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. 2021 , 18,	13
769	Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. 2021 , 11, 9894	3
768	Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis. 2021 , 27, 2160-2176	4
767	Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights. 2021 , 22,	9

766	Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand. 2021 , 13, e14858	1
765	Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway. 2021 , 12, 589273	5
764	Usefulness of Triglyceride to High-Density Lipoprotein Ratio and Alanine Aminotransferase for Predicting Insulin Resistance and Metabolic Syndrome in the Japanese Population. 2021 , 19, 225-232	0
763	Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. 2021 , 27, 1864-18827	
762	Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis. 2021 , 21, 91	1
761	Enoyl coenzyme A hydratase 1 alleviates nonalcoholic steatohepatitis in mice by suppressing hepatic ferroptosis. 2021 , 320, E925-E937	6
760	Iron oxide nanoparticles aggravate hepatic steatosis and liver injury in nonalcoholic fatty liver disease through BMP-SMAD-mediated hepatic iron overload. 2021 , 15, 761-778	4
759	Assessment of Classification Models and Relevant Features on Nonalcoholic Steatohepatitis Using Random Forest. 2021 , 23,	2
758	The albumin/starch scaffold and its biocompatibility with living cells. 2021 , 27, 102164	2
757	Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. 2021 , 6, CD013156	2
756	Non-alcoholic fatty liver disease is associated with subclinical coronary artery disease in otherwise healthy individuals. 2021 , 50, 500-502	
755	High Prevalence of Nonalcoholic Fatty Liver Disease Among Adolescents and Young Adults With Hypopituitarism due to Growth Hormone Deficiency. 2021 , 27, 1149-1155	1
754	Urinary Phthalate Levels Associated with the Risk of Nonalcoholic Fatty Liver Disease in Adults: The Korean National Environmental Health Survey (KoNEHS) 2012-2014. 2021 , 18,	1
753	Efficacy of phytosomal curcumin among patients with non-alcoholic fatty liver disease. 2021 , 91, 278-286	5
752	Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. 2021 , 3, 100261	4
751	Reactive Hyperglycaemia Connected with Low Glycated Haemoglobin [Risk Factor for Cardiovascular Adverse Events. 2021 , 2, 85-96	
750	Association of sex hormones with hepatic steatosis in men with chronic hepatitis B. 2021 ,	0
749	Role of hepatosteatosis in the prognosis of COVID 19 disease. 2021 , 80, 1-5	0

748	Does a high intake of green leafy vegetables protect from NAFLD? Evidence from a large population study. 2021 , 31, 1691-1701	3
747	Hydralazine as a Versatile and Universal Matrix for High-Molecular Coverage and Dual-Polarity Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. 2021 , 93, 9083-9093	6
746	A Decreased Response to Resistin in Mononuclear Leukocytes Contributes to Oxidative Stress in Nonalcoholic Fatty Liver Disease. 2021 , 1	2
745	n-3 PUFAs protect against adiposity and fatty liver by promoting browning in postnatally overfed male rats: a role for NRG4. 2021 , 93, 108628	5
744	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. 2021 , 7, CD013157	2
743	The Effect of Laser Therapy Along With Mediterranean Diet Versus Mediterranean Diet Only on Older Adults With Non-alcoholic Fatty Liver Disease: A Randomized Clinical Trial. 2021 , 12, e39	1
742	Dynamic Nuclear Polarization Magnetic Resonance Imaging for the Evaluation of Redox-Related Diseases and Theranostics. 2021 ,	0
741	Body weight gain rather than body weight variability associated with increased risk of nonalcoholic fatty liver disease. 2021 , 11, 14428	2
740	Hepatic steatosis: a risk factor for increased COVID-19 prevalence and severity-a computed tomography study. 2021 , 11, 61	1
739	Amomum villosum Lour. fruit extract ameliorates high-fat diet-induced body mass gain and adipogenic pathways in C57BL/6 mice. 2021 , 33, 101473	1
738	Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population. 2021 , 53, 866-872	7
737	Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. 2021 , 14, 1353-1365	0
736	Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis. 2021 , 13,	3
735	Evaluation of Renal Microvascular Damage by Measuring Microalbuminuria in Non-Alcoholic Fatty Liver Disease [A Study from Punjab, India. 2021 , 8, 2497-2502	
734	The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease. 2021 , 13, e16687	2
733	Comparative Analysis of the Effects of Long-Term 3,5-diiodothyronine Treatment on the Murine Hepatic Proteome and Transcriptome Under Conditions of Normal Diet and High-Fat Diet. 2021 , 31, 1135-1146 ³	
732	Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. 2021 , 60, 2167-2174	4
731	Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease. 2021 , 40, 380-388	0

730	Intervention by picoside II on FFAs induced lipid accumulation and lipotoxicity in HepG2 cells. 2021 , 12, 465-473	2
729	Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. 2021 ,	1
728	Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects. 2021 , 14, 3439-3444	2
727	Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice. 2021 ,	7
726	Increased Risk of Nonalcoholic Fatty Liver Disease in Individuals with High Weight Variability. 2021 , 36, 845-854	1
725	Quantitative assessment of fatty liver using ultrasound attenuation imaging. 2021 , 48, 465-470	1
724	Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis. 2021 , 87, 204-240	10
723	Sarcopenia modifies the associations of nonalcoholic fatty liver disease with all-cause and cardiovascular mortality among older adults. 2021 , 11, 15647	2
722	Olive oil-derived nitro-fatty acids: protection of mitochondrial function in non-alcoholic fatty liver disease. 2021 , 94, 108646	2
721	Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults. 2021 , 9,	1
720	Abbreviated MR Protocols for Chronic Liver Disease and Liver Cancer. 2021 , 29, 321-327	0
719	Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease. 2021 , 48, 471-480	0
718	Kaempferol and Kaempferide Attenuate Oleic Acid-Induced Lipid Accumulation and Oxidative Stress in HepG2 Cells. 2021 , 22,	2
717	Non-alcoholic fatty liver disease: Update on treatment options and translational implications of sleep disruption. 2021 , 5, 032-038	
716	Obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study. 2021 , 21, 321	
715	Perchlorate exposure does not induce obesity or non-alcoholic fatty liver disease in zebrafish. 2021 , 16, e0254500	1
714	The efficacy and safety of acupuncture in nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. 2021 , 100, e27050	0
713	The association between urinary bisphenol A levels and nonalcoholic fatty liver disease in Korean adults: Korean National Environmental Health Survey (KoNEHS) 2015-2017. 2021 , 26, 91	0

712	Adverse Maternal Environment and Postweaning Western Diet Alter Hepatic CD36 Expression and Methylation Concurrently with Nonalcoholic Fatty Liver Disease in Mouse Offspring. 2021 , 151, 3102-3112	
711	Ameliorative effects of extract and main component cirsimaritin in mice model of high-fat diet-induced metabolic dysfunction-associated fatty liver disease. 2021 , 9, 6060-6068	0
710	Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma. 2021 ,	0
709	Evaluation of the reciprocal interaction between hepatic steatosis and type 2 diabetes: a comparative analysis with respect to anti-diabetic treatment, glycemic control, renal and hepatic function. 1	0
708	The feasibility of T2 mapping in the assessment of hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease: a preliminary study. 2021 , 76, 709.e13-709.e18	1
707	Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders. 2021 , 12, 729828	2
706	Black Mulberry Extract Elicits Hepatoprotective Effects in Nonalcoholic Fatty Liver Disease Models by Inhibition of Histone Acetylation. 2021 , 24, 978-986	1
705	Multiparametric US for Identifying Patients with High-Risk NASH: A Derivation and Validation Study. 2021 , 301, 625-634	0
704	Deep Learning Prediction of Voxel-Level Liver Stiffness in Patients with Nonalcoholic Fatty Liver Disease. 2021 , 3, e200274	1
703	IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study. 2021 , 10, 1315-1325	3
702	Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications. 2022 , 2343, 19-35	2
701	Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. 2021 , 19, 572-581	6
700	The role of Sirtuin 2 in sustaining functional integrity of the liver. 2021 , 285, 119997	3
699	Non-Invasive Photothermal Strain Imaging of Non-Alcoholic Fatty Liver Disease in Live Animals. 2021 , 40, 2487-2495	2
698	Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?. 2021 , 12, 1479-1493	1
697	A Matter of Fat: Body Fat Distribution and Cardiometabolic Disease in Africa. 2022 , 2343, 37-56	
696	Higher dietary insulinaemic potential is associated with increased risk of liver steatosis and fibrosis. 2021 ,	1
695	Serum creatinine levels and risk of nonalcohol fatty liver disease in a middle-aged and older Chinese population: A cross-sectional analysis. 2021 , e3489	0

694	Nonobese mice with nonalcoholic steatohepatitis fed on a choline-deficient, l-amino acid-defined, high-fat diet exhibit alterations in signaling pathways. 2021 , 11, 2950-2965	1
693	Metabolic surgery.. 2022 , 59, 101059	
692	Organ Transplantation in Kuwait and the Recent Initiation of a Liver Program. 2021 , 105, 2125-2127	0
691	Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®). 2021 , 40, 60-66	2
690	Association of xenobiotic-metabolizing enzymes (GSTM1 and GSTT 1), and pro-inflammatory cytokines (TNF- α and IL-6) genetic polymorphisms with non-alcoholic fatty liver disease. 2021 , 48, 1225-1231	2
689	Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?. 2021 , 10,	9
688	Pathogenesis of NASH and Promising Natural Products. 2021 , 19, 12-27	3
687	The triglycerides and glucose index is strongly associated with hepatic steatosis in children with overweight or obesity. 2021 , 180, 1755-1760	3
686	Obesity and Non-Alcoholic Fatty Liver Disease: Pathophysiology and Management Focused. 2021 , 3, 6-12	
685	Obesity, Metabolic Syndrome and Disorders of Energy Balance. 2021 , 939-1003	0
684	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. 2021 , 17, 12	16
683	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.	0
682	Nutritional supplementation for non-alcohol-related fatty liver disease: a network meta-analysis.	2
681	Lipids, Atherogenic Dyslipidemia, and Therapy. 347-408	1
680	Non-Alcoholic Fatty Liver Disease. 245-277	7
679	Histopathologic Classification of Liver Pathologies. 2006 , 17-51	1
678	Ultrasonographic Anthropometry: An Application to the Measurement of Liver and Abdominal Fat. 2012 , 2227-2242	1
677	Periodontitis and Liver Diseases. 2014 , 197-209	2

676	Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?. 2010 , 593, 109-36	20
675	Racial Differences in Childhood Obesity: Pathogenesis and Complications. 2010 , 75-89	2
674	Obesity-Induced Non-alcoholic Fatty Liver Disease (NAFLD): Role of Hyperhomocysteinemia. 2020 , 181-192	0
673	Management of the Obese Patient. 2016 , 173-193	1
672	TNF/TNF Receptors. 2010 , 161-177	4
671	Apoptosis and Mitochondria. 2010 , 439-453	2
670	Reactive Oxygen Species (ROS) and Liver Disease Therapy. 2014 , 1809-1838	1
669	Predicting Health Care Risk with Big Data Drawn from Clinical Physiological Parameters. 2014 , 88-98	2
668	Alteration of Liver MMP-9/TIMP-1 and Plasma Type IV Collagen in the Development of Rat Insulin Resistance. 2014 , 531-543	1
667	Traditional Markers in Liver Disease. 2017 , 3-22	1
666	Metabolomics Profiling of the Effects of Taurine Supplementation on Dyslipidemia in a High-Fat-Diet-Induced Rat Model by H NMR Spectroscopy. 2017 , 975 Pt 1, 329-336	2
665	Long-term intake of 9-PAHPA or 9-OAHPA modulates favorably the basal metabolism and exerts an insulin sensitizing effect in obesogenic diet-fed mice. 2021 , 60, 2013-2027	11
664	Disorders of the Liver and Biliary Tract. 2010 , 1153-1171	1
663	Epidemiology and Risk Factors Involved in Alcoholic Liver Disease. 2005 , 467-480	2
662	Fatty Liver Disease. 2011 , 595-606	1
661	Retinol Binding Protein-4 Circulating Levels Were Higher in Nonalcoholic Fatty Liver Disease Vs. Histologically Normal Liver From Morbidly Obese Women.	4
660	Alteration of serum amino acid profiles by dietary adenine supplementation inhibits fatty liver development in rats. 2020 , 10, 22110	1
659	DNA copy number and structural variation (CNV) contributions to adult and childhood obesity. 2020 , 48, 1819-1828	2

658	Acute Elevated Resistin Exacerbates Mitochondrial Damage and Aggravates Liver Steatosis Through AMPK/PGC-1 β Signaling Pathway in Male NAFLD Mice. 2021 , 53, 132-144	3
657	Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study. 2020 , 23, 1553-1563	3
656	Metabolic Consequences of Obesity. 2008 , 149-173	6
655	The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. 2013 , 47, 280-6	28
654	The association of nonalcoholic steatohepatitis and hepatocellular carcinoma. 2020 , 32, 1566-1570	5
653	Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. 2010 , 22, 1449-57	44
652	Focal fat sparing of the liver: a nonmalignant cause of focal FDG uptake on FDG PET/CT. 2014 , 39, e359-61	10
651	Prospective association between adherence to the Mediterranean diet and hepatic steatosis: the Swiss CoLaus cohort study. 2020 , 10, e040959	2
650	Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population. 2012 , 22, 92-9	21
649	Degradation of splicing factor SRSF3 contributes to progressive liver disease. 2019 , 129, 4477-4491	32
648	Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. 2020 , 130, 1453-1460	145
647	Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. 2004 , 113, 414-24	75
646	Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. 2004 , 113, 414-424	146
645	Molecular mediators of hepatic steatosis and liver injury. 2004 , 114, 147-152	1404
644	Molecular mediators of hepatic steatosis and liver injury. 2004 , 114, 147-52	712
643	Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. 2008 , 118, 3725-37	193
642	Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. 2011 , 121, 1412-23	94
641	Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease. 2017 , 127, 583-592	31

640	Quantitative evaluation of hepatic integrin α expression by positron emission tomography imaging using F-FPP-RGD in rats with non-alcoholic steatohepatitis. 2020 , 10, 118	2
639	Obesity and Type 2 Diabetes. 2007 , 139-154	2
638	Inhibition Effect of Ornithogalum caudatum Ait Polysaccharide on High Fat Diet-Induced Weight Gaining in Mice. 2015 , 03, 185-190	1
637	Metabolic profiling of adolescent non-alcoholic fatty liver disease. 2018 , 3, 166	13
636	Metabolic profiling of adolescent non-alcoholic fatty liver disease. 2018 , 3, 166	11
635	Monitoring of liver function in patients with fatty liver disease in combination with coronary heart disease and type 2 diabetes. 2013 , 26, 376-378	1
634	Relationship between non-alcoholic fatty liver disease and coronary heart disease. 2020 , 8, 4688-4699	9
633	Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. 2020 , 8, 1361-1384	27
632	Farnesoid X receptor-Acting through bile acids to treat metabolic disorders. 2010 , 35, 635-642	8
631	High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. 2010 , 5, e11578	96
630	Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice. 2010 , 5, e13858	44
629	Intestinal activation of Notch signaling induces rapid onset hepatic steatosis and insulin resistance. 2011 , 6, e20767	9
628	Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet. 2011 , 6, e24084	87
627	Tumor necrosis factor α -converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. 2011 , 6, e25587	17
626	Hepatocyte IKK2 protects Mdr2 ^{-/-} mice from chronic liver failure. 2011 , 6, e25942	11
625	Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. 2012 , 7, e34198	51
624	Insulin concentration modulates hepatic lipid accumulation in mice in part via transcriptional regulation of fatty acid transport proteins. 2012 , 7, e38952	20
623	Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. 2012 , 7, e41183	38

622	VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. 2012 , 7, e45425	76
621	Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. 2012 , 7, e46584	69
620	Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. 2013 , 8, e61803	55
619	Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice. 2013 , 8, e61870	31
618	Liver fat content, evaluated through semi-quantitative ultrasound measurement, is associated with impaired glucose profiles: a community-based study in Chinese. 2013 , 8, e65210	13
617	High Fat Diet Induces Liver Steatosis and Early Dysregulation of Iron Metabolism in Rats. 2013 , 8, e66570	64
616	Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. 2013 , 8, e68953	27
615	Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. 2014 , 9, e80169	168
614	Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. 2014 , 9, e88569	33
613	Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. 2014 , 9, e98689	30
612	Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans. 2014 , 9, e109123	29
611	Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees. 2014 , 9, e110680	33
610	OXPHOS-Mediated Induction of NAD ⁺ Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease. 2015 , 10, e0125617	22
609	Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. 2015 , 10, e0133496	58
608	Euterpe oleracea Mart.-Derived Polyphenols Protect Mice from Diet-Induced Obesity and Fatty Liver by Regulating Hepatic Lipogenesis and Cholesterol Excretion. 2015 , 10, e0143721	62
607	Activation of Kupffer Cells Is Associated with a Specific Dysbiosis Induced by Fructose or High Fat Diet in Mice. 2016 , 11, e0146177	21
606	The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. 2016 , 11, e0146337	105
605	Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. 2016 , 11, e0153497	79

604	Vitamin D Levels Are Inversely Associated with Liver Fat Content and Risk of Non-Alcoholic Fatty Liver Disease in a Chinese Middle-Aged and Elderly Population: The Shanghai Changfeng Study. 2016 , 11, e0157515	17
603	Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. 2016 , 11, e0157580	40
602	Waist Gain Is Associated with a Higher Incidence of Nonalcoholic Fatty Liver Disease in Korean Adults: A Cohort Study. 2016 , 11, e0158710	8
601	Investigating Nonalcoholic Fatty Liver Disease in a Liver-on-a-Chip Microfluidic Device. 2016 , 11, e0159729	98
600	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. 2016 , 11, e0167776	12
599	Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. 2017 , 12, e0172575	38
598	Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study. 2017 , 12, e0174291	36
597	Association between the hyperuricemia and nonalcoholic fatty liver disease risk in a Chinese population: A retrospective cohort study. 2017 , 12, e0177249	11
596	Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. 2017 , 12, e0178473	42
595	Gender difference in NASH susceptibility: Roles of hepatocyte Ikk β and Sult1e1. 2017 , 12, e0181052	11
594	The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. 2017 , 12, e0187066	11
593	Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. 2013 , 1, 131-7	38
592	Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. 2015 , 3, 78-84	59
591	Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. 2017 , 5, 67-75	15
590	Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease. 2020 , 8, 414-423	11
589	Effect of Daily Caper Fruit Pickle Consumption on Disease Regression in Patients with Non-Alcoholic Fatty Liver Disease: a Double-Blinded Randomized Clinical Trial. 2017 , 7, 645-650	9
588	Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. 2018 , 10, 213-219	10
587	Increased serum fetuin-B concentration is associated with HOMA- β and indices of liver steatosis in women with polycystic ovary syndrome: a pilot study. 2019 , 8, 1159-1167	5

586	Associations of circulating chemerin and adiponectin concentrations with hepatic steatosis. 2019 , 8, 1097-1107	5
585	Past, Present, and Future of Hepatitis B and Fatty Liver in Bangladesh. 2017 , 6,	4
584	The Effects of Electroacupuncture for Treatment of Patients with Non-Alcoholic Fatty Liver Disease: Prospective Randomized Controlled Study. 2015 , 15, 1-8	60
583	Alanine Aminotransferase levels are Associated with Cardiometabolic Risk Markers in Hispanic/Latino Farmworkers. 2018 , 4, 20-25	1
582	[Impact of lipid lowering therapy on liver function]. 2009 , 150, 1205-12	1
581	[Role of fatty liver in metabolic syndrome]. 2010 , 151, 1430-3	0
580	Diabetes Mellitus and Prediabetes in Patients with Hepatocellular Carcinoma in a Tertiary Philippine Hospital. 2017 , 32, 32-37	1
579	Prevalence of the hemochromatosis gene mutation in patients with nonalcoholic steatohepatitis and correlation with degree of liver fibrosis. 2006 , 43, 224-8	10
578	Lifestyle Intervention and Vitamin E Therapy in Obese Children with Nonalcoholic Fatty Liver Disease. 2012 , 4, 62-5	2
577	Key points of etiopathogenesis of non-alcoholic fatty liver disease. 2019 , 21, 219-222	3
576	Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. 2016 , 7, 5728-37	25
575	Congenital and environmental factors associated with adipocyte dysregulation as defects of insulin resistance. 2007 , 4, 77-84	12
574	The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. 2019 , 7, 429	22
573	Sarcopenia Is an Independent Risk Factor for NAFLD in COPD: A Nationwide Survey (KNHANES 2008-2011). 2020 , 15, 1005-1014	5
572	Psoriasis: a personalized approach to therapy. The preferred choice of systemic agents considering comorbid pathologies. 2020 , 28-34	2
571	SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. 2020 , 59, 1931-1937	14
570	Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances. 2017 , 10, 207-225	46
569	Caracterización de pacientes con enfermedad del hígado graso no alcohólica en un hospital de alta complejidad, Colombia 2013. 2014 , 29, 342-346	2

568	[Elevated body mass index and fatty liver]. 2008 , 136, 122-5	17
567	Non-invasive biomarkers in predicting non-alcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis. 2020 ,	8
566	Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. 2009 , 54, 177-82	30
565	A defense system against multiple diseases via biological garbage clearance mediated by soluble scavenger proteins. 2015 , 35, 203-209	1
564	EFFECTS OF HIGH FAT DIET INDUCED OBESITY ON FEMALE RAT LIVERS (A HISTOCHEMICAL STUDY). 2005 , 2,	20
563	Obesity and T2DM in Youth. 2008 , 125-137	1
562	Clinical significance of serum alanine aminotransferase and lifestyle intervention in children with nonalcoholic fatty liver disease. 2016 , 59, 362-367	4
561	Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. 2020 , 35, e104	2
560	Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia. 2020 , 35, e164	2
559	Quantitative Evaluation of Hepatic Steatosis Using Normalized Local Variance in a Rat Model: Comparison with Histopathology as the Reference Standard. 2019 , 20, 1399-1407	2
558	Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH. 2012 , 18, 279-86	10
557	Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. 2013 , 19, 266-72	59
556	The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study. 2018 , 24, 392-401	21
555	Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights. 2020 , 26, 728-735	9
554	[Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease]. 2008 , 14, 1-3	2
553	[Nonalcoholic steatohepatitis: pathogenesis and treatment]. 2008 , 14, 12-27	3
552	[Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis]. 2008 , 14, 77-88	33
551	[Validity and reliability of the nonalcoholic fatty liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors]. 2010 , 16, 29-37	3

550	Development and validation of a simple index system to predict nonalcoholic fatty liver disease. 2011 , 17, 19-26	12
549	Apoptosis and diagnosis of nonalcoholic steatohepatitis. 2011 , 17, 247-9	1
548	Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin. 2012 , 61, 185-93	9
547	Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes. 2020 , 12,	10
546	Is there an effective therapy available for non-alcoholic fatty liver disease?. 2009 , 1,	2
545	The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. 2020 , 10, 542-555	3
544	Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events. 2020 , 12, 65-88	1
543	Perspectives of nonalcoholic fatty liver disease research: a personal point of view. 2020 , 1, 85-107	10
542	Nonalcoholic fatty liver disease and portal hypertension. 2020 , 1, 149-169	8
541	Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: a multicenter randomized controlled trial. 2008 , 6, 128-33	11
540	Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. 2008 , 14, 22-8	120
539	Non-invasive means of measuring hepatic fat content. 2008 , 14, 3476-83	198
538	Blood F2-isoprostanes are significantly associated with abnormalities of lipid status in rats with steatosis. 2008 , 14, 4677-83	10
537	Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases. 2009 , 15, 1093-8	6
536	Olive oil consumption and non-alcoholic fatty liver disease. 2009 , 15, 1809-15	102
535	Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. 2009 , 15, 5193-9	35
534	A better parameter in predicting insulin resistance: obesity plus elevated alanine aminotransferase. 2009 , 15, 5598-603	15
533	Clinical features and risk factors of patients with fatty liver in Guangzhou area. 2004 , 10, 899-902	15

532	Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. 2005 , 11, 2346-50	14
531	Nonalcoholic fatty liver disease in developing countries. 2005 , 11, 3808-9	2
530	Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. 2005 , 11, 5314-21	38
529	Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. 2005 , 11, 5834-9	48
528	Is adiponectin level a predictor of nonalcoholic fatty liver disease in nondiabetic male patients?. 2005 , 11, 5874-7	18
527	Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw. 2005 , 11, 1339-44	33
526	Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. 2006 , 12, 4369-76	42
525	Fatty liver, carotid disease and gallstones: a study of age-related associations. 2006 , 12, 5826-33	46
524	Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. 2006 , 12, 7821-5	38
523	Pathogenesis and management issues for non-alcoholic fatty liver disease. 2007 , 13, 4539-50	187
522	Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation. 2007 , 13, 649-50	28
521	Prevalence of fatty liver disease and its risk factors in the population of South China. 2007 , 13, 6419-24	171
520	Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. 2010 , 16, 1436-41	100
519	Steatosis and steatohepatitis in postmortem material from Northwestern Greece. 2010 , 16, 3944-9	46
518	Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology. 2010 , 16, 5280-5	34
517	Leptin in hepatocellular carcinoma. 2010 , 16, 5801-9	46
516	Pro12Ala polymorphism of the peroxisome proliferator-activated receptor α in patients with fatty liver diseases. 2010 , 16, 5830-7	30
515	Adiponectin, a key adipokine in obesity related liver diseases. 2011 , 17, 2801-11	170

514	Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. 2011 , 17, 3082-91	89
513	IB kinase-beta inhibitor attenuates hepatic fibrosis in mice. 2011 , 17, 5203-13	12
512	Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. 2012 , 18, 1781-8	49
511	Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. 2012 , 18, 156-67	63
510	Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. 2013 , 19, 6453-7	23
509	Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies. 2013 , 19, 1359-71	17
508	NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis. 2014 , 20, 4987-93	66
507	Role of liver biopsy in nonalcoholic fatty liver disease. 2014 , 20, 9026-37	104
506	Nonalcoholic fatty liver disease and the heart in children and adolescents. 2014 , 20, 9055-71	24
505	Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?. 2014 , 20, 9072-89	85
504	Role of diet and lifestyle changes in nonalcoholic fatty liver disease. 2014 , 20, 9338-44	75
503	Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. 2014 , 20, 10108-14	16
502	Osthol attenuates hepatic steatosis via decreased triglyceride synthesis not by insulin resistance. 2014 , 20, 11753-61	11
501	Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. 2014 , 20, 12566-73	12
500	Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. 2014 , 20, 14205-18	236
499	Delayed ethanol elimination and enhanced susceptibility to ethanol-induced hepatosteatosis after liver resection. 2014 , 20, 18249-59	1
498	Cholecystectomy does not significantly increase the risk of fatty liver disease. 2015 , 21, 3614-8	7
497	Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. 2016 , 22, 394-406	10

496	Fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment using computed tomography volumetry. 2016 , 22, 8949-8955	5
495	Effect of liver cirrhosis on long-term outcomes after acute respiratory failure: A population-based study. 2017 , 23, 2201-2208	9
494	Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease. 2017 , 23, 2771-2784	40
493	Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis. 2018 , 24, 4132-4151	11
492	Freeze-dried Si-Ni-San powder can ameliorate high fat diet-induced non-alcoholic fatty liver disease. 2019 , 25, 3056-3068	9
491	Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. 2019 , 25, 3664-3668	5
490	Association between non-alcoholic fatty liver disease and obstructive sleep apnea. 2020 , 26, 2669-2681	11
489	Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. 2020 , 26, 4933-4944	2
488	Effects of low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. 2003 , 9, 2045-9	35
487	Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats. 2020 , 22, 2948-2956	2
486	Serum Fetuin A Level, Liver Enzymes Activities and Insulin Resistance in Patients with Type 2 Diabetes. 2015 , 15, 229-234	2
485	Histological Evaluation of the Rats Testis Following Administration of a Herbal Tea Mixture. 2008 , 3, 464-470	8
484	Effect of Rosa canina Distilled Water on Tamoxifen-treated Male Wistar Rats. 2020 , 23, 173-180	5
483	Nonalcoholic fatty liver disease. 2006 , 35, 290-4, 297-9	12
482	Towards a more complete understanding of the occurrence and toxicities of the cylindrospermopsins. 2015 , 2, 827-851	4
481	[The association of cardiovascular risk factors with nonalcoholic fatty liver disease in health checkup examinees]. 2008 , 41, 407-12	5
480	Aggravation of nonalcoholic steatohepatitis by moderate alcohol consumption is associated with decreased SIRT1 activity in rats. 2013 , 2, 252-9	17
479	Fatty liver disease in diabetes mellitus. 2015 , 4, 101-8	78

478	Carotenoids and non-alcoholic fatty liver disease. 2015 , 4, 161-71	27
477	Association Between Appendectomy and Fibrosis Progression in Nonalcoholic Fatty Liver Disease. 2013 , 6, 17-25	3
476	A Close Relationship between Non-Alcoholic Fatty Liver Disease Marker and New-Onset Hypertension in Healthy Korean Adults. 2020 , 50, 695-705	5
475	Predictors Related to the Non-alcoholic Fatty Liver Disease. 2010 , 31, 94	3
474	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. 2020 , 44, 382-401	16
473	Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus. 2010 , 30, 25-32	11
472	Glycogen hepatopathy in a 13-year-old male with type 1 diabetes. 2011 , 31, 424-7	11
471	Role of Eglutamyl transferase levels in prediction of high cardiovascular risk among patients with non-alcoholic fatty liver disease. 2016 , 143, 30-6	6
470	Systematic review of statins in sepsis: There is no evidence of dose response. 2016 , 20, 534-41	6
469	The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. 2015 , 21, 139-45	16
468	Reversal of liver fibrosis. 2009 , 15, 72-9	70
467	The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease. 2016 , 7, 28	55
466	The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. 2016 , 7, 59	48
465	Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?. 2015 , 4, 45-52	32
464	Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. 2016 , 5, 28	34
463	The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. 2017 , 6, 40	33
462	Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study. 2020 , 9, 390-394	9
461	Determination of association between nonalcoholic fatty liver disease and carotid artery atherosclerosis among nondiabetic individuals. 2020 , 9, 1182-1186	2

460	Association of nonalcoholic fatty liver and chronic kidney disease: An analysis of 37,825 cases from health checkup center in Taiwan. 2020 , 32, 65-69	3
459	High Fat Diet-Induced Changes in Hepatic Protein Abundance in Mice. 2012 , 5, 60-66	9
458	Insulin resistance with impaired fasting glucose increases the risk of NAFLD. 2013 , 03, 170-176	4
457	Polymorphisms in methylenetetrahydrofolate reductase gene: Their impact on liver steatosis and fibrosis of chronic hepatitis c patients. 2014 , 04, 73-80	1
456	Effect of Vitamin E and Alpha Lipoic Acid in Nonalcoholic Fatty Liver Disease: A Randomized, Placebo-Controlled, Open-Label, Prospective Clinical Trial (VAIN Trial). 2014 , 04, 199-207	3
455	PNPLA3 and TNF- α G238A Genetic Polymorphisms in Egyptian Patients with Different Grades of Severity of NAFLD. 2016 , 06, 53-64	3
454	Hypolipidemic Activity of Olive Oil (<i>Olea europaea</i>) against High Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) in Mice. 2015 , 05, 73-83	4
453	The Effect of Atorvastatin on Liver Function among Patients with Coronary Heart Disease in Gaza Strip. 2014 , 05, 781-788	2
452	A defect in the activities of Δ^5 and Δ^6 desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease. 2011 , 2, 176-88	12
451	Nonalcoholic steatohepatitis and insulin resistance in children. 2014 , 5, 917-23	12
450	One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation. 2018 , 10, 956-965	3
449	Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. 2011 , 3, 219-27	13
448	CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy. 2013 , 5, 189-95	8
447	Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. 2014 , 6, 800-11	52
446	Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. 2014 , 6, 263-73	78
445	Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort. 2015 , 7, 1586-94	16
444	Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: Pathology and beyond. 2015 , 7, 1905-12	16
443	Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma. 2015 , 7, 2155-61	47

442	Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. 2015 , 7, 2459-69	22
441	Egg consumption and risk of non-alcoholic fatty liver disease. 2017 , 9, 503-509	23
440	Nonalcoholic Fatty Liver Disease in South Asia. 2016 , 6, 154-162	11
439	Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan. 2016 , 10, 437-45	20
438	Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. 2017 , 11, 674-683	7
437	Serum levels of gamma-glutamyl transferase are associated with cardiovascular disease in obstructive sleep apnea syndrome. 2013 , 33, 584-90	2
436	Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus. 2010 , 30, 25-32	10
435	Role of Soluble Adiponectin Receptor 2 in Non-Alcoholic Fatty Liver Disease in Children. 2019 , 22, 470-478	2
434	Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. 2020 , 23, 189-230	56
433	Sleep apnea and fatty liver disease: The growing link and management issues. 2014 , 4, 11	2
432	Anthropometric and biochemical characteristics of patients with nonalcoholic fatty liver diagnosed by non-invasive diagnostic methods. 2014 , 68, 22-6	8
431	Monoacylglycerol O-acyltransferase 1 (MGAT1) localizes to the ER and lipid droplets promoting triacylglycerol synthesis. 2017 , 50, 367-372	10
430	Effects of Medicinal herb Extracts and their Components on Steatogenic Hepatotoxicity in Sk-hep1 Cells. 2011 , 27, 211-6	13
429	Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. 2014 , 4, 81-92	19
428	Non-alcoholic fatty liver disease (NAFLD)--a novel common aspect of the metabolic syndrome. 2006 , 150, 101-4	17
427	The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. 2015 , 159, 442-8	5
426	Effect of aerobic exercise training on non-alcoholic fatty liver disease induced by a high fat diet in C57BL/6 mice. 2014 , 18, 339-46	46
425	Predictive Factors of Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Undergoing Bariatric Surgery. 2017 , 17,	1

424	Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD). 2018 , 18,	6
423	Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease. 2014 , 16, e12669	12
422	Metabolic syndrome, insulin resistance and Fatty liver in obese Iranian children. 2014 , 16, e6656	7
421	Obesity and Air Pollution: Global Risk Factors for Pediatric Non-alcoholic Fatty Liver Disease. 2011 , 11, 794-802	23
420	Comparison of Portal Vein Doppler Indices and Hepatic Vein Doppler Waveform in Patients with Nonalcoholic Fatty Liver Disease with Healthy Control. 2011 , 11, 740-744	16
419	Steatosis and steatohepatitis found in adults after death due to non-burn trauma. 2019 , 74, e1070	2
418	Protective effect of grape seed proanthocyanidins against liver ischemic reperfusion injury: particularly in diet-induced obese mice. 2012 , 8, 1345-62	18
417	Lipoprotein metabolism in nonalcoholic fatty liver disease. 2013 , 27, 1-13	53
416	Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease. 2019 , 28, 129-138	18
415	Accuracy of Multi-echo Dixon Sequence in Quantification of Hepatic Steatosis. 2020 , 12, e7103	1
414	Association between Inflammatory Biomarkers and Nutritional Status in Fatty Liver. 2020 , 9, 182-194	1
413	Extract of <i>Siraitia grosvenorii</i> (Luo Han Guo) protects against hepatic fibrosis in mice on a choline-deficient, methionine-lowered, L-amino acid-defined, high-fat diet without trans fatty acids. 2021 , 8, 135-145	0
412	The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease. 2021 , 9,	3
411	Oral Pathobiont-Induced Changes in Gut Microbiota Aggravate the Pathology of Nonalcoholic Fatty Liver Disease in Mice. 2021 , 12, 766170	5
410	Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma. 2021 , 10,	1
409	Microtechnology-based models: Mimicking liver function and pathophysiology. 2021 , 5, 041505	2
408	Leber- und Gallenwegstherapeutika. 2003 , 505-516	
407	Histopathologic and Radiologic Classification of Liver Pathologies. 2003 , 47-103	

- 406 Erkrankungen von Leber, Gallenwegen und Pankreas. **2003**, 863-954
- 405 Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. **2003**, 73-85
- 404 Nonalcoholic Fatty Liver Disease. **2004**, 733-736
- 403 Pathogenesis and Management of Non-alcoholic Steatohepatitis. **2005**, 48, 169
- 402 Chronic Liver Disease and Transplantation. **2005**, 530-543
- 401 Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in Patients with Childhood-Onset Adult Growth Hormone Deficiency. **2005**, 14, S24_85-S24_88
- 400 Psychosocial Assessment of Adult Liver Transplant Recipients. **2005**, 395-404
- 399 Leber und Gallenblase/-wege. **2005**, 143-183
- 398 Statiny v lechenii dislipidemii pri sakharnom diabete 2 tipa. **2005**, 2, 21-26
- 397 The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease. **2006**, 2006, 440-442 1
- 396 Prevalence of Metabolic Syndrome in Type 2 DM Patients with Non-alcoholic Fatty Liver. **2006**, 30, 442 1
- 395 Liver Disease. **2006**,
- 394 Cirrhosis and Portal Hypertension: Pathologic Aspects. **2007**, 1527-1540
- 393 [Ultrasonography findings of liver in textile workers for diagnosing nonalcoholic fatty liver disease]. **2007**, 135, 532-5 1
- 392 Selected Organ System Abnormalities. **2007**, 137-482
- 391 Gastric Bypass Surgery Improves Metabolic and Hepatic Abnormalities Associated With Nonalcoholic Fatty Liver Disease. **2007**, 2007, 442-443
- 390 Clinical significance of acanthosis nigricans in children and adolescents with obesity induced metabolic complications. **2007**, 50, 987 4
- 389 Nonalcoholic Fatty Liver Disease and Diabetes Mellitus. **2007**, 553-560

- 388 The Liver, Glucose Homeostasis, and Insulin Action in Type 2 Diabetes Mellitus. **2008**, 343-372
- 387 Liver Transplantation for Nonalcoholic Fatty Liver Disease. **2009**, 169-190
- 386 Erkrankungen des Gastrointestinalsystems. **2009**, 841-1057
- 385 Resultados metabólicos de la cirugía bariátrica. **2009**, 388-393
- 384 Leber und Gallenblase/-wege. **2009**, 171-212 1
- 383 The Metabolic Syndrome. **2009**, 69-81 1
- 382 Potential role of ursodeoxycholic acid and its side-chain modified derivatives in the treatment of non-alcoholic fatty liver disease and associated atherosclerosis. **2009**, 151-156
- 381 Liver: Normal Anatomy, Imaging Techniques, and Diffuse Diseases. **2009**, 1455-1499 1
- 380 Metabolic Disease and Hepatocellular Carcinoma. **2009**, 283-307
- 379 Biosynthesis and Storage of Fatty Acids. **2009**, 195-203
- 378 Prevalence of Fatty Liver and Its Association with Indices of Obesity, Liver Function and Hyperlipidemia among Adult Males. **2009**, 10, 1414-1423 2
- 377 Association of Alcoholic & Nonalcoholic Fatty Liver Disease with Metabolic Syndrome in Health Screen Examinees of Men. **2009**, 9, 237-246
- 376 Using Parenteral Fish Oil In Nash. **2009**, 81-95
- 375 Clinical usefulness of glucose tolerance test in nonalcoholic fatty liver disease patients without overt diabetes mellitus. **2010**, 51, 586-588
- 374 Nonalcoholic Fatty Liver Disease. **2010**, 534-538
- 373 Fatty Liver. **2011**, 437-447
- 372 La stâto-hpatite non alcoolique. Influence de la nutrition, de la physiopathologie au traitement. **2011**, 35-46
- 371 2.?????????????????????????????????????. **2011**, 42, 67-68

- 370 Prevalência de esteatose hepática e consumo de álcool em participantes do Projeto Atividade Física na Vila. **2011**, 6, 46-51
- 369 Patología de hígado graso no-alcohólico (HGNA) asociada a obesidad: mecanismos patogénicos. **2011**, 11,
- 368 Epidemiology of Liver Disease in Human Immunodeficiency Virus-Infected Persons. **2012**, 9-13 1
- 367 Validity of Ultrasonography in the Diagnosis of Non-alcoholic Fatty Liver Disease in Living Liver Donors. **2011**, 11, 342-348
- 366 Chronic HCV and HIV Coinfection. **2012**, 75-91
- 365 Elevated Levels of Serum Ferritin May be Related to Non-Alcoholic Steatohepatitis. **2011**, 1, 13-20
- 364 Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). **2012**, 399-407
- 363 Obesity-associated steatotic liver exhibits aberrant or altered sphingolipid composition and preferentially accumulates ceramide species containing long chain fatty acids. **2012**, 04, 1578-1587 1
- 362 Modern CT and MR Applications. **2012**, 297-313
- 361 The Role of Inflammatory Mediators in the Pathogenesis of Nonalcoholic Fatty Liver Disease. **2012**, 15, 74 1
- 360 Effects of Tong Xin Lou (TXL) on levels of serum lipid in high fat diet-induced dyslipidemia in mice. **2012**, 27, 107-112 1
- 359 Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. **2013**, 497-506
- 358 Nutrition and Alcoholic and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol. **2013**, 523-532
- 357 Effect of Aerobic Exercise and Gym-ball Exercise on the Liver Function Test Index, Adipokines, and Cardiovascular Risk Factors in Obese Children with Nonalcoholic Fatty Liver Disease. **2012**, 22, 1261-1267 1
- 356 Lifestyle Intervention and Vitamin E Therapy in Obese Children with Nonalcoholic Fatty Liver Disease. **2012**, 3,
- 355 N. **2013**, 729-749
- 354 A Hierarchy of Healing: The Therapeutic Order. **2013**, 18-33 1
- 353 Role of Protein Tyrosine Phosphatase 1B in Hepatocyte-Specific Insulin and Growth Factor Signaling. **2013**, 107-127

- 352 EVALUATION OF CARDIOVASCULAR RISK BY CAROTID INTIMA MEDIA THICKNESS IN NON ALCOHOLIC FATTY LIVER DISEASE. **2013**, 2, 8110-8114
- 351 Hepatosteatosi and Primary Hepatoma. **2014**, 1-7
- 350 Obese Patients in Critical Care: Nutritional Support Through Enteral and Parenteral Routes. **2014**, 1-17
- 349 Comparison of the Characteristics of Patients with diabetes as Diagnosed Using Three Different Tests. **2014**, 4, 71
- 348 Fructose, High Fructose Corn Syrup, Sucrose, and Nonalcoholic Fatty Liver Disease. **2014**, 325-339 1
- 347 Obesity. **2014**, 127-146
- 346 The Improvement Effect of Fermented Angelica gigas Nakai Powder Against Orotic Acid-induced Fatty Liver in Rats. **2014**, 24, 411-418
- 345 Fatty Liver Vulnerability to Hypoxic and Inflammatory Stress. **2014**, 27-52
- 344 Hepatitis C virus capsid protein and intracellular lipids interplay and its association with hepatic steatosis. **2014**, 14, e17812 5
- 343 Hepatosteatosi and Primary Hepatoma. **2015**, 1365-1371
- 342 Role of adipokines in the pathogenesis of nonalcoholic fatty liver disease. **2015**, 4, 31 0
- 341 [Transplantation of left lateral liver sector to child from mother with liver steatosis]. **2015**, 77-79
- 340 Sublethal Injuries and Deaths of Cells and Tissues. **2015**, 265-285
- 339 Diagnosis of experimental steatohepatosis using ultrasound shear wave elastography. **2015**, 26, 109-113 0
- 338 Atherosclerosis and Liver Function Tests in Coronary Angiography Patients. **2015**, 64, 333-7 2
- 337 Correlation between Non-Alcoholic Fatty Liver Disease and Carotid Intima-Media Thickness in Patient with Type II Diabetes. **2015**, 8, 35-41 0
- 336 Gastrointestinal Manifestations of Systemic Diseases. 2399-2439
- 335 LIPID METABOLISM DISORDERS IN PATIENTS WITH CHRONIC HEPATITIS C. **2015**, 50-56 1

334 Nonalcoholic Fatty Liver Disease Post-Liver Transplantation. **2016**, 145-152

333 Clinical Research on the Turbidity Relief Formula in the Treatment of Nonalcoholic Fatty Liver Disease. **2016**, 05, 60-35

332 Non-alcoholic Fatty Liver Disease in Obesity. **2016**, 159-179

331 Metabolic Syndrome and the Liver. **2016**, 149-177

330 Heart Disease and the Liver: Interactions Between the Heart and the Liver. **2016**, 179-202

329 Metabolic Disease and Hepatocellular Carcinoma. **2016**, 287-301

328 SONOGRAPHICALLY DIAGNOSED NON-ALCOHOLIC FATTY LIVER AS A PREDICTOR OF METABOLIC SYNDROME. **2016**, 5,

327 A Case Study on A Patient with Non-Alcoholic Fatty Liver Disease (NAFLD) by Using Ultrasound. **2016**, 37, 151-157

4

326 The Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With and Without Coronary Artery Disease. **2016**, 5,

325 Metabolic Effects of Foenugreek, Nigella and Termis: Review Article. 3, 90-96

324 A STUDY OF NONALCOHOLIC FATTY LIVER DISEASE AND FATTY LIVER INDEX IN TYPE 2 DIABETES MELLITUS PATIENTS. **2016**, 3, 3001-3006

323 Fatty liver formation in fulminant type 1 diabetes. **2015**, 2016,

322 COMPLICATIONS OF STATIN THERAPY AND THEIR MANAGEMENT. **2016**, 5, 4745-4750

321 Non-Alcoholic Fatty Liver Disease Frequency among Healthy Blood Donors in the West of Iran. **2016**, 2, 001-004

320 STUDY OF NON-ALCOHOLIC STEATOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN A TERTIARY HOSPITAL. **2016**, 5, 6360-6363

319 Treatment of Hepatic Malignancies and Disorders: The Role of Liver Bioengineering. **2017**, 249-276

318 INDIAN DIABETES RISK SCORE FOR NONALCOHOLIC FATTY LIVER DISEASE. **2016**, 3, 5700-5705

317 Parenchymal preservation in hepatic resectional surgery. **2017**, 1631-1643.e2

- 316 Lipotoxicity in Non-parenchymal Liver Cells. **2017**, 1-21
- 315 Pentraxin 3 (PTX3) as a Biomarker of Liver Disease. **2017**, 603-621 2
- 314 Biomarkers in Focus: Alanine Aminotransferase. **2017**, 267-280 1
- 313 Genetics of Liver Diseases. **2017**, 43-65
- 312 [Clinical and metabolic features of nonalcoholic fatty liver disease in men and women]. **2017**, 89, 45-51
- 311 On the Impact of Nonalcoholic Fatty Liver Disease, Confirmed by Biopsy, on the Results of the Two-Dimensional Shear Elastography. **2017**, 88-95
- 310 The Herbal Composition Gangjihwan from Ephedra intermedia, Lithospermum erythrorhizon and Rheum palmatum Ameliorates Hepatic Inflammation and Fibrosis in Obese C57BL/6J Mice and HepG2 Cells. **2017**, 23, 144-153
- 309 ASSOCIATION OF INTESTINAL AMOEBIASIS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)- A CASE-CONTROL STUDY. **2017**, 4, 3577-3581 0
- 308 Which Method is Superior in the Diagnosis of Nonalcoholic Fatty Liver and Steatohepatitis in Children?. **2017**, 17,
- 307 The Distribution and Characteristics of Abnormal Findings Regarding Fasting Plasma Glucose and HbA1c - Based on Adults Except for Known Diabetes. **2017**, 49, 239-247 1
- 306 Non Alcoholic Fatty Liver Disease: Assessment of Lipid Profile Estimation in Different Grades of Fatty Liver on Ultrasound. **2018**, 08, 70-83
- 305 Abnormal Liver Tests. **2018**, 507-518
- 304 Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms. **2018**, 64, 735-741
- 303 SONOGRAPHIC CORRELATION OF CAROTID INTIMA MEDIA THICKNESS AND HEPATIC ECHOTEXTURE WITH SERUM LIPID PROFILE. **2018**, 7, 3380-3384
- 302 New approaches to correction of hyperammonemia in patients with non-alcohol steatohepatitis □ liquidators of consequences of the accident at Chernobyl APP and personnel of the Federal Fire Service of the EMERCOM of Russia. **2018**, 26-34
- 301 Nonalcoholic Fatty Liver Diseases among Recently Diagnosed Patients with Diabetes Mellitus and Risk Factors. **2019**, 9, 9-13 2
- 300 Silent Gallbladder Stone Associated with Nonalcoholic Fatty Liver Disease in a Scenario of Insulin Resistance in Young Adults. **2019**, 23, 226-229
- 299 Hepatocellular Carcinoma. **2019**, 207-234

- 298 THE ROLE OF HYPERURUREMIA IN PROGRESSION AND PATHOGENESIS OF NON-ALCOHOLIC FATTY LIVER DISEASE. **2019**, 3, 145-150
- 297 Hepatoprotective Effect of Fresh Grape Juice Prepared by a Low-Speed Masticating Juicer in db/db Mice. **2019**, 24, 95-101 1
- 296 BIOCHEMICAL PROFILE AND VARIOUS TREATMENT MODALITIES OF PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH). **2019**, 8, 1405-1407
- 295 Association of Non-Alcoholic Fatty Liver Disease with Increased Carotid Intima-Media Thickness Considering Other Cardiovascular Risk Factors. **2019**, 16, 0
- 294 Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of non-alcoholic steatohepatitis.
- 293 The association between coronary artery disease and nonalcoholic fatty liver disease and noninvasive imaging methods. **2019**, 16, em165
- 292 Clinical and Metabolic Profiles of Patients with Lean Non-Alcoholic Fatty Liver Diseases (NAFLD) Attending a Tertiary Health Care Centre of North-Eastern Region. **2019**, 6, 3192-3196
- 291 A Hierarchy of Healing. **2020**, 11-24.e4
- 290 Semi-quantitative ultrasound assessment of nonalcoholic fatty liver disease highlightens early subclinical atherosclerotic vascular damage: From risk factors to vascular damage. **2020**, 0
- 289 Consumption of a high energy density diet triggers microbiota dysbiosis, hepatic lipidosis, and microglia activation in the nucleus of the solitary tract in rats.
- 288 Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: A nationwide population-based study in Korea.
- 287 Assessment of Glutathione Level in Non-Alcoholic Fatty Liver Disease Patients. **2020**, 3, 19-22 1
- 286 Hepatogenic diabetes is an old term and new meaning. **2020**, 19-24
- 285 GeñiBen Gñññe Yñsek Fruktozlu Mññ Òrubu ve Sañk Etkileri Ñerine Bir Derleme. 1
- 284 A STUDY TO DETERMINE FOLLOW-UP STRATEGY FOR DIFFERENTIATING A TRUE INACTIVE CARRIERS FROM CHRONIC HEPATITIS PATIENTS WITH HBEAG NEGATIVE BY THE HBV DNA CUTOFF VALUE. **2020**, 1-2
- 283 Could Disease Activity Score in 28 Joints-Gamma-glutamyl Transferase Use Improve Cardiovascular Disease Risk Management in Rheumatoid Arthritis?. **2020**, 47, 1729-1731
- 282 Dexmedetomidine ameliorates high-fat diet-induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice. **2021**, 9, e00700 5
- 281 Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis. **2020**, 20, 1800-1808 1

- 280 Effect of Circuit Resistance Training and L-Carnitine Supplementation on Body Composition and Liver Function in Men with Non-Alcoholic Fatty Liver Disease. **2019**, 8, 1
- 279 Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: A nationwide population-based study in Korea.
- 278 MR spectroscopy of the liver - a reliable non-invasive alternative for evaluating non-alcoholic fatty liver disease. **2020**, 61, 73-80 1
- 277 Efficacy of powder (a polyherbal formulation) and lifestyle modification in the management of nonalcoholic fatty liver disease-A randomized placebo-controlled clinical trial.. **2020**, 41, 98-106
- 276 Real-Time Morphing of the Visible Man Liver with Intrahepatic Vasculatures. **2020**, 150-159
- 275 Obesity. **2020**, 165-184
- 274 Apricot. **2020**, 523-545 0
- 273 Non-invasive Assessment of Non-alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. **2020**, 115-139 1
- 272 Alkoholische Lebererkrankungen (ALD). **2020**, 159-186
- 271 Ultrasound elastography in patients with fatty liver disease. **2020**, 53, 47-55 4
- 270 Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: A nationwide population-based study in Korea.
- 269 Imaging methods in the assessment of nonalcoholic fatty liver disease. **2020**, 53, IX-X
- 268 NMR microsystem for label-free characterization of 3D nanoliter microtissues.
- 267 Perspectives in liver redox imbalance: Toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action. **2021**, 5
- 266 Lipidomic-based investigation into the therapeutic effects of polyene phosphatidylcholine and Babao Dan on rats with non-alcoholic fatty liver disease. **2021**, 36, e5271
- 265 Raman imaging analysis of microvesicular and macrovesicular lipid droplets in non-alcoholic fatty liver disease.
- 264 Keratins as Targets in and Modulators of Liver Diseases. **2006**, 120-130
- 263 Should non-alcoholic fatty liver disease be treated differently in elderly patients?. 249-250

262	Ectopic Fat and the Metabolic Syndrome. 2006 , 125-136	
261	Molecular mechanisms of fibrosis progression in non-alcoholic steatohepatitis (NASH). 75-82	
260	Nutrition Aspects of Liver Failure. 2008 , 85-106	1
259	Sleep and Quality of Life in Obesity. 2008 , 445-452	
258	Diffuse Liver Diseases. 2021 , 69-97	
257	Pseudolesions in the Cirrhotic Liver. 2021 , 229-266	
256	Impact of Fasting Lipid Profile on Chronic Kidney Disease Patients Having Fatty Liver Disease. 2020 , 12, e11146	1
255	Obstructive sleep apnea and severity of nonalcoholic fatty liver disease. 2021 , 33, 1104-1109	3
254	Increased hepatocellular uptake of long chain fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol use, contributing to development of steatohepatitis in both settings. 2005 , 116, 335-44; discussion 345	25
253	Hepatosteatosi s with hypobetalipoproteinemia. 2007 , 99, 284-6	9
252	Frequency of nonalcoholic fatty liver disease and degree of hepatic steatosis in African-American patients. 2006 , 98, 1613-5	19
251	Non alcoholic fatty liver disease and metabolic syndrome. 2009 , 13, 9-19	295
250	Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. 2010 , 2, 95-104	90
249	The treatment of hepatic encephalopathy in the cirrhotic patient. 2010 , 6, 1-12	1
248	Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation. 2010 , 3, 675-80	28
247	PURLs: statins for patients with nonalcoholic fatty liver?. 2011 , 60, 536-8	6
246	The HBV DNA cutoff value for discriminating patients with HBeAgnegative chronic hepatitis B from inactive carriers. 2011 , 11, 351-7	2
245	N-acetylcysteine improves liver function in patients with non-alcoholic Fatty liver disease. 2010 , 10, 12-6	34

244	A case of cryoglobulinemia associated with nonalcoholic steatohepatitis. 2012 , 8, 279-81	1
243	Evaluation of relationship between grading of fatty liver and severity of atherosclerotic finding. 2012 , 5, 251-6	4
242	Association between Insulin Resistance, Metabolic Syndrome and Nonalcoholic Fatty Liver Disease in Chinese Adults. 2012 , 41, 45-9	8
241	Hepatic fat assessment using advanced Magnetic Resonance Imaging. 2012 , 2, 213-8	5
240	What is the real function of the liver 'function' tests?. 2012 , 81, 30-6	47
239	The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS. 2013 , 11, 725-32	15
238	Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. 2012 , 25, 45-51	47
237	Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. 2012 , 8, 661-8	28
236	Probiotics and Nonalcoholic Fatty liver Disease. 2013 , 5, 129-36	37
235	The effect of an aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non alcoholic fatty liver disease. 2013 , 6, S112-6	11
234	Effect of non-alcoholic fatty liver disease on carotid artery intima-media thickness as a risk factor for atherosclerosis. 2014 , 7, 55-62	12
233	Recurrence of Disease Following Liver Transplantation: Nonalcoholic Steatohepatitis vs Hepatitis C Virus Infection. 2011 , 2, 57-65	8
232	The effect of weight reduction on ultrasonographic findings of nonalcoholic Fatty liver. 2010 , 2, 5-8	
231	Genetic variation I148M in patatin-like phospholipase 3 gene and risk of non-alcoholic fatty liver disease among Filipinos. 2014 , 7, 2129-36	10
230	The hepatoprotective and hypolipidemic effects of Spirulina () supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study. 2014 , 27, 387-394	18
229	Association between non-alcoholic fatty liver disease and ischemic stroke. 2014 , 13, 144-8	16
228	Assessment of hepatic steatosis on contrast enhanced computed tomography in patients with colorectal cancer. 2014 , 7, 4342-6	6
227	Sonographic assessment of fatty liver: intraobserver and interobserver variability. 2014 , 7, 5453-60	28

226	Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. 2009 , 10, 1049-60	91
225	Evaluation of Nonalcoholic Fatty Liver Disease in C57BL/6J Mice by Using MRI and Histopathologic Analyses. 2015 , 65, 409-15	5
224	Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis. 2015 , 15, 1-58	5
223	Higher serum total bilirubin concentration is associated with lower risk of renal insufficiency in an adult population. 2015 , 8, 19212-22	6
222	Liver fat content is negatively associated with atherosclerotic carotid plaque in type 2 diabetic patients. 2015 , 5, 792-8	7
221	A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging. 2015 , 34, 189-94	17
220	Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. 2016 , 9, 158-73	44
219	Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. 2006 , 2, 282-291	8
218	8-pCPT-cGMP prevents mitochondrial depolarization and improves the outcome of steatotic partial liver transplantation. 2017 , 9, 69-83	3
217	Therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced fatty liver disease, fibrosis and inflammation in rabbit. 2017 , 9, 3827-3841	3
216	Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. 2017 , 10, S1-S7	20
215	Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis. 2017 , 3, 35-40	2
214	A randomized controlled trial comparing effects of a low-energy diet with n-3 polyunsaturated fatty acid supplementation in patients with non-alcoholic fatty liver disease. 2019 , 24, 21	4
213	Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. 2019 , 12, 46-54	3
212	Role of mitochondrial depolarization and disrupted mitochondrial homeostasis in non-alcoholic steatohepatitis and fibrosis in mice. 2019 , 11, 190-204	10
211	Mortality disparities: A comparison with the Haudenosaunee in New York State. 2018 , 2,	
210	NASH and cryptogenic cirrhosis: a histological analysis. 2009 , 8, 346-52	40
209	Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. 2021 , 16, 196-206	0

208	An Emerging Facet of Diabetes Mellitus: The Nexus of Gastrointestinal Disorders. 2021 , 13, e18245	
207	Diagnosis of steatohepatitis and fibrosis in biopsy-proven nonalcoholic fatty liver diseases: including two-dimension real-time shear wave elastography and noninvasive fibrotic biomarker scores.. 2022 , 12, 1800-1814	0
206	PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD. 2021 , 21, 434	1
205	Priming, Triggering, Adaptation and Senescence (PTAS): A Hypothesis for a Common Damage Mechanism of Steatohepatitis. 2021 , 22,	
204	Association of Hepatic Steatosis Index with Nonalcoholic Fatty Liver Disease Diagnosed by Non-Enhanced CT in a Screening Population.. 2021 , 11,	4
203	Nonalcoholic Fatty Liver Disease. 2022 , 911-930	
202	A new perspective on NAFLD: focusing on lipid droplets. 2021 ,	8
201	Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort. 2021 ,	2
200	Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. 2021 ,	
199	Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage. 2021 , 1-8	0
198	Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis. 2017 , 3, 35	5
197	Increasing risk factors of non-alcoholic fatty liver disease, a look into chronic periodontitis and insulin resistance.. 2022 ,	
196	Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.. 2022 , 104, 108503	3
195	The Echogenic Liver: Steatosis and Beyond. 2020 , 37, 308-314	0
194	The Multifaceted Actions of Curcumin in Obesity.. 2021 , 1328, 81-97	0
193	One-Hour Postload Plasma Glucose in Obese Indian Adults with Nonalcoholic Fatty Liver Disease: An Observational Study from North India.. 2021 , 25, 450-455	0
192	Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease.. 2022 , 23,	1
191	The Role of Tea Tree Oil in Alleviating Palmitic Acid-Induced Lipid Accumulation in Bovine Hepatocytes.. 2021 , 8, 814840	1

190	Hepatic galectin-3 is associated with lipid droplet area in non-alcoholic steatohepatitis in a new swine model.. 2022 , 12, 1024	1
189	The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients.. 2022 , 19,	2
188	Quantitative Evaluation of Hepatic Steatosis Using Advanced Imaging Techniques: Focusing on New Quantitative Ultrasound Techniques.. 2022 , 23, 13-29	4
187	Mediterranean Diet and Fatty Liver Risk in a Population of Overweight Older Italians: A Propensity Score-Matched Case-Cohort Study.. 2022 , 14,	0
186	Effect of Persimmon Extracts on High-Fat Diet-Induced Lipid Accumulation and Liver Damage. 2022 , 51, 1-11	
185	Evaluation of Dose-Dependent Obesity and Diabetes-Related Complications of Water Chestnut (Fruit of) Extracts in Type II Obese Diabetic Mice Induced by 45% Kcal High-Fat Diet.. 2022 , 58,	1
184	Lipid droplets associated perilipins protein insights into finding a therapeutic target approach to cure non-alcoholic fatty liver disease (NAFLD). 2022 , 8,	3
183	Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions.. 2022 , 127, 129	8
182	Association between neck circumference and non-alcoholic fatty liver disease: cross-sectional analysis from ELSA-Brasil.. 2022 ,	
181	Oxidative Stress in Non-Alcoholic Fatty Liver Disease. 2022 , 2, 30-76	1
180	Therapeutic Effects of Milk Thistle (L.) and Artichoke (L.) on Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Rats.. 2022 , 2022, 2868904	1
179	Boosting effects of Cranberry and Cinnamaldehyde for pioglitazone amelioration of liver steatosis in rat via suppression of HIF-1 β /Smad/Eatenin signaling. 2022 , 90, 104973	
178	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.. 2021 ,	3
177	Novel insights into the effect of Xiaoyao san on corticosterone-induced hepatic steatosis. 2022 , Publish Ahead of Print,	0
176	The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience.. 2022 , 101896	0
175	Regulated in Development and DNA Damage Response 1 Protects Hepatocytes Against Palmitate-induced Lipotoxicity. 2022 , 27, 70-78	
174	Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis.. 2022 , 152, w30138	
173	Early unhealthy eating habits underlie morpho-functional changes in the liver and adipose tissue in male rats.. 2022 , 1	0

- 172 Clinical features, treatment and rehabilitation of new coronavirus infection in patients with metabolic syndrome. **2022**, 12, 5-25
- 171 Metabolic imaging reveals a non-alcoholic hepatic steatosis. **2022**,
- 170 Plasma Calcium and Phosphorus Levels and Cardiovascular Disease Risks in Egyptian Type 2 Diabetic Patients. **2022**, 10, 502-513
- 169 Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy.. **2022**, 23, 1
- 168 Risk of Nonalcoholic Fatty Liver Disease Is Associated with Urinary Phthalate Metabolites Levels in Adults with Subclinical Hypothyroidism: Korean National Environmental Health Survey (KoNEHS) 2012-2014.. **2022**, 19, 0
- 167 Usefulness of Probiotics in the Management of NAFLD: Evidence and Involved Mechanisms of Action from Preclinical and Human Models.. **2022**, 23, 1
- 166 Efficacy of B-mode ultrasound-based attenuation for the diagnosis of hepatic steatosis: a systematic review/meta-analysis.. **2022**, 1, 0
- 165 Amino Acid-Related Metabolic Signature in Obese Children and Adolescents.. **2022**, 14, 0
- 164 Hepatic Glycogenesis: An Underdiagnosed Entity?. **2022**, 14, e23853
- 163 Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases.. **2022**, 12, 774335 2
- 162 Nonalcoholic Fatty Liver Disease: Could It Be the Next Medical Tsunami?. **2022**, 14, e23806 0
- 161 Indole alkaloids of *Alstonia scholaris* (L.) R. Br. alleviated nonalcoholic fatty liver disease in mice fed with high-fat diet.. **2022**, 12, 14 1
- 160 The promising role of CCL2 as a noninvasive marker for nonalcoholic steatohepatitis diagnosis in Egyptian populations.. **2021**, 33, 0
- 159 Nonalcoholic Fatty Liver Disease-Associated Liver Fibrosis Is Linked with the Severity of Coronary Artery Disease Mediated by Systemic Inflammation.. **2021**, 2021, 6591784 2
- 158 Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis.. **2021**, 8, 0
- 157 The chemoprevention of spirulina platensis and garlic against diethylnitrosamine induced liver cancer in rats via amelioration of inflammatory cytokines expression and oxidative stress.. **2022**, 11, 22-31 1
- 156 Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects.. **2021**, 11, 2
- 155 Fetuin-A in newly detected type 2 diabetes mellitus as a marker of non-alcoholic fatty liver disease.. **2021**, 40, 556 3

- 154 The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis.. **2021**, 9, 1
- 153 Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. **2021**, 16, 196-206 0
- 152 Targeting Mitochondrial ROS-Mediated Ferroptosis by Quercetin Alleviates High-Fat Diet-Induced Hepatic Lipotoxicity.. **2022**, 13, 876550 0
- 151 The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas.. **2022**, 0
- 150 Prevalence and Risk Factors of Elevated Alanine Aminotransferase in Korean Adolescents. **2022**, 12, 86-92
- 149 Subcellular delivery of lipid nanoparticles to endoplasmic reticulum and mitochondria.. **2022**, e1803 0
- 148 An Overview of the TRP-Oxidative Stress Axis in Metabolic Syndrome: Insights for Novel Therapeutic Approaches.. **2022**, 11, 0
- 147 Image_1.JPEG. **2018**,
- 146 Table_1.DOCX. **2018**,
- 145 Image_1.TIF. **2018**,
- 144 Image_2.TIF. **2018**,
- 143 Image_3.TIF. **2018**,
- 142 Dietary L-carnitine regulates liver lipid metabolism simultaneously activating fatty acid oxidation and suppressing endoplasmic reticulum stress in large yellow croaker fed with high-fat diets.. **2022**, 1-34 0
- 141 The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk non-alcoholic fatty liver disease in primary care.. **2022**, 0
- 140 The Role of Neuregulin-1 in Steatotic and Non-Steatotic Liver Transplantation from Brain-Dead Donors. **2022**, 10, 978 0
- 139 Periodontal Disease and Nonalcoholic Fatty Liver Disease: New Microbiome-Targeted Therapy Based on the Oral-Liver Axis Concept. 1 0
- 138 Endoplasmic Reticulum Stress in Liver Diseases.. **2022**, 4
- 137 The obesity epidemic: The role of radiology. 22-27 2

136	MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.. 2022 ,	3
135	Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study.. 2022 ,	0
134	Impact of Evolutionary Changes in Nonalcoholic Fatty Liver Disease on Lung Function Decline. 2022 ,	
133	Association of serum and fecal bile acid patterns with liver fibrosis in biopsy-proven nonalcoholic fatty liver disease: An observational study. 2022 , Publish Ahead of Print,	0
132	Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. 2022 ,	
131	Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma. 2022 , 22,	0
130	The burden and risks of emerging complications of diabetes mellitus.	4
129	Label-free metabolic imaging of non-alcoholic-fatty-liver-disease (NAFLD) liver by volumetric dynamic optical coherence tomography.	1
128	Association between serum apolipoprotein B and atrial fibrillation: a case-control study. 2022 , 12,	1
127	Metabolic actions of the growth hormone-insulin growth factor-1 axis and its interaction with the central nervous system.	0
126	Hypolipidemic Effects of Soy Protein and Isoflavones in the Prevention of Non-Alcoholic Fatty Liver Disease- A Review.	0
125	Evaluated Glomerular Filtration Rate Is Associated With Non-alcoholic Fatty Liver Disease: A 5-Year Longitudinal Cohort Study in Chinese Non-obese People. 9,	0
124	Synthesis and biological evaluation of tyrosine derivatives as peripheral 5HT2A receptor antagonists for nonalcoholic fatty liver disease. 2022 , 239, 114517	0
123	Statins in Alcoholic and Non-Alcoholic Fatty Liver Disease and Chronically Elevated Liver Enzymes. 2022 , 13, 229-252	
122	Associations of peroxisome proliferator-activated receptor- α Pro12Ala polymorphism with non-alcoholic fatty liver disease: A meta-analysis. 2022 , 108261	1
121	Non-alcoholic fatty liver disease and the impact of genetic, epigenetic and environmental factors in the offspring. 2022 , 28, 2890-2899	1
120	Association of the Metabolic Dysfunction-Associated Fatty Liver Disease with Serum Uric Acid-to-Creatinine Ratio.	1
119	Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. 2022 , 23, 7841	4

- 118 Persimmon Water Extract Suppresses Hepatic Lipotoxicity by Regulating Lipid Metabolites. **2022**, 25, 710-721
- 117 Liver-on-a-Chip devices: The Pros and Cons of Complexity. 0
- 116 Local fat content determines global and local stiffness in fatty livers.
- 115 Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis. **2022**, 190, 109981 2
- 114 Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia. **2022**, 10, 1770 0
- 113 Relationship between the High Fatty Liver Index and Risk of Fracture. **2022**, 1
- 112 Advances in ultrasound elastography for nonalcoholic fatty liver disease. **2022**,
- 111 Iodine Images in Dual-energy CT: Detection of Hepatic Steatosis by Quantitative Iodine Concentration Values.
- 110 Cinnabarinic acid provides hepatoprotection against non-alcoholic fatty liver disease. JPET-AR-2022-001301 1
- 109 Antihyperlipidemic effect and increased antioxidant enzyme levels of aqueous extracts from Liupao tea and green tea in vivo. 0
- 108 Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease. 13, 2
- 107 Apolipoprotein A4 Restricts Diet-Induced Hepatic Steatosis via SREBF1-Mediated Lipogenesis and Enhances IRS-PI3K-Akt Signaling. 2101034 1
- 106 Demographic, clinical and laboratory predictors of hepatic steatosis and fibrosis by elastography.
- 105 Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. **2022**, 2
- 104 The role of miRNAs in metabolic diseases.. **2022**, 29, 0
- 103 The ketogenic diet prevents steatosis and insulin resistance by reducing lipogenesis, diacylglycerol accumulation, and PKC activity in male rat liver. 0
- 102 Proteomic analysis of the effect of high-fat-diet and voluntary physical activity on mouse liver. **2022**, 17, e0273049
- 101 Analysis of hepatic markers and lipid profile of patients submitted to gastric by-pass after 2 years □ Cohort retrospective. **2022**, 81, 104211

100	Non-Alcoholic Fatty Liver Disease and Steatohepatitis. 2022,	0
99	An Assessment of Atherosclerotic Cardiovascular Disease in Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus.	0
98	Long non-coding RNA in Non-alcoholic fatty liver disease. 2022, 1-35	0
97	Peroxisome Proliferator-Activated Receptor γ Has a Protective Effect on Fatty Liver Caused by Excessive Sucrose Intake. 2022, 10, 2199	0
96	Elevated alanine aminotransferase is associated with biphasic insulin secretion in the healthy elderly Han Chinese population. 2022, 50, 030006052211151	0
95	S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma. 2022, 23, 11030	0
94	Effects of Time-Restricted Feeding (16/8) Combined with a Low-Sugar Diet on the Management of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. 2022, 111847	0
93	The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis. 2022, 20,	1
92	Vitamin D Status and Steatohepatitis in Obese Diabetic and Non-Diabetic Patients. 2022, 11, 5482	0
91	Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. 2022, 14, 4473	2
90	Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease. 2022, 28, 5111-5128	1
89	Association of Hepatic Steatosis With Coronary Artery Disease by Studying the Role of Individual and Demographic Risk Factors. 2022,	0
88	Asociaci3n entre el 3ndice de masa corporal y el grado de fibrosis hep3tica medida por elastografi3 en tiempo real (Supersonic). 2022, 37, 269-275	0
87	Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus Non-alcoholic fatty liver disease: a longitudinal cohort analysis. 2022, 100762	2
86	A Case of Glycogenic Hepatopathy as a Complication of Poorly Controlled Type 1 Diabetes Mellitus. 2022, 2022, 1-5	0
85	Triglyceride affects the association between estimated glomerular filtration rate and the onset of non-alcoholic fatty liver disease: A second analysis of a Chinese cohort study. 9,	0
84	The role of oxidized lipid species in insulin resistance and NASH in children. 13,	0
83	Ameliorating Effects of Geumnyeonyijin-tang Water Extract on Obesity-Induced T2DM and Related Complications in Mice. 2022, 43, 606-624	0

82	Non-alcoholic fatty liver disease: an epigenetic view of pathogenesis and a new treatment options. 2022 , 171-176	0
81	Ginsenoside Rg3-enriched Korean red ginseng extract attenuates Non-Alcoholic Fatty Liver Disease by way of suppressed VCAM-1 expression in liver sinusoidal endothelium. 2022 ,	0
80	Red Pepper Seeds Inhibit Hepatic Lipid Accumulation by Inducing Autophagy via AMPK Activation. 2022 , 14, 4247	0
79	Clinical features of chronic hepatitis B patients with lean non-alcoholic fatty liver disease.	0
78	Liver Brain Interactions: Focus on FGF21 a Systematic Review. 2022 , 23, 13318	3
77	Consequences of Childhood Obesity. 2009 , 38, 75-81	10
76	Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage. 2022 ,	0
75	Prognostic value of De Ritis ratio with aspartate aminotransferase and alanine aminotransferase within the reference range. 2023 , 538, 46-52	1
74	Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD. 2022 , 10, 2806	0
73	O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease. 2022 , 11, 3637	1
72	A meta-analysis of the diagnostic accuracy of serum type IV collagen 7S concentration for the staging of liver fibrosis in nonalcoholic fatty liver disease.	0
71	Waist-to-Height Ratio Associated Cardiometabolic Risk Phenotype in Children with Overweight/Obesity.	0
70	RF coil design for improving human liver fat quantification in a portable single-side MR system.	0
69	Differences of lipid proton compositions and fatty acids between alcoholic fatty liver and high-fat diet fatty liver animal models :9.4T magnetic resonance spectroscopy study.	0
68	Metabolic-associated fatty liver disease and the risk of cardiovascular disease. 2023 , 47, 102063	0
67	Pharmacometabolomic assessment of vitamin E loaded human serum albumin nanoparticles on HepG2 cancer cell lines. 2023 , 79, 104017	0
66	Consumption of the cell-free or heat-treated fractions of a pitched kefir confers some but not all positive impacts of the corresponding whole kefir. 13,	0
65	Mitochondrial Peroxiredoxin III Protects against Non-Alcoholic Fatty Liver Disease Caused by a Methionine-Choline Deficient Diet. 2023 , 12, 9	0

- 64 Thymoquinone attenuates hepatic lipid accumulation by inducing autophagy via AMPK / mTOR / ULK1 -dependent pathway in nonalcoholic fatty liver disease. 1
- 63 Theobroma cacao and Theobroma grandiflorum: Botany, Composition and Pharmacological Activities of Pods and Seeds. **2022**, 11, 3966 2
- 62 Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different. **2022**, 23, 16226 1
- 61 Lower serum PRL is associated with the development of non-alcoholic fatty liver disease: a retrospective cohort study. **2022**, 22, 0
- 60 The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network. **2022**, 14, 6151 0
- 59 Automated Segmentation and Morphological Characterization of Hepatic Steatosis and Correlation with Histopathology. **2022**, 0
- 58 De Ritis ratio and long-term major cardiovascular adverse events in patients undergoing elective percutaneous coronary intervention. 0
- 57 Oxidative Stress in Nonalcoholic Fatty Liver Disease: Pathogenesis and Antioxidant Therapies. **2004**, 52, 506-514 0
- 56 Abnormal Liver Tests. **2022**, 623-635 0
- 55 RANKL Is Independently Associated with Increased Risks of Non-Alcoholic Fatty Liver Disease in Chinese Women with PCOS: A Cross-Sectional Study. **2023**, 12, 451 0
- 54 Effects of Different Vegetable Oils on the Nonalcoholic Fatty Liver Disease in C57/BL Mice. **2023**, 2023, 1-10 0
- 53 Phosphatidylethanolamines Are Associated with Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Adults and Induce Liver Cell Metabolic Perturbations and Hepatic Stellate Cell Activation. **2023**, 24, 1034 0
- 52 Targeting integrin pathways: mechanisms and advances in therapy. **2023**, 8, 1
- 51 Alaska Pollock (*Gadus chalcogrammus*) Protein and Hydrolyzed Polypeptides: A Systematic Review of its Potential Biological Activities. 0
- 50 Capparis zeylanica L. root extract promotes apoptosis and cell cycle arrest, inhibits epithelial-to-mesenchymal transition and triggers E-cadherin expression in breast cancer cell lines. **2023**, 13, 0
- 49 CX08005, a Protein Tyrosine Phosphatase 1B Inhibitor, Attenuated Hepatic Lipid Accumulation and Microcirculation Dysfunction Associated with Nonalcoholic Fatty Liver Disease. **2023**, 16, 106 0
- 48 Worsening nutritional status in non-obese patients with inflammatory bowel disease is reflected by nonalcoholic fatty liver disease: a retrospective study. 0
- 47 Association between non-nutritive sweetener consumption and liver enzyme levels in adults: a systematic review and meta-analysis of randomized clinical trials. 0

- 46 Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia. **2023**, 11, 10 ○
- 45 Hgado graso (parte 1): aspectos generales, epidemiologā, fisiopatologā e historia natural. **2022**, 37, 420-433 ○
- 44 Liver fibrosis for the dermatologist: a review. ○
- 43 Preclinical and clinical evidence for the treatment of non-alcoholic fatty liver disease with soybean: A systematic review and meta-analysis. 14, ○
- 42 Relationship of Helicobacter pylori Infection with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. **2023**, 2023, 1-13 ○
- 41 The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial. 13, ○
- 40 Regulation of fat storesEndocrinological pathways. **2023**, 193-204 ○
- 39 Plasma proteomic signature of fatty liver disease: the Rotterdam Study. Publish Ahead of Print, ○
- 38 Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis. **2023**, 102, e32734 ○
- 37 Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease. **2023**, ○
- 36 Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease. **2023**, 21, ○
- 35 Serum from Adolescents with High Polyphenol Intake Exhibits Improved Lipid Profile and Prevents Lipid Accumulation in HepG2 Human Liver Cells. **2023**, 2023, 1-12 ○
- 34 Efficacy and safety of nanoparticles of glibenclamide and organomodified layered double hydroxides in diabetics rats. **2023**, 634, 122678 ○
- 33 Non-alcoholic Fatty Liver Disease in Overt Hypothyroidism: A Cross-Sectional Study in a Tertiary Care Hospital. **2023**, ○
- 32 Associations of altered hepatic gene expression in American lifestyle-induced obesity syndrome diet-fed mice with metabolic changes during NAFLD development and progression. **2023**, 115, 109307 ○
- 31 Novel measures for the diagnosis of hepatic steatosis using contrast-enhanced computer tomography images. **2023**, 160, 110708 ○
- 30 Differences of Lipid Proton Compositions and Fatty Acids Between Alcoholic Fatty Liver and High-Fat Diet Fatty Liver Animal Models: 9.4 T Magnetic Resonance Spectroscopy Study. **2023**, 54, 347-358 ○
- 29 The use of phase angle in patients with digestive and liver diseases. ○

- 28 Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. 29, 967-996 ○
- 27 Regulatory Effects and Molecular Mechanisms of Tea and Its Active Compounds on Nonalcoholic Fatty Liver Disease. ○
- 26 Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus. **2023**, 11, e003066 1
- 25 Therapeutic and Preventive Effects of Aqueous Extracts of *Arctium lappa* L. and *Cichorium intybus* L. against Fatty Liver in Rats. **2022**, 10, 53-61 ○
- 24 Analysis of the Genetic Relationship between Atherosclerosis and Non-Alcoholic Fatty Liver Disease through Biological Interaction Networks. **2023**, 24, 4124 ○
- 23 Raman imaging of rat nonalcoholic fatty liver tissues reveals distinct biomolecular states. ○
- 22 Fibrose-Grad der Leber im Visier. **2023**, 17, 23-25 ○
- 21 Comparison of portal vein hemodynamics with ultrasound-based elastography for the prediction of liver fibrosis in patients with chronic liver disease. **2023**, 13, ○
- 20 Correlation between CT Abdominal Anthropometric Measurements and Liver Density in Individuals with Non-Alcoholic Fatty Liver Disease. **2023**, 59, 500 ○
- 19 Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease. **2023**, 13, ○
- 18 STUDY OF CLINICAL PROFILE OF PATIENTS OF NON ALCOHOLIC FATTY LIVER DISEASE AND ITS ASSOCIATION WITH METABOLIC SYNDROME. **2023**, 44-46 ○
- 17 Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors. ○
- 16 Risk Factors of Non-alcoholic Fatty Liver Disease in the Iranian Adult Population: A Systematic Review and Meta-analysis. **2023**, 23, ○
- 15 From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. **2023**, 11, 883 ○
- 14 Natural Product Skatole Ameliorates Lipotoxicity-Induced Multiple Hepatic Damage under Hyperlipidemic Conditions in Hepatocytes. **2023**, 15, 1490 ○
- 13 *Bombax ceiba* Linn. leaf extract rich in phenolic compounds to mitigate non-alcoholic fatty liver-related complications in experimental model. **2023**, ○
- 12 The Association between Advanced Liver Fibrosis and Mortality Is Modified by Dietary Quality among Korean Adults: Results from the Korea National Health and Nutrition Examination Survey with Mortality Data. **2023**, 15, 1501 ○
- 11 Role of Nutrition in the Etiopathogenesis and Prevention of Nonalcoholic Fatty Liver Disease (NAFLD) in a Group of Obese Adults. **2023**, 59, 638 ○

- 10 Mouse strain-dependent variation in metabolic associated fatty liver disease (MAFLD): a comprehensive resource tool for pre-clinical studies. **2023**, 13,
- 9 Efficacy Confirmation Test of Black Cumin (*Nigella sativa* L.) Seeds Extract Using a High-Fat Diet Mouse Model. **2023**, 13, 501
- 8 Yellow tea: more than turning green leaves to yellow. 1-18
- 7 A Healthy Diet is Associated with a Lower Risk of Hepatic Fibrosis. **2023**,
- 6 Hepatic triglyceride content is intricately associated with numerous metabolites and biochemical pathways.
- 5 Polycystic ovary syndrome and nonalcoholic fatty liver disease. **2024**, 92-99
- 4 Sex- and reproductive status-specific relationships between body composition and non-alcoholic fatty liver disease.
- 3 Vegetable Oil-Peroxidation Product Hydroxynonenal Causes Hepatocyte Injury and Steatosis via Hsp70.1 and BHMT Disorders in the Monkey Liver. **2023**, 15, 1904
- 2 Intestinal BMP-9 locally upregulates FGF19 and is down-regulated in obese patients with diabetes. **2023**, 111934
- 1 Nationwide Demographic Characteristics of Nonalcoholic Fatty Liver Disease in South Korea between 2010 and 2021.